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FOREWORD
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes. Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is 
also presented but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological 
properties. Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy 
of information to determine a substance's health effects. ATSDR identifies data needs that are significant 
to protection of public health.
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is 
available or being developed to determine levels of exposure that present a significant risk to 
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of 
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals; 
interested private sector organizations and groups; and members of the public.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel 
and was made available for public review. Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR.
Christopher J. Portier, Ph.D.
Assistant Administrator 
Agency for Toxic Substances and Disease Registry
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*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(1) directs the Administrator of ATSDR to .effectuate and implement the health related
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “ .estab lish  and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR.
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Q UICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections o f Interest
C hapter 1: Public Health S tatem ent: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
C hapter 2: Relevance to Public H ealth : The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
C hapter 3: H ealth Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics : Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 C hildren’s Susceptibility
Section 6.6 Exposures of C hildren
O ther Sections of Interest:
Section 3.8 B iom arkers of Exposure and Effect
Section 3.11 M ethods for Reducing Toxic Effects
ATSDR Information Center
Phone: I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association o f Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
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1. PUBLIC HEALTH STATEMENT
This public health statement tells you about 1,3-butadiene and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. 1,3-Butadiene has been found in at least 13 of the 1,699 current or former 
NPL sites. Because not all NPL sites were tested for 1,3-butadiene, the number of sites where this 
chemical is found may increase in the future as more sites are evaluated. This information is important 
because these sites may be sources of exposure and exposure to this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to 1,3-butadiene, many factors will determine whether you will be harmed. These 
factors include the dose (how much), the duration (how long), and how you come in contact with it. You 
must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, 
and state of health.
1.1 W HAT IS 1,3-BUTADIENE?
D escrip tion 1,3-Butadiene is a colorless gas with a mild gasoline-like 
odor.
Uses About 60% o f 1,3-butadiene is used to make man-made 
rubber, which is then used mostly fo r car and truck tires. 
1,3-Butadiene is also used to make certain types of 
plastics such as acrylics.
See Chapters 4 and 5 for more information on the sources, properties, and uses of 1,3-butadiene.
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1.2 W HAT HAPPENS TO 1,3-BUTADIENE WHEN IT ENTERS THE ENVIRONMENT?
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S ou rces Large amounts o f 1,3-butadiene are released into the air 
by industrial sources. Industrial releases to w ater and soil 
are relatively low.
Automobile exhaust is a constant source o f 1,3-butadiene 
release into the air. O ther sources o f 1,3-butadiene 
include cigarette sm oke and the sm oke o f wood fires.
Forest fires are considered to be a natural source of 
1,3-butadiene in the air.
B reak-dow n
• A ir
• W a te r and  soil
Half o f the 1,3-butadiene in the air will likely be broken 
down in about 6 hours.
1,3-Butadiene that is spilled onto w ater or soil will likely 
evaporate quickly into the air based on its physical and 
chemical properties.
See Chapters 5 and 6 for more information on 1,3-butadiene in the environment.
1.3 HOW MIGHT I BE EXPOSED TO 1,3-BUTADIENE?
A ir The primary way you can be exposed to 1,3-butadiene is by 
breathing air containing it. Releases o f 1,3-butadiene into the air 
occur from:
•  vehicle exhaust
•  tobacco smoke
• wood burning
• burning o f rubber and plastic
•  forest fires
•  accidental or intentional release at manufacturing plants
The average amount o f 1,3-butadiene in the air is between 
0.04 and 0.9 parts o f 1,3-butadiene per billion parts o f air (ppb) in 
cities and suburban areas.
W o rkp lace  a ir W orkers in the production o f rubber, plastics, and resins are likely 
exposed to higher levels o f 1,3-butadiene.
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Food and  d rinking  w a te r 1,3-Butadiene has been measured at very low levels in plastic or 
rubber o f food containers, but it has not been found often in food 
samples.
Exposure to 1,3-butadiene through ingestion o f food and drinking 
water is expected to be very low compared to exposure through 
breathing contaminated air.
G asoline People may be exposed to small amounts o f 1,3-butadiene if 
gasoline gets on the ir skin or by breathing a ir that contains gasoline 
fumes.
1.4 HOW CAN 1,3-BUTADIENE ENTER AND LEAVE MY BODY?
E nter y o u r body 1,3-Butadiene in a ir can be absorbed from the lungs and enter the 
blood stream.
Leave y o u r body 1,3-Butadiene is broken down to other chem icals in the liver.
About half o f inhaled 1,3-butadiene is broken down and exhaled, 
while most o f the remaining chemical is broken down and excreted 
in the urine. 1,3-Butadiene typically leaves the body by 10 hours.
For more information on how 1,3-butadiene enters and leaves the body, see Chapter 3.
1.5 HOW CAN 1,3-BUTADIENE AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
In laboratory animals, 1,3-butadiene causes inflammation o f nasal 
tissues, changes to lung, heart, and reproductive tissues, 
neurological effects, and blood changes.
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C ancer Studies o f workers exposed to 1,3-butadiene suggest that workers
may have an increased risk fo r cancers o f the blood and lymphatic
system.
Laboratory animals have developed cancer in multiple body tissues
after exposure to 1,3-butadiene fo r 13 weeks or longer. Animals
appear to be most sensitive to blood and lymphatic system
cancers.
The International Agency fo r Research on Cancer (IARC), National
Toxicology Program (NTP), and EPA all classify 1,3-butadiene as a
human carcinogen.
1.6 HOW CAN 1,3-BUTADIENE AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.
Effects in ch ildren It is likely that children would show the same health effects as 
adults. W e do not know whether children are more sensitive to the 
effects of 1,3-butadiene.
B irth  defects W e do not know whether 1,3-butadiene causes birth defects in 
people. Some studies have found decreases in fetal weight and 
skeletal defects in laboratory animals exposed to 1,3-butadiene.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1,3-BUTADIENE?
W o od  burning Take precautions to m inimize the amount o f smoke released into 
the home during wood burning.
V eh ic le  engines Make sure vehicle engines are turned o ff when in an enclosed 
space such as a garage.
V eh ic le  tra ffic Minimize tim e spent near areas o f heavy vehicle tra ffic  and avoid 
living very close to busy roads.
T ob acco  sm oke Families can reduce exposure to 1,3-butadiene by avoiding tobacco 
smoke, particularly indoors.
1. PUBLIC HEALTH STATEMENT
1.8 IS THERE A MEDICAL TEST TO DETERMINE W HETHER I HAVE BEEN EXPOSED TO
1,3-BUTADIENE?
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W e currently have no reliable medical test to determ ine if someone 
has been exposed to 1,3-butadiene. However, scientists are 
working on tests to show if 1,3-butadiene attaches to compounds in 
the blood, such as proteins or deoxyribonucle ic acid (DNA).
1.9 W HAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
Some regulations and recommendations for 1,3-butadiene include the following:
Levels in b reath ing  a ir  
set by EPA
EPA has set a reference concentration in breathing air o f 0.9 ppb 
fo r 1,3-butadiene.
Levels in d rink ing  w a te r  
set by EPA
EPA has not set levels in drinking water fo r 1,3-butadiene.
Levels in w o rkp lace  a ir  
set by O S H A
OSHA set a legal limit o f 1 ppm fo r 1,3-butadiene in air averaged 
over an 8-hour w ork day.
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1.10 W HERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and 
technical assistance number at 1-8OO-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by 
writing to:
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Human Health Sciences (proposed)
1600 Clifton Road NE 
Mailstop F-62 
Atlanta, GA 30333 
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,3-BUTADIENE IN THE 
UNITED STATES
1.3-Butadiene is a highly volatile gas that is used in the production of synthetic rubber; the major end use 
of the synthetic rubber is automobile tires. 1,3-Butadiene is also used for the production of high impact 
polystyrene and acrylonitrile-butadiene-styrene (ABS) resin plastics The predominant source of
1.3-butadiene in the atmosphere is industrial releases, which can occur during manufacturing, use, 
transport, and storage of the chemical. Automobile exhaust is a constant source of low levels of
1.3-butadiene release to the atmosphere. Minor sources of 1,3-butadiene in the atmosphere include 
cigarette smoke, wood burning (including forest fires), and the burning of rubber and plastics. In the 
atmosphere, 1,3-butadiene is expected to undergo photo-initiated destruction with a half-life of 
approximately 6 hours. Relatively low levels of 1,3-butadiene are released to water and soil. 1,3-Buta­
diene in water or soil is expected to rapidly evaporate to the atmosphere.
Inhalation is the predominant route of exposure for the general population. Mean concentrations of
1.3-butadiene in the air in cities and suburban areas ranges from 0.1 to 2 ^g/m3 (0.04-1 ppb); the average 
background concentration of 0.13 ^g/m3 (0.59 ppb) has been estimated. Higher atmospheric 
concentrations have been measured in areas near oil refineries, chemical manufacturing plants, and plastic 
and rubber factories where 1,3-butadiene is manufactured or used; concentrations as high as 40 ^g/m3 
(18 ppb) have been measured near industrial sites. Within the general population, smokers (and 
individuals exposed to secondhand smoke) and individuals inhaling smoke from wood fires are likely to 
be exposed to higher levels of 1,3-butadiene. Workers involved in the production of rubber, plastics, and 
resins are most likely to receive the largest exposures. No data are available to quantify general 
population exposure to 1,3-butadiene by other routes of exposure, but it is expected to be very low 
compared to breathing contaminated air. Low levels of 1,3-butadiene have been detected in U.S. drinking 
water supplies; however, specific quantitative data were not located. 1,3-Butadiene has also been 
measured at very low levels in the plastic or rubber of food containers and has been found in a few food 
samples.
Several biomarkers of exposure have been identified for 1,3-butadiene; these include 1,3-butadiene 
urinary metabolites, M1 and M2, and three hemoglobin adducts, A^-(2-hydroxy-3-butenyl)valine 
(MHB-Val), Af-(2,3,4-trihydroxybutyl)valine (THB-Val), and ^ ,^-(2,3-dihyroxy-1,4-butadyl)valine 
(pyr-Val), which are surrogate biomarkers for the 1,3-butadiene metabolites 1,2 epoxy-3-butene (EB),
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1.2-dihydroxy-3,4-epoxybutane (EBD), and 1,2:3,4-diepoxybutane (DEB), respectively. In workers, the 
levels of urinary metabolites and hemoglobin adducts have been shown to correlate with 1,3-butadiene 
exposure levels. However, background levels for the general population have not been established for 
these biomarkers of exposure.
2.2 SUMMARY OF HEALTH EFFECTS
The available data for 1,3-butadiene exposure and toxicity in humans and animals are limited to 
inhalation exposures; the effects from significant oral or dermal exposures are not known. Information on 
the toxicity of 1,3-butadiene in humans comes from case reports and epidemiology studies that primarily 
focused on the potential carcinogenicity of 1,3-butadiene. Slight eye irritation and difficulty in focusing 
on instrument scales were reported by two men exposed to 2,000 or 4,000 ppm 1,3-butadiene for 6­
7 hours; however, this was not reported when the two men were exposed to 8,000 ppm for 8 hours. 
Psychomotor tests conducted in these subjects did not find alterations at 2,000-8,000 ppm. Numerous 
epidemiological studies of multiple occupational cohorts, including one encompassing 15,000 workers, 
have associated a higher incidence of hemato-lymphopoietic cancer mortality among exposed workers. 
Although most of these workers were co-exposed to other organic compounds, including styrene, 
benzene, and dithiocarbamates, multivariate analysis suggested that the estimates of 1,3-butadiene 
exposure provided the best correlation with the rates of lympho-hematopoietic cancers.
Numerous target organs for 1,3-butadiene toxicity have been identified in well-conducted laboratory 
studies ranging from single episode to lifetime exposures. Observed effects include death, neurological 
dysfunction, reproductive and developmental effects, hematological and lymphoreticular effects, and 
cancer. Evaluation of the relevance of adverse health effects observed in laboratory animals to human 
health is encumbered by large species differences in the metabolism of 1,3-butadiene. The metabolism of
1.3-butadiene in humans and laboratory animals involves the same enzymatic pathways; however, there 
are notable quantitative differences in the production and detoxification of several reactive metabolites, 
particularly, EB, DEB, and EBD; see Sections 3.4.2 and 3.5.3 for more information on species 
differences. Mice, the most sensitive species, are more efficient at converting 1,3-butadiene to EB and 
converting EB to DEB. Using pyr-Val hemoglobin adduct levels as a biomarker for blood DEB levels, an 
exposure to approximately 1 ppm 1,3-butadiene resulted in mouse DEB levels that were 50 times higher 
than rats and 1,000 times higher than humans. Although the mode of action has not been elucidated for 
all toxic end points, there are strong data to support the reactive metabolites as the causative agents for the 
ovarian atrophy, cancer, and genotoxic effects observed in laboratory animals. Without information on
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the mode of action, particularly the causative agent, the reader should use caution in evaluating the 
relevance of the animal data presented in this section to human health.
Lesions of the respiratory tract (olfactory tissues and lungs), liver, kidney, stomach, and eyes have been 
seen in mice exposed to >200 ppm for intermediate durations, but these lesions are typically epithelial or 
endothelial hyperplasias and are precancerous in nature. Non-neoplastic lesions of the liver (necrosis) in 
rats and kidney (renal nephrosis) in mice occurred following intermediate-duration exposure to 625 or
8,000 ppm, respectively.
Although no biologically relevant alterations in hematological parameters have been observed in
1,3-butadiene workers, changes in the blood and lymphoid tissues are common observations in rodents 
exposed for intermediate and chronic durations. Decreases in red blood cell counts and hemoglobin 
concentration occurred at 65 ppm in mice, progressing to macrocytic megaloblastic anemia from 
exposures of 200 ppm. These effects are likely associated with observed changes in normal bone marrow 
function, as indicated by reduced circulation of erythrocytes and leukocytes, and increased proliferative 
activity with no associated change in bone marrow cellularity. Lymphoreticular toxicity in mice was 
indicated by significant changes in thymus weight and lesions in lymphoid organs following intermediate- 
duration exposures to 625-1,250 ppm in mice. A reversible suppression of cytotoxic T-lymphocyte 
generation to mastocytoma cells and a depression of spleen cellularity were observed at these exposures. 
The changes in spleen and thymus weights, lymphocytic differentiation, and appearance of lymphoid 
lesions comport with the onset of lymphoma in mice after chronic exposure to 1,3-butadiene.
Reproductive and developmental effects are the most sensitive non-cancer effects observed in rodents. 
Wavy ribs and skeletal abnormalities occurred in offspring of rats exposed to 1,000-8,000 ppm during 
gestation days (GDs) 6-15. In mice, exposure of pregnant dams to 40 ppm on GDs 6-15 resulted in a 5% 
decrease in fetal body weight among male mice. Exposure of mice to >200 ppm resulted in >19% 
reductions in fetal weight. A possible dominant lethal effect was observed in mice in which increased 
fetal deaths occurred from exposure to 200 ppm. The lowest lowest-observed-adverse-effect level 
(LOAEL) identified for intermediate-duration exposures was 12.5 ppm in male mice mated with 
unexposed females, resulting in increased late fetal death, exencephaly, and skull abnormalities of fetuses. 
Serious lesions of reproductive tissues in male and female mice have arisen from intermediate- and 
chronic-duration exposures. Ovarian atrophy, including complete loss of oocytes, follicles, and corpora 
lutea, occurred in mice exposed to 200 ppm for 9 months and as low as 6.25 ppm for 2 years. Male mice
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were somewhat less sensitive, with testicular atrophy observed after 15-month exposures to 625 ppm
1,3-butadiene.
The consistent carcinogenic responses in rodent bioassays support the associations derived in 
epidemiological studies between hemato-lymphopoietic cancer and 1,3-butadiene exposure. In rats, 
2-year exposure to 1,000 or 8,000 ppm resulted in increased incidences of tumors of the testes, pancreas, 
uterus, mammary gland, Zymbal gland, and thyroid. In mice, exposure to 200 ppm for 40 weeks resulted 
in increased tumor incidences of lymphopoietic system, heart, lung, stomach, liver, and eye. These same 
tumors developed in mice in as little as 13 weeks after exposure to 625 ppm. Chronic exposure of mice to 
concentrations of 20 ppm (males) and 6.25 ppm (females) of 1,3-butadiene resulted in increased tumor 
development in the lymphopoietic system, heart, lung, stomach, liver, eye, mammary glands, and ovaries.
2.3 MINIMAL RISK LEVELS (MRLs)
Inhalation MRLs
The toxicity of 1,3-butadiene following inhalation exposure has been examined in epidemiology studies, 
intermediate- and chronic-duration studies in rats and mice, reproductive toxicity studies in mice, and 
developmental toxicity studies in rats and mice. The epidemiological studies have primarily focused on 
carcinogenicity and have found increases in lympho-hematopoitic cancers. Observed effects found in 
animal studies include neurological dysfunction, reproductive and developmental effects, hematological 
and lymphoreticular effects, and cancer. Acute exposures have resulted in fetal effects (decreased growth 
and skeletal defects) (DOE/NTP 1987b; Irvine 1981) and reproductive effects (increased intrauterine 
death following male-only exposure) (DOE 1988b). Intermediate-duration exposures in mice resulted in 
precancerous lesions of the respiratory tract (olfactory tissues and lungs), liver, kidney, stomach, and eyes 
(NTP 1984, 1993). Non-neoplastic lesions of the liver (necrosis) in rats and kidney (renal nephrosis) in 
mice occurred following intermediate-duration inhalation exposure. In mice, intermediate-duration 
inhalation exposure also resulted in decreases in red blood cell counts and hemoglobin concentration, 
progressing to macrocytic megaloblastic anemia (NTP 1993), decreases in spleen and thymus weight 
(NTP 1993), and depressed splenic cellularity (Thurmond et al. 1986). Chronic-duration inhalation 
exposure studies identified a number of targets of toxicity in mice including, bone marrow, lungs, heart, 
forestomach, Harderian gland, testes, ovaries, and uterus (NTP 1984, 1993); neoplastic lesions were also 
observed in a number of tissues. In rats, chronic exposure resulted in histological alterations in the lungs 
and increased severity of nephropathy (Owen et al. 1987).
1,3-BUTADIENE
2. RELEVANCE TO PUBLIC HEALTH
11
Comparison of rat and mouse data identifies large differences in sensitivity to 1,3-butadiene, which are 
due to metabolic differences between species. As discussed in Sections 3.4.2 and 3.5.3, quantitative 
differences between humans, rats, and mice in the rate of formation of reactive metabolites, particularly 
EB and DEB have been found. These differences result in higher tissue levels of reactive metabolites in 
rodents than in humans (Bond et al. 1993; Csanady et al. 1992; Dahl et al. 1991; Filser et al. 2001, 2007, 
2010; Henderson et al. 1996, 2001; Himmelstein et al. 1997; Kirman et al. 2010a; Krause and Elfarra 
1997; Schmidt and Loeser 1985; Thornton-Manning et al. 1995b). Following inhalation exposure to
1,3-butadiene, blood EB levels were 2-8 times higher in mice as compared to rats (Filser et al. 2007) and 
the maximum butadiene-diol levels were 4 times higher in mice than rats (Filser et al. 2007). The DEB 
levels were >100-fold higher in mice as compared to rats (Filser et al. 2007). At a similar exposure level 
(1 ppm), mice produce approximately 1,000 times as much DEB as humans, as measured using pyr-Val 
hemoglogin adduct as a biomarker and 50 times as much DEB as rats (Swenberg et al. 2011).
The Agency usually considers humans more sensitive than animals and makes an adjustment to the point 
of departure to account for species differences when deriving an MRL from an animal study. If possible, 
chemical-specific data, such as physiologically based pharmacokinetic (PBPK) modeling, is used to 
account for toxicokinetic differences between species. Although PBPK models for 1,3-butadiene have 
been developed in rodents (Johanson and Filser 1993; Kohn and Melnick 1993, 1996, 2000) and a 
preliminary model has been developed in humans (Brochot et al. 2007), the models are limited in their 
ability to predict internal doses for key metabolites (Kirman and Grant 2012). An alternative to using 
PBPK models would be to use a biomarker of exposure to reactive metabolites. Several biomarkers of 
exposure have been identified for reactive 1,3-butadiene metabolites including MHB-Val hemoglobin 
adducts, THB-Val hemoglobin adducts, and pyr-Val hemoglobin adducts, which have been shown to be 
good surrogate biomarkers for EB, EBD, and DEB, respectively (Georgieva et al. 2010; Slikker et al. 
2004). However, there are limited mechanistic data that would allow identification of the 1,3-butadiene 
metabolite(s) (or parent compound) that is responsible for the non-neoplastic effects, with the exception 
of ovarian atrophy observed in mice, which is likely due to DEB.
In the absence of chemical-specific data, the Agency generally applies an uncertainty factor of 10 to 
account for interspecies differences in toxicokinetic and toxicodynamic properties. However, the 
toxicokinetic data for 1,3-butadiene indicate that mice are many-fold more sensitive than humans. Thus, 
the Agency can only use an uncertainty factor of 1 (or not apply an uncertainty factor [UF]), which in the 
case of 1,3-butadiene, may cause the MRL to overestimate the risk to humans. Therefore, in this instance,
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the Agency has elected to not derive inhalation MRLs for 1,3-butadiene. Brief discussions of the 
available literature for each duration period are presented below.
Acute-Duration Inhalation MRL. Death and neurological effects have been observed in rats, mice, and 
rabbits exposed to 8,000-250,000 ppm from <1 to 4 hours (Carpenter et al. 1944; Shugaev 1969). Studies 
examining nonlethal effects were limited to three developmental toxicity studies and a reproductive 
toxicity study. Significant increases in the occurrence of major skeletal defects, predominantly wavy ribs, 
were observed in the offspring of Sprague-Dawley rats exposed to 1,000 or 8,000 ppm 1,3-butadiene 
6 hours/day on GDs 6-15 (Irvine 1981). Other non-concentration-related effects included an increase in 
minor skeletal defects at 200 ppm, but not at higher concentrations, and increases in the occurrence of 
minor external/visceral defects at 1,000 ppm, but not at 8,000 ppm. The study also found decreases in 
fetal growth (body weight and crown-rump length) at 8,000 ppm and decreases in maternal weight gain at 
>200 ppm; at 8,000 ppm, maternal body weight gain was 45% lower than controls. The investigators 
noted that the increase in the occurrence of wavy ribs was likely secondary to the decrease in maternal 
weight gain. In a second rat developmental toxicity study, no developmental effects (including alterations 
in occurrence of skeletal defects, fetal body weight, or maternal body weight) were observed in Sprague- 
Dawley rats exposed to 40-1,000 ppm 6 hours/day on GDs 6-15 (DOE/NTP 1987a). In a mouse 
developmental toxicity study, decreases in fetal body weight were observed in the offspring of CD-1 mice 
exposed to >40 ppm 6 hours/day on GDs 6-15 (DOE/NTP 1987b). The male fetal body weights were 5, 
18, and 23% lower than controls and no significant alterations in female body weight were observed; 
interpretation of these results is limited by the lack of statistical adjustment for litter size. In the 
reproductive toxicity study, the mating of male CD-1 mice exposed to >200 ppm 6 hours/day for 5 days 
with unexposed females resulted in significant increases in dams with two or more intrauterine deaths 
(DOE/NTP 1988b). This effect was only observed when the mating occurred 1 week post-exposure, 
suggesting that the mature spermatozoa and/or spermatids were the targets.
The limited available data on the toxicity of 1,3-butadiene following acute-duration inhalation exposure 
suggest that mice are more sensitive than rats for developmental effects. Exposures to 1,3-butadiene has 
resulted in decreases in fetal body weights in mice at >40 ppm (DOE/NTP 1987b) and rats at >200 ppm 
(Irvine 1981), dominant lethal effects in mice at >200 ppm (DOE/NTP 1988b), and increases in skeletal 
malformations in rat fetuses at >1,000 ppm (Irvine 1981). The no-observed-adverse-effect levels 
(NOAELs) were 40 ppm for dominant lethal effects in mice and 200 ppm for skeletal defects in rats. As 
noted previously, the Agency has elected to not derive an acute-duration inhalation MRL for
1,3-butadiene due to the large species differences in the metabolism of 1,3-butadiene and the lack of
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chemical-specific data to adjust for these differences, which may result in the MRL overestimating the 
risk to humans.
Intermediate-Duration Inhalation MRL. Intermediate-duration exposures resulted in death in mice 
exposed to 5,000 ppm, 6 hours/day for 5 weeks (NTP 1984) and 200 ppm, 6 hours/day for 40 weeks 
(NTP 1993). No systemic effects were seen in rats or mice exposed to 8,000 ppm, 6 hours/day for 13­
14 weeks, with the exception of a 13% body weight reduction in mice exposed to 2,500 ppm (NTP 1984). 
Exposure of mice to 625 ppm, 6 hours/day for 40 weeks resulted in pre-cancerous hyperplasia of the 
respiratory and gastrointestinal systems (epithelial hyperplasia), as well as a 19% reduction in thymus 
weight. Multi-site cancer was observed in mice after 13-52 weeks of exposure to 200 ppm for 
6 hours/day (NTP 1993). Hematological effects included decreased erythrocyte counts, hemoglobin 
concentration, and red blood cell volume in mice at 62.5 ppm and macrocytic megaloblastic anemia at 
200 ppm, administered 6 hours/day for 40 weeks (NTP 1993). Reproductive effects in mice were the 
most sensitive effects observed, with ovarian atrophy occurring at exposures of 200 ppm, 6 hours/day for 
40 weeks (NTP 1993). The most sensitive developmental effects observed were exencephalies, skull 
abnormalities, and late fetal death in the offspring of unexposed female mice mated with male mice 
exposed to 12.5 ppm for 10 weeks (Anderson et al. 1996).
The Agency has elected to not derive an intermediate-duration inhalation MRL for 1,3-butadiene due to 
the large species differences in the metabolism of 1,3-butadiene and the lack of chemical-specific data to 
adjust for these differences, which may result in the MRL overestimating the risk to humans.
Chronic-Duration Inhalation MRL. Chronic-duration exposures resulted in increased mortality in rats 
and mice exposed to 8,000 or 20 ppm, 6 hours/day for 2 years. Rats exposed to 8,000 ppm, 6 hours/day 
for 2 years exhibited increased lung weight and metaplasia and kidney nephrosis (Owen and Glaister 
1990; Owen et al. 1987). In mice, exposure to 1,250 ppm for 65 weeks resulted in nasal olfactory 
epithelial atrophy in mice (NTP 1984). Hepatic necrosis, forestomach epithelial hyperplasia, 
megaloblastic anemia, and endothelial hyperplasia of the heart were observed in mice exposed to 
625 ppm (6 hours/day, 5 days/week) for 61-65 weeks (NTP 1984, 1993); testicular atrophy and preputial 
gland hyperplasia were observed in mice exposed to 625 ppm for 2 years (NTP 1993). Ovarian atrophy 
was observed in mice exposed to 62.5 ppm for 65 weeks or 6.25 ppm for 2 years (NTP 1993); complete 
destruction of oocytes, follicles, and corpora lutea was also observed. Alveolar epithelial hyperplasia was 
observed in mice following a 2-year exposure to 6.25 ppm (NTP 1993). In addition to the noncancerous 
effects, mammary gland tumors developed in rats exposed to 1,000 ppm, 6 hours/day for 2 years (Owen
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and Glaister 1990; Owen et al. 1987), while multi-site cancer was observed in mice at 625 ppm,
6 hours/day for 61 weeks (NTP, 1984) and lung cancer occurred in mice following exposure to 6.25 ppm, 
6 hours/day for 2 years (NTP 1993).
Considerable species differences were observed in the chronic-duration studies in terms of observed 
effects and sensitivity. The lowest LOAEL in rats is 8,000 ppm for lung and kidney effects and the 
lowest LOAEL in mice is 6.25 ppm for ovarian and lung effects. Renal effects have not been observed in 
mice exposed to up to 625 ppm for 2 years (NTP 1993) and ovarian effects were not observed in rats 
exposed to concentrations as high as 8,000 ppm for 2 years (Owen et al. 1987). The differences in 
sensitivity and possibly critical targets are most likely related to species differences in 1,3-butadiene 
metabolism. As noted previously, mice produce substantially more DEB than rats; one study (Thornton- 
Manning et al. 1995b) found that peak tissue levels of DEB were 40-160-fold greater in mice than rats.
A comparison of blood DEB levels estimated from pyr-Val hemoglobin adduct levels found that at 
similar exposure levels (approximately 1 ppm), mouse DEB levels were 50 times higher than in rats and
1,000 times higher than in humans (Swenberg et al. 2011). In the absence of human data for 
noncarcinogenic effects following chronic exposure, the species differences in metabolism necessitate 
estimating human equivalent concentrations for each end point and comparing these values in order to 
identify the most likely critical target in humans. The available data provide strong evidence that the
1,3-butadiene metabolite, DEB, is the causative agent of the ovarian atrophy observed in mice (Doerr et 
al. 1996). Mechanistic data that could be used to identify relevant internal dose metrics for other sensitive 
end points in rats and mice were not identified, which precludes a comparison of human equivalent 
concentrations for each sensitive target. Thus, the Agency has elected to not derive a chronic-duration 
inhalation MRL for 1,3-butadiene; the lack of chemical-specific data to adjust for the large species 
differences in metabolism may result in the MRL overestimating the risk to humans.
Although ATSDR considers that the lack of data that can be used to evaluate the most sensitive target of 
chronic toxicity in humans precludes derivation of a chronic-duration inhalation MRL, the U.S. EPA 
(IRIS 2012), the Texas Commission on Environmental Quality (TCEQ) (Grant et al. 2010), and Kirman 
and Grant (2012) have derived chronic risk assessment values based on ovarian atrophy in mice. These 
three approaches share several commonalities, but also have several differences. All three approaches use 
a time-to-response benchmark dose (BMD) model; EPA and TCEQ used incidence data from the National 
Toxicology Program (NTP 1993) chronic mouse study and Kirman and Grant (2012) used incidence data 
from intermediate- and chronic-duration rat and mouse studies. The EPA approach did not make any 
adjustments for chemical-specific differences in metabolism. TCEQ derived chemical-specific
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uncertainty factors to account for species differences in DEB formation, whereas Kirman and Grant 
(2012) ran the BMD modeling using an internal dose metric for DEB. A summary of these risk 
assessment values are presented in Table 2-1 and a more detailed discussion of the three approaches 
follows.
EPA (IRIS 2012). In 2002, EPA derived a reference concentration (RfC) of 0.0009 ppm based on a 
BMCL10 of 0.88 ppm using the concentration-response data for ovarian atrophy in mice exposed to
1.3-butadiene for 2 years (NTP 1993) and an uncertainty factor of 1,000 (3 for interspecies extrapolation 
with dosimetric adjustments, 10 for intraspecies variability, 3 for incomplete database, and 10 for 
extrapolation to a level below the 10% effect level). The BMD modeling used the Weibull time-to- 
response model and incorporated the incidence data from the interim and final sacrifices; the data were 
modeled to include extra risk only until age 50 years. Human equivalent concentrations were calculated 
by adjusting the BMCL10 for intermittent exposure (6 hours/day, 5 days/week) and multiplying the 
adjusted BMCL10 by an RGDR (ratio of blood:gas partition coefficients) of 1.
Texas Commission on Environmental Quality (Grant et al. 2010). The TCEQ (Grant et al. 2010) 
derived a chronic reference value of 0.0154 ppm based on a BMCL05 of 0.462 ppm for ovarian atrophy in 
mice (NTP 1993) and a total uncertainty factor of 30. Similar to EPA, the Weibull time-to-response 
model was used for BMD analysis of the ovarian atrophy incidence data for mice exposed to
1.3-butadiene for 2 years (9- and 15-month interim sacrifice data were also included in the model). The 
component uncertainty factors were 1 for animal to human extrapolation, 10 for intraspecies variability, 
and 3 for database deficiencies (lack of a multigenerational reproductive study). Both the intraspecies and 
the interspecies uncertainty factors were divided into toxicokinetic and toxicodynamic components. For 
the intraspecies uncertainty factor, a default value of 3 was used to account for toxicodynamic factors 
because data are lacking on the key sequence of events and how DEB interacts in different subpopulations 
to produce ovarian atrophy; a toxicokinetic factor of 3 was used because metabolic genetic 
polymorphisms may account for differences in susceptibility of 2-3.5-fold in humans. For the 
interspecies uncertainty factor, 3 was used for toxicodynamic differences because data are not available 
on possible differences on how DEB would react in different species to produce ovarian atrophy; a 
toxicokinetic factor of 0.3 was selected to account for species differences in 1,3-butadiene metabolism. 
The basis of this 0.3 factor was: (1) a comparison of the levels of DEB-specific hemoglobin adduct (pyr- 
Val adduct) formation in mice and humans; (2) a comparison of total 1,3-butadiene metabolite levels in 
the blood; and (3) comparisons of DEB blood concentrations, DEB tissue levels, and blood area-under-
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Table 2-1. Summary of Available Chronic Risk Assessment Values for
1,3-Butadiene
Source
Source of data for 
benchmark
analysis POD
UF (UFL , 
UFa , UFh , 
UF d b ) Issues and considerations
EPA
(IRIS 2012)
2-Year mouse 
study (including 
interim sacrifices)
BM CL10: 1,000 The RfC does not have a chem ical-specific
0.88 ppm (10, 3, 10, 3) adjustment fo r the increased production of
DEB (reactive metabolite) in mice, as 
compared to humans.
TCEQ 2-Year mouse
(Grant et al. study (including 
2010) interim sacrifices)
BMCL05: S0
0.462 ppm (NA, 1, 10, S)
Does not take into consideration that ovarian 
atrophy may not be the most sensitive target 
in humans and that effects due to exposure 
to other reactive metabolites may occur at 
lower doses.
Accounts fo r species differences by 
quantifying toxicokinetic differences between 
mice and humans and selecting the low end 
o f the range as an uncertainty factor to 
account fo r interspecies toxicokinetic 
differences.
Kirman and 
Grant 2012
Intermediate and 
chronic rat and 
mouse studies
BMCL01 : 
1.5 ppm
10
(NA, S, 1, S)
Does not take into consideration that ovarian 
atrophy may not be the most sensitive end 
point in humans and that effects due to 
exposure to other reactive metabolites may 
occur at lower doses.
Accounts fo r species differences by 
including rat incidence data in BMD model 
and using pyr-Val hemoglobin adduct levels 
as a biom arker o f DEB levels.
Does not take into consideration that ovarian 
atrophy may not be the most sensitive end 
point in humans and that effects due to 
exposure to other reactive metabolites may 
occur at lower doses.
BMCL = 95% lower confidence limit of the benchmark concentration; BMD = benchmark dose;
DEB = 1,2:3,4-diepoxybutane; LOAEL = lowest-observed-adverse-effect level; NA = not applicable;
NOAEL = no-observed-adverse-effect level; POD = point of departure; RfC = reference concentration;
UF = uncertainty factor: UF l  = extrapolation from NOAEL to LOAEL; UFa  = extrapolation from animals to humans; 
UFh  = human variability; UFd b  = database limitations
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the-curve levels in rats and mice; these comparisons resulted in a range of toxicokinetic uncertainty 
factors of 0.01-0.2 and the value of 0.3 was selected.
Kirman and Grant (2012). Kirman and Grant (2012) based their RfC of 0.2 ppm on a BMCL0i of
1.5 ppm for ovarian atrophy and an uncertainty factor of 10 (3 for extrapolation from animals to humans 
and 3 for database deficiencies [lack of a multigenerational study and lack of dose-response data for 
follicle depletion]). A multi-stage Weibull time-to-response BMD model was applied to the combined 
dose-response data for ovarian atrophy in mice exposed for 2 years (including 40- and 65-week interim 
sacrifices (NTP 1993), mice exposed for 61 weeks (NTP 1984), mice exposed for 13 weeks (Bevan et al. 
1996), rats exposed for 2 years (Owen et al. 1987), and rats exposed for 13 weeks (Bevan et al. 1996). To 
account for species differences in the metabolism of 1,3-butadiene, the BMD model was run using blood 
DEB levels as the internal dose metric. Blood DEB levels were estimated using a multistep process that 
usedpyr-Val adduct burden as a biomarker for DEB levels. Pyr-Val adduct burdens were estimated using 
data on pyr-Val adduct efficiency (amount of adducts formed per ppm of 1,3-butadiene in air) in rats and 
mice as a function of 1,3-butadiene exposure concentration following a 4-week exposure (6 hours/day,
5 days/week). The estimated pyr-Val adduct burden were then used to calculate blood DEB 
concentrations using species-specific rate constants for the reaction of DEB with the terminal valine of 
hemoglobin and erythrocyte lifespan. For the time-to-response model, the exposure duration of interest 
was set equal to the window of susceptibility for ovotoxicity. Since the window of susceptibility is 
dependent on the number of follicles present at birth, the model was run for three scenarios: an average 
number of follicles at birth, the lower bound of central tendency for number of follicles, and the upper 
bound of the central tendency for the number of follicles; the range of susceptibility for depletion of 
follicle reserves for 95% of the population ranges from 8.5 higher and 8.5 lower than the average 
individual. The BMD model also included a 3-fold shift to account for toxicokinetic variation among 
humans. Since the model accounts for toxicokinetic and toxicodynamic differences in humans, no 
additional uncertainty factors were added to account for human variability.
Oral MRLs
There are no data available for effects in humans or animals exposed orally to 1,3-butadiene. For this 
reason, no acute-, intermediate-, or chronic-duration oral MRLs could be derived.
2. RELEVANCE TO PUBLIC HEALTH
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3. HEALTH EFFECTS
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of 1,3-butadiene. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
1,3-BUTADIENE
3. HEALTH EFFECTS
20
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 1,3-butadiene 
are indicated in Table 3-1 and Figure 3-1. Because cancer effects could occur at lower exposure levels, 
Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 1 in
10.000 to 1 in 1,000,000 (10-4 to 10-6), as developed by EPA.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
3.2.1.1 Death
Information on the lethality of 1,3-butadiene in humans is limited. A number of occupational exposure 
studies have examined mortality ratios in 1,3-butadiene workers, the results of these studies are discussed 
in subsequent sections on the primary effects.
No deaths were seen in B6C3F1 mice exposed to <8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week, for 
2 weeks (NTP 1984). The majority of rabbits died when exposed to 250,000 ppm 1,3-butadiene for an 
average of 23 minutes (Carpenter et al. 1944). The LC50 values calculated for mice and rats exposed for 
2 and 4 hours, respectively, was 122,000 and 129,000 ppm, respectively (Shugaev 1969).
Intermediate-duration exposures produced no deaths in rats exposed for 6 hours/day, 5/days/week, for 
13 weeks to 8,000 ppm (Crouch et al. 1979), or in rats, guinea pigs, rabbits, and dogs during 8 months of 
exposure to 6,700 ppm (Carpenter et al. 1944). Increased mortality was seen in mice exposed to
5.000 ppm, but not 2,500 ppm, for 6 hours/day, 5 days/week, for 14 weeks (NTP 1984). The lowest
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intermediate-duration exposure resulting in death was observed in mice receiving 200 ppm for
6-hours/day, 5 days/week, for 40 weeks (NTP 1993), ostensibly from the early development of 
neoplasms.
During chronic exposure to 625 and 1,250 ppm of 1,3-butadiene for 61 weeks, significantly increased 
mortality, primarily due to cancer, was found in B6C3F1 mice (NTP 1984). Similar results were obtained 
in another study using a much lower concentration (20 ppm) (NTP 1993). Exposure of rats to 8,000 ppm
1.3-butadiene resulted in statistically significant increased mortality from cancer when compared with 
controls (Owen et al. 1987). The LC50 values and all reliable LOAEL values for death in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.2 Systemic Effects
Respiratory Effects. Workers exposed to 1,3-butadiene gas during the manufacture of rubber 
complained of irritation of the eyes, nasal passages, throat, and lungs (Wilson 1944). In some, coughing, 
fatigue, and drowsiness developed. All symptoms disappeared on removal from the gas. The associated 
exposure levels were not reported.
No effects in respiratory tissues were observed in rats, guinea pigs, rabbits, or dogs inhaling up to 
6,700 ppm 1,3-butadiene for 7.5 hours/day, 6 days/week, for 8 months (Carpenter et al. 1944) or in rats or 
mice exposed to 8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week, for 13-14 weeks (Crouch et al. 
1979; NTP 1984). No effects were observed in lungs of mice exposed to concentrations as high as 
625 ppm for 6 hours/day, 5 days/week, for 9 months (NTP 1993).
An increase in chronic inflammation of the nasal cavity, fibrosis, cartilaginous metaplasia, osseous 
metaplasia, atrophy of the sensory epithelium, and hyperplasia of the respiratory epithelium were 
observed in mice exposed to 1,250 ppm for 2 years (NTP 1984). Lungs of rats exposed chronically to
8,000 ppm 1,3-butadiene exhibited metaplasia (Owen and Glaister 1990; Owen et al. 1987). Atrophy of 
the nasal olfactory epithelium was observed in mice exposed to concentrations as high as 1,250 ppm
1.3-butadiene for 6 hours/day, 5 days/week, for 61 weeks (NTP 1993), while alveolar epithelial 
hyperplasia (a possible precancerous lesion) occurred in mice exposed to 6.25 ppm 6 hours/day,
5 days/week for 2 years (NTP 1993).
Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation
Exposure/
D uration /
Key to  Species
F igure (Strain) (Route)
LOAEL
System
NOAEL
(ppm )
Less Serious 
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
ACUTE EXPOSURE
Death
1 Rat 1 d 
4 h/d 129000 (LC50)
S hugaev1969
2 Mouse 1 d
2h/d 122000 (LC50) S hugaev1969
Rabbit
System ic
4 Rat
1 d
23 min/d
10 d 
6 hr/d 
Gd 6-15
Bd Wt 200 F (decreased maternal 
body weight gain)
250000
8000 F (45% decreased
maternal body weight 
gain)
Carpenter et al. 1944
Irvine 1981
N euro log ica l
5 Human 1 d
6-8 hr/d 8000
Carpenter et al. 1944
6 Rabbit
R eproductive
7 Mouse 
(B6C3F1)
1 d
23 min/d
5 d
6 h/d
250000 (anesthesia)
1000 M (73% increase in number 
of abnormal sperm 
heads)
Carpenter et al. 1944
DOE/NTP 1988a
3
Mouse 5 days1 y 200 M (increased intrauterine DOE/NT P 1988b
CD-1 5 days death)
8
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
System
NOAEL
(ppm )
Less Serious 
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
D evelopm enta l
9 Rat
(Sprague-
Dawley)
10 d 
6 hr/d 
Gd 6-15
1000 DOE/NTP 1987a
10 Rat 10 d 
6 hr/d 
Gd 6-15
200 8000 (decreased fetal growth)
1000 (major skeletal 
malformations)
Irvine 1981
11 Mouse 
(CD-1)
10 d 
6 hr/d 
GD 6-15
40 M (decreased fetal BW in 
males)
DOE/NTP 1987b
INTERMEDIATE EXPOSURE
Death
12 Mouse 14 wk
5 d/wk
6 hr/d
5000 (increased mortality) NTP 1984
13 Mouse
(B6C3F1)
13-52 wk 
6 hr/d 
5 d/wk
200 (increased mortality from NTP 1993  
40 weeks of exposure)
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
System
NOAEL
(ppm )
Less Serious 
(ppm)
LOAEL
Serious
(ppm )
Reference 
C hem ical Form C om m ents
S ystem ic
14 Rat
15 Mouse
13 wk
5 d/wk
6 hr/d
Resp 8000
Cardio 8000
Hemato 8000
Musc/skel 8000
Hepatic 8000
Renal 8000
Dermal 8000
Ocular 8000
3-24 wk 
6 d/wk Hemato
6 hr/d
Crouch et al. 1979
1250 M (macrocytic
megaloblastic anemia 
starting at 6 weeks)
Irons et al. 1986a, b
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
System
NOAEL
(ppm )
LOAEL
Less Serious 
(ppm)
Serious
(ppm)
Reference 
C hem ical Form C om m ents
16 Mouse 14 wk
5 d/wk
6 hr/d
Resp 8000
Cardio 8000
Gastro 8000
Musc/skel 8000
Hepatic 8000
Renal 8000
Dermal 8000
Bd Wt 1250 2500 M (13% decreased body 
weight)
NTP 1984
17 Mouse 13-52 wk
(B6C3F1) 6 hr/d
5 d/wk
Resp 200 M (alveolar epithelial 
hyperplasia after 40 
weeks)
NTP 1993
Cardio 200 M (endothelial hyperplasia 
after 40 weeks)
Ocular 200 M 625 M (Harderian gland
hyperplasia after 26 
weeks)
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
E xposure/
D ura tion /
Key to  Species
F igure (Strain) (Route)
NOAEL 
System  (ppm )
LOAEL
Less Serious
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
18 Mouse 40 wk
(B6C3F1) 6 hr/d
5 d/wk
Resp 200 M 625 M (alveolar epithelial
hyperlasia)
NTP 1993
Cardio
Gastro
625
200 625 (forestomach epithelial 
hyperplasia)
Hemato 62.5 M (decreased erythrocyte 
counts, hemoglobin 
concentration, and red 
cell volume)
200 F (macrocytic
megaloblastic anemia)
Im m uno/ Lym phore t
19 Mouse
(B6C3F1)
40 wk 
6 hr/d 
5 d/wk
Musc/skel 625
Hepatic 625 F
Bd Wt 625
625 F (19% reduction in relative 
thymus weight)
NTP 1993
20 Mouse 6-24 wk
5 d/wk
6 hr/d
1250 (lymphoid organ 
histopathology)
Thurmond et al. 1986
N euro log ica l
21 Rat 13 wk
5 d/wk
6 hr/d
8000 Crouch et al. 1979
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D ura tion /
F requency
(Route)
LOAEL
System
NOAEL
(ppm)
Less Serious
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
22 Mouse
R eproductive
2 3  Mouse 
(CD)
14 wk
5 d/wk
6 hr/d
10 wk 
6 h/d 
5 d/wk
8000 NTP 1984
12.5 M (increase in late fetal Anderson et al. 1996 
deaths, exencephalies, 
and skull abnormalities)
2 4  Mouse 
(CD)
4 wk 
6 h/d
5 d/wk
12.5 M 65 M (increases in early fetal
deaths)
Anderson et al. 1998
25 Mouse 
(B6C3F1)
Cancer
26 Mouse 
(B6C3F1)
40 wk 
6 hr/d 
5 d/wk
13-52 wk 
6 hr/d 
5 d/wk
62.5 F 200 F (ovarian atrophy) NTP 1993
200 M (CEL:lymphocytic NTP 1993
lymphoma, histiocytic 
sarcoma, cardiac 
hemangiosarcoma, 
alveolar/bronchiolar 
adenoma/carcinoma, 
forestomach squamous 
cell papilloma/carcinoma, 
hepatocellular adenoma,
Harderian gland 
adenoma/adenocarcinoma 
preputial gland 
carcinoma)
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
LOAEL
System
NOAEL
(ppm )
Less Serious 
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
CHRONIC EXPOSURE
Death
27 Rat 105-111 wk
5 d/wk
6 hr/d
1000 8000 (increased mortality) Owen et al. 1987, Owen and 
Glaister 1990
28 Mouse 61 wk
5 d/wk
6 hr/d
625 (increased mortality) NTP 1984
2 9  Mouse 2 yr
(B6C3F1) 6 hr/d
5 d/wk
S ystem ic
30 Rat 105-111 wk
5 d/wk
6 hr/d
20 (increased mortality)
Resp 1000 8000 (increased organ weight,
metaplasia)
NTP 1993
Owen et al. 1987, Owen and 
Glaister 1990
Cardio
Gastro
Hemato
Hepatic
Renal
Dermal
Ocular
8000
8000
8000
8000
1000
8000
8000
8000 (nephrosis)
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
E xposure/
D ura tion /
F requency
(Route)
LOAEL
System
NOAEL
(ppm )
Less Serious
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
31 Mouse 61 wk
5 d/wk
6 hr/d
Resp 625 1250 (atrophy o f nasal
olfactory epithelium)
NTP 1984
Cardio
Gastro
Musc/skel
Hepatic
Renal
Dermal
1250
1250
1250
625 (endothelial hyperplasia) 
625 (epithelial hyperplasia)
625 (hepatic necrosis)
32 Mouse 2 yr
(B6C3F1) 6 hr/d
5 d/wk
Resp 6.25 M (alveolar epithelial 
hyperplasia)
NTP 1993
Cardio 200 625 (endothelial hyperplasia)
Gastro 625 F (forestomach epithelial
hyperplasia)
200 F (forestomach epithelial 
hyperplasia)
Musc/skel 625
Hepatic
Bd Wt 625
62.5 (liver necrosis)
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
Exposure/
D uration /
F requency
(Route)
System
NOAEL
(ppm)
LOAEL
Less Serious 
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
33 Mouse
(B6C3F1)
65 wk 
6 hr/d 
5 d/wk
Hemato 200 625 (macrocytic NTP 1993
megaloblastic anemia)
N euro log ica l
34 Rat 105-111 wk
5 d/wk
6 hr/d
Bd Wt 625
8000 Owen et al. 1987, Owen and 
Glaister 1990
3 5  Mouse
R eproductive
36 Rat
61 wk
5 d/wk
6 hr/d
105-111 wk
5 d/wk
6 hr/d
1250
8000
NTP 1984
Owen et al. 1987, Owen and Only examined 
Glaister 1990 histopathology
3 7  Mouse 61 wk
5 d/wk
6 hr/d
625 (gonadal atrophy) NTP 1984
3 8  Mouse 2 yr
(B6C3F1) 6 hr/d
5 d/wk
6.25 F (ovarian atrophy) NTP 1993
3 9  Mouse 65 wk
(B6C3F1) 6 hr/d
5 d/wk
20 F 62.5 F (ovarian atrophy) NTP 1993
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Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (continued)
Key to Species
Figure (Strain)
E xposure/
D ura tion /
F requency
(Route)
LOAEL
System
NOAEL
(ppm )
Less Serious 
(ppm)
Serious
(ppm )
Reference 
C hem ical Form C om m ents
Cancer
40 Rat 105-111 wk
5 d/wk
6 hr/d
1000 (CEL: mammary gland Owen et al. 1987, Owen and
adenoma and sarcoma) Glaister 1 " 0
41 Mouse 61 wk
5 d/wk
6 hr/d
625 (CEL:alveolar/bronchiolar NTP 1984 
adenoma or carcinoma, 
malignant lymphoma, 
hemangiosarcoma, 
forestomach squamous 
cell papilloma or 
carcinoma, mammary 
gland carcinoma, ovarian 
granulosa cell tumor)
42 M 6C 3F1) 6 hi/d 6 2 5  F (C E L  NTP 1993(B6C3F1) 56 dh/rw/dk alveolar/bronchiolar
adenoma/carcinoma)
a The number corresponds to entries in Figure 3-1.
Bd W t = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); F = Female; Gastro = gastrointestinal; Gd = gestational day; Hemato = hematological; hr = 
hour(s); Immuno/Lymphoret = immunological; LC50 = lethal concentration, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); Musc/skel = 
musculoskeletal; NOAEL = no-observed-adverse-effect level; Resp = respiratory; wk = week(s); yr = year(s)
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Figure 3-1 Levels of Significant Exposure to 1,3-Butadiene - Inhalation
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Figure 3-1 Levels of Significant Exposure to 1,3-Butadiene - Inhalation (Continued)
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Figure 3-1 Levels of Significant Exposure to 1,3-Butadiene - Inhalation (Continued)
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Cardiovascular Effects. In a retrospective epidemiological study of middle-aged workers in the 
rubber industry, excessive mortality was noted for certain types of cardiovascular diseases, mainly 
chronic rheumatic and arteriosclerotic heart diseases (McMichael et al. 1974). Furthermore, increased 
mortality for arteriosclerotic heart disease was reported among black males in the rubber industry 
(Matanoski and Schwartz 1987). This result was also reported in an update of the original study 
(Matanoski et al. 1988, 1990). However, increased mortality from cardiovascular disease was not 
observed in three other cohorts of SBR and 1,3-butadiene monomer workers (Cowles et al. 1994; Divine 
and Hartman 1996, 2001; Ward et al. 1995). Thus, it is unclear if cardiovascular disease is likely to be 
caused by 1,3-butadiene exposure.
No cardiovascular lesions were found in mice or rats exposed to 8,000 ppm 1,3-butadiene 6 hours/day,
5 days/week, for 13-14 weeks (Crouch et al. 1979; NTP 1984). Endothelial hyperplasia in the heart (an 
early preneoplastic lesion) was observed in mice after exposure to 200 ppm for 6 hours/day, 5 days/week 
for 40 weeks (NTP 1993) or 625 ppm 6 hours/day, 5 days/week for 61 weeks or 2 years (NTP 1984, 
1993). No exposure-related histopathological cardiac lesions were found in rats exposed chronically to 
up to 8,000 ppm for 2 years (Owen et al. 1987).
Gastrointestinal Effects. No studies were located regarding noncancer gastrointestinal effects in 
humans after inhalation exposure to 1,3-butadiene.
No significant incidences of gastrointestinal tract lesions were observed in mice following exposure to
8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week, for 14 weeks (NTP 1984) or 200 ppm for
6 hours/day, 5 days/week for 40 weeks (NTP 1993). In a chronic-duration study, high incidences of 
forestomach epithelial hyperplasia (a possible preneoplastic lesion) were observed in mice exposed to 
625 ppm for 6 hours/day, 5 days/week for 61 weeks (Melnick et al. 1990a; NTP 1984) and for 2 years 
(NTP 1993). No exposure-related nonneoplastic gastrointestinal lesions were found in rats exposed 
chronically to up to 8,000 ppm for 6 hours/day, 5 days/week for 2 years (Owen et al. 1987).
Hematological Effects. A hematological survey of workers at a styrene-butadiene rubber plant 
revealed little indication of bone marrow toxicity among the workers (Checkoway and Williams 1982). 
Styrene and 1,3-butadiene were the most significant chemicals in the atmosphere; benzene and toluene 
were present in much lower concentrations. A group of eight tank farm workers (workers who load and 
unload chemicals from storage tanks; mean level exposure of 20 ppm) demonstrated slightly lower levels
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of red blood cells, hemoglobin, platelets, and neutrophils compared with other workers, but these findings 
were within the normal range. Tsai et al. (2005) examined a number of hematological end points in a 
petrochemical production facility in which the current time-weighted average (TWA) 1,3-butadiene 
exposure level was 0.25 ppm; prior to 1997, the TWA concentration was 4.55 ppm. As compared to 
unexposed controls, no significant alterations in total or differential leukocyte levels, erythrocyte levels, 
hemoglobin levels, mean corpuscular volume, or platelet levels were found. An older study of workers 
from one of the facilities examined by Tsai et al. (2005) also found no significant alterations in total and 
differential leukocyte levels, erythrocyte levels, hemoglobin levels, platelet levels, or mean corpuscular 
volume (Cowles et al. 1994); the mean 1,3-butadiene concentration was 3.5 ppm.
No signs of blood dyscrasias were found among 164 animals (rats, rabbits, guinea pigs, dogs) exposed to 
concentrations up to 6,700 ppm of 1,3-butadiene for 8 months (Carpenter et al. 1944). The results were 
supported by a 3-month study in which no effects on hematological indices were found in rats after 
exposure to 8,000 ppm of 1,3-butadiene (Crouch et al. 1979).
A treatment-related macrocytic megaloblastic anemia was observed in B6C3F1 and NIH mice exposed to 
1,250 ppm 1,3-butadiene for 6 hours/day, 6 days/week for 6-24 weeks, but not after a 3-week exposure to 
the same concentration (Irons et al. 1986a, 1986b). The bone marrow damage was expressed as reduced 
numbers of red blood cells, decreased hemoglobin concentration and hematocrit, and increased mean 
corpuscular volume of circulating erythrocytes. The changes were observed in both strains, 
independently of the occurrence of murine leukemia viruses in the animals. Male mice exposed to 
>62.5 ppm for 6 hours/day, 5 days/week for 40 weeks exhibited decreased red blood cell counts, 
hemoglobin concentration, and hematocrit (NTP 1993). Leukopenia and lymphopenia occurred at 
>200 ppm. Females exhibited macrocytic megaloblastic anemia and bone marrow atrophy after exposure 
to 200 and 625 ppm, respectively, 6 hours/day, 5 days/week for 40 weeks (NTP 1993).
Macrocytic megaloblastic anemia and bone marrow hyperplasia was also observed in mice exposed 
chronically to 625 ppm 1,3-butadiene 6 hours/day, 5 days/week for 65 weeks (NTP 1993). Surviving 
females, but not males, in this study exhibited increased bone marrow cellularity.
In contrast to the findings in mice, no effects on hematology or blood chemistry of Sprague-Dawley rats 
were observed after exposure to 1,000 and 8,000 ppm of 1,3-butadiene for 105-111 weeks (Owen et al. 
1987).
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Musculoskeletal Effects. No studies were located regarding musculoskeletal effects of 1,3-buta­
diene in humans after inhalation exposure.
No musculoskeletal effects were observed in mice and rats exposed to 8,000 ppm 1,3-butadiene 
6 hours/day, 5 days/week for 13-14 weeks (Crouch et al. 1979; NTP 1984) or in mice exposed to 
625 ppm 6 hours/day, 5 days/week from 40 or 65 weeks or 2 years (NTP 1993).
Hepatic Effects. No studies were located regarding hepatic effects of 1,3-butadiene in humans after 
inhalation exposure.
No histopathological changes in livers of rats (Crouch et al. 1979) or mice (NTP 1984) were found after 
intermediate-duration exposure to 1,3-butadiene. The relative liver weights of both sexes of Sprague- 
Dawley rats were elevated after the chronic exposure to 1,3-butadiene (1,000 and 8,000 ppm); however, 
this finding was not associated with any pathological changes (Owen et al. 1987). Mice exposed to 
>625 ppm 6 hours/day, 5 days/week for 61 weeks had a significant increase in liver necrosis (NTP 1984).
Renal Effects. No studies were located regarding renal effects in humans after inhalation exposure to
1,3-butadiene.
The results of urinalysis in 164 animals, including rats, guinea pigs, rabbits, and dogs were all normal 
after an 8-month exposure to concentrations up to 6,700 ppm of 1,3-butadiene (Carpenter et al. 1944), but 
the methods were poorly described. These results were supported, however, in rats after 13 weeks of 
exposure to concentrations up to 8,000 ppm of 1,3-butadiene (Crouch et al. 1979). Nephrosis was found 
among male rats after 111 weeks of exposure to 8,000 ppm, but not 1,000 ppm, of 1,3-butadiene (Owen 
et al. 1987). No non-neoplastic renal lesions were observed in mice exposed to 8,000 ppm 6 hours/day,
5 days/week for 14 weeks (NTP 1984) or 625 ppm 6 hrs/day, 5 days/week, for 40 weeks to 2 years.
Dermal Effects. No studies were located regarding dermal effects in humans after inhalation exposure 
to 1,3-butadiene.
No histopathological dermal changes were found in rats or mice after 13-14 weeks exposure to
8,000 ppm 1,3-butadiene (Crouch et al. 1979; NTP 1984), in rats after 111 weeks exposure to 8,000 ppm 
(Owen et al. 1987), or in mice after 40 weeks to 2 years exposure to 625 ppm (NTP 1993).
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Ocular Effects. Two men reported slight irritation of the eyes and difficulty in focusing on instrument 
scales during 6-7 hours exposure to 2,000 and 4,000 ppm 1,3-butadiene (Carpenter et al. 1944).
Ophthalmologic examination of the eyes of dogs and rabbits disclosed no signs of injury during the 
course of exposure to up to 6,700 ppm 1,3-butadiene for 8 months (Carpenter et al. 1944). After the 
termination of the experiment, histological examination revealed that the sclera, cornea, and ciliary body 
were normal. Sections of the optic nerve with adjacent retina showed no myelin sheath degeneration. 
Although the ophthalmological examination was described in detail, the study was limited by the small 
number of animals used.
No histopathological ocular changes were found in rats or mice after 13-14 weeks exposure to 8,000 ppm 
(Crouch et al. 1979; NTP 1984) or in rats after 111 weeks exposure to 8,000 ppm 1,3-butadiene (Owen 
et al. 1987). Increased Harderian gland hyperplasia (a precancerous lesion) was observed in male mice 
exposed to >62.5 ppm 6 hours/day, 5 days/week for 65 weeks and 2 years (NTP 1993); this effect is not 
relevant to humans because they do not have Harderian glands.
Body W eight Effects. Body weights were reduced by 13% in male mice exposed to 2,500 ppm
1,3-butadiene 6 hours/day, 5 days/week for 14 weeks, but were not significantly different from controls 
when exposed to 1,250 ppm 6 hours/day, 5 days/week for 61 weeks or when exposed to 625 ppm 
6 hours/day, 5 days/week for 2 years (NTP 1993)
3.2.1.3 Immunological and Lymphoreticular Effects
No studies were located regarding immunological effects of 1,3-butadiene in humans after inhalation 
exposure.
After 3-21 weeks of exposure to 1,250 ppm 1,3-butadiene, an increased expression of murine leukemia 
virus (MuLV) was observed in hematopoietic tissues of B6C3F1 mice, but not in NIH mice (Irons et al. 
1987a). Furthermore, altered regulation of the stem cell development in B6C3F1 mice was reported after 
a similar exposure (Leiderman et al. 1986).
Intermediate-duration exposure of female mice to 62.5 ppm 1,3-butadiene 6 hours/day, 5 days/week for 
40 weeks resulted in a 17% reduction in relative spleen weight, while exposure to 625 ppm for the same
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duration resulted in a 19% reduction in thymus weight (NTP 1993). By 65 weeks, relative spleen weights 
in 625 ppm females had increased to 57% higher than controls.
Immunological changes were detected after evaluation of specific humoral and cell-mediated immunity in 
B6C3F1 mice exposed to 1,250 ppm 1,3-butadiene for 6, 12, or 24 weeks (Thurmond et al. 1986). 
Suppression of cytotoxic T-lymphocyte generation to mastocytoma cells was observed after 6 weeks, but 
recovered after 12 weeks of exposure. The histological examination of lymphoid organs showed 
depressed spleen cellularity after 24 weeks of exposure; this value is recorded as a LOAEL for 
immunological effects in Table 3-1 and plotted in Figure 3-1, although it is not known how these changes 
affect immunocompetency.
3.2.1.4 Neurological Effects
Psychomotor responses of two men inhaling 2,000, 4,000, or 8,000 ppm 1,3-butadiene for 6-8 hours/day 
on different days were evaluated by Carpenter et al. (1944). At the two higher concentrations, the 
subjects performed a steadiness test; at the highest concentration, a tapping rate test was also performed. 
Results after 1,3-butadiene exposure were identical to those obtained before exposure.
Rabbits exposed to 250,000 ppm of 1,3-butadiene went through all stages of anesthesia to death in the 
average time of 23 minutes (Carpenter et al. 1944). Less than 2 minutes of exposure was required for loss 
of motor and labyrinth reflexes.
No effects on erythrocyte or brain cholinesterase or on neuromuscular function tests were found in rats 
exposed to up to 8,000 ppm for 13 weeks (Crouch et al. 1979). In intermediate and chronic exposure 
studies in mice and rats, no treatment-related histopathological lesions were found in organs and tissues of 
the nervous system (brain, spinal cord, sciatic nerves) (Crouch et al. 1979; NTP 1984; Owen and Glaister 
1990; Owen et al. 1987). Tests results for neurological function (i.e., loss of balance on a rotating cone) 
were possibly confounded by the mammary tumors interfering with the mobility of rats (NTP, 1984).
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.5 Reproductive Effects
No studies were located regarding reproductive effects in humans after inhalation exposure to 1,3-buta­
diene. A concentration-related increase in the incidence of sperm-head abnormalities occurred in
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B6C3F1 mice after exposure to 1,000 (73% increase) and 5,000 ppm (129% increase) of 1,3-butadiene 
6 hours/day for 5 days (DOE/NTP 1988a). No impairment of fertility was noted when groups of male 
and female rats, rabbits, or guinea pigs were exposed to <6,700 ppm 1,3-butadiene (Carpenter et al.
1944).
No treatment-related histopathological effects were seen in reproductive organs of rats or mice exposed to
8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week for 13-14 weeks (Crouch et al. 1979; NTP 1984). 
Reduction in the number of round and elongated sperm heads was seen in mice exposed to 130 ppm 
6 hours/day, 5 days/week for 4 weeks, but this was not associated with changes in fertility (Anderson et 
al. 1998). Ovarian and uterine atrophy occurred in female mice exposed to 200 ppm 6 hours/day,
5 days/week for 40 weeks (NTP 1993), while testicular atrophy was seen in male mice exposed to 
625 ppm for the same duration. Exposure of female mice to 62.5 or >6.25 ppm 1,3-butadiene
6 hours/day, 5 days/week for 65 weeks or 2 years, respectively, resulted in an increased incidence of 
ovarian atrophy (NTP 1993). Affected females had no evidence of oocytes, follicles, or corpora lutea.
An increase in testicular atrophy and preputial gland hyperplasia was observed in males only after 
exposure to 625 ppm 6 hours/day, 5 days/week for 2 years (NTP 1993). In contrast, no histological 
alterations were observed in the gonads of rats exposed to up to 8,000 ppm 6 hours/day, 5 days/week for 
2 years (Owen et al. 1987).
In untreated female mice mated with males exposed to >200 ppm 6 hours/day for 5 days, a significant 
increase in the number of females with two or more intrauterine deaths were observed (DOE/NTP 1988b). 
This effect was only observed in animals mated during the first week post-exposure. Additional effects 
included increases in early implantation loss at 1,000 ppm during the first post-week of exposure and at 
200 and 1,000 ppm during the second week post-exposure; implantation losses were not significantly 
increased in the mice exposed to 5,000 ppm. Early fetal death was also observed in untreated female 
mice mated to males exposed to 65 ppm for 6 hours/day, 5 days/week for 4 weeks (DOE/NTP 1988a). 
Fetal toxicity was observed following the mating of untreated female mice with males exposed to
12.5 ppm 1,3-butadiene 6 hours/day, 5 days/week for 10 weeks (Anderson et al. 1996). Observed effects 
included an increase in late fetal death, exencephaly, and skull abnormalities.
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3.2.1.6 Developmental Effects
No studies were located regarding developmental effects in humans after inhalation exposure to 1,3-buta­
diene.
When exposed to concentrations up to 8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week during 
GDs 6-15, Sprague-Dawley rats showed signs of dose-related maternal and fetal toxicity (Irvine 1981). 
Depressed body weight gain among dams was observed at >200 ppm, and fetal growth (body weight and 
crown-rump length) was significantly decreased in the 8,000 ppm group. A significant increase in the 
number of litters with fetuses showing minor skeletal defects was observed at 200 ppm, but not at
1.000 or 8,000 ppm; however, an increase in the number of fetuses with irregular ossification was 
observed at 8,000 ppm. Significant increases in the number of litters with fetuses showing major skeletal 
defects were observed at 1,000 and 8,000 ppm. The majority of the major skeletal defects were wavy 
ribs; abnormalities of the skull, spine, sternum, long bones, and ribs were also observed at 8,000 ppm. A 
significant increase in the number of litters with fetuses showing minor external/visceral defects was 
observed at 1,000 ppm, but not at 8,000 ppm. In a study in which female Sprague-Dawley rats were 
exposed to 40-1,000 ppm during GDs 6-15 (DOE/NTP 1987a), some skeletal abnormalities and 
ossification reductions were found in the fetuses, but were not statistically significant and were not 
considered to be treatment-related. In mice, a 5-23% decrease in fetal body weight gain, primarily 
among male mice, was observed after exposure of dams during GDs 6-15 to 40-1,000 ppm 1,3-buta­
diene. The magnitude of the decreased fetal body weight in males was 5, 18, and 23% in the 40, 200, and
1.000 ppm groups, respectively. The investigators reported that the decreased fetal body weight was 
statistically significant in males at all dose levels; however, the statistical method used (ANOVA) did not 
account for differences in litter size. Increased incidences of extra ribs and reduced ossification of 
sternebrae were found in fetuses from groups exposed to 200 ppm and 1,000 ppm, respectively 
(DOE/NTP 1987b).
The highest NOAEL value and all reliable LOAEL values for developmental effects in rats for the acute 
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.7 Cancer
Retrospective epidemiological studies of mortality among workers in the rubber industry were conducted 
in SBR (polymer) production workers and 1,3-butadiene monomer workers. For SBR workers, the 
primary cohort is comprised of largely overlapping cohorts from multiple SBR facilities in the United
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States and Canada examined by investigators at John Hopkins (Matanoski and Schwartz 1987; Matanoski 
et al. 1989b, 1990) and the University of Alabama at Birmingham (Cheng et al. 2007; Delzell et al. 1996; 
Graff et al. 2005; Macaluso et al. 1996; Sathiakumar et al. 2005, 2007). Mortality among three 
independent cohorts of male 1,3-butadiene monomer production workers has been studied and updated on 
several occasions, including cohorts from Union Carbide (Ward et al. 1995), Texaco (Divine 1990;
Divine et al. 1993), and Shell (Cowles et al. 1994).
Matanoski et al. 1990 (in an update of the Matanoski and Schwartz 1987 cohort) found increased 
standardized mortality ratios (SMRs) of 532 (1 case), 656 (95% confidence interval [CI]=135-1,906), and 
482 (95% CI=59-1,762) for lymphosarcoma, leukemia, and other lymphatic neoplasms, respectively, in 
black SBR production workers; white workers exhibited an SMR of 230 (95% CI=92-473) for other 
lymphatic neoplasms. In white maintenance workers, SMRs of 144 (95% CI=53-314) and 166 (95% 
CI=93-275) were observed for esophageal and stomach cancer, respectively. An odds ratio of 9.4 for 
leukemia was observed in SBR workers in a nested case-control study of the Matanoski and Schwartz 
(1987) cohort of SBR workers (Matanoski et al. 1989b). No such association was found for exposure to 
styrene. Several investigators at the University of Alabama at Birmingham examined cancer mortality in 
a cohort of over 15,000 North American SBR workers (Cheng et al. 2007; Delzell et al. 1996; Graff et al. 
2005; HEI 2006; Macaluso et al. 1996; Sathiakumar et al. 2005, 2007). Delzell et al. (1996) found 
increased SMRs for leukemia of 265 (95% CI=141-453) for maintenance and 431 (95% CI=207-793) for 
laboratory workers. Macaluso et al. (1996) derived a relative rate value of 4.5 for leukemia development 
(no confidence interval reported) associated with a cumulative exposure of 80 ppm-years. In an update of 
these studies (Sathiakumar et al. 2005), an increase in deaths from all types of leukemia (SMR of 258; 
95% CI=156-403) was found among hourly employees with 20-29 years since hire and >10 years of 
employment. Increases in leukemia deaths were also found among workers in the polymerization (SMR 
of 204; 95% CI=121-322), maintenance labor (SMR of 326; 95% CI=178-456), and laboratory (SMR of 
326; 95% CI=178-546) operations. However, no increases in a specific type of leukemia were found. 
Similarly, Graff et al. (2005) reported increased relative risks for leukemia of 2.9 (95% CI=1.4-6.4) and
3.7 (95% CI=1.7-8.0) among workers with cumulative 1,3-butadiene exposures of 184.7-<435.0 and
425.0 ppm-years. When the relative risks were adjusted for exposure to styrene and dimethyldithio- 
carbamate, age, and years since hire, only the highest cumulative exposure group had a confidence 
interval that included 1 (relative risk of 3.0, 95% CI=1.0-9.2). When workers were divided into two 
categories based on exposure to >100 and <100 ppm, associations between 1,3-butadiene cumulative 
exposure and leukemia were found for both groups, although the association was weaker at the lower 
concentration (relative risk of 2.0; 95% CI=0.6-6.0 for cumulative exposure to >124.7 ppm-years) than at
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the higher concentration (relative risk of 3.7; 95% CI= 1.3-11.1 for cumulative exposure of >247.6 ppm- 
years) and the trend was only statistically significant in the >100 ppm workers (HEI 2006). A more 
recent paper by Graff and associates (Graff et al. 2009) used uncertainty analysis to evaluate the impact of 
potential exposure estimate inaccuracies on the leukemia relative risks. The investigators concluded that 
analysis of the complete probability distribution of 1,3-butadiene exposure estimate supported the 
association between 1,3-butadiene cumulative exposure and increased leukemia risk. Using personal 
monitoring device data collected from 1977 to 1991, Sathiakumar et al. (2007) compared measured
1.3-butadiene levels with estimated levels. The mean measured 1,3-butadiene level (across all years and 
job categories) was 5.2 ppm and the mean estimated concentration was 4.7 ppm; the estimated
1.3-butadiene levels tended to underestimate concentrations that were greater than 7 ppm. Cheng et al.
(2007) found a significant trend for the association of leukemia in SBR workers and increasing 
cumulative exposure or number of “peak” exposures (>100 ppm). They also reported a minimal 
association (relative rate of 1.03) of leukemia in SBR workers receiving an estimated 5 ppm
1.3-butadiene exposure for 20 years (100 ppm-years). Examination of possible associations between
1.3-butadiene exposure and increased deaths from other cancer types, including non-Hodgkin’s 
lymphoma, Hodgkin’s lymphoma, and multiple myeloma were not found in this cohort (HEI 2006). 
Increases in the risk of colorectal and prostate cancer were observed in some subgroups of SBR workers; 
however, no consistent exposure-response trends were found (HEI 2006).
These results in SBR workers with 1,3-butadiene exposure are supported by studies in 1,3-butadiene 
monomer production workers. Downs et al. (1987) calculated an SMR of 235 (no CI reported) for 
lymphosarcoma and reticular cell sarcoma. No increase in mortality from cancer of gastrointestinal, 
respiratory, urinary, and skeletal systems was associated with monomer exposure. Divine (1990) and 
Divine et al. (1993) reported similar results in a follow-up study of this cohort (SMR of 452 [95% 
CI=165-984]) for lymphosarcoma. Divine and Hartman (2001) followed this cohort for an additional 
5 years and found a statistically significant increase in SMR (141; 95% CI=105-186) for all 
lymphohematopoietic cancer. Subcohort analyses showed that increases in lymphohematopoietic cancers 
appear to be restricted to monomer workers employed before 1950 and for the shortest duration (Divine 
and Hartman 1996, 2001). Elevations were also seen for leukemia (SMR of 129; 95% CI=77-204) and 
non-Hodgkin’s lymphoma (SMR of 148; 95% CI=89-231), but the elevation was not statistically 
significant. Additionally, higher SMRs for leukemia and non-Hodgkin’s lymphoma were found in 
workers with shorter employment durations. No significant associations were found between cumulative
1.3-butadiene exposure (defined as a combination of job exposure class, calendar time, and length of time 
in job) and the relative risk for lymphohematopoietic cancers, leukemia, or non-Hodgkin’s lymphoma
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(Divine and Hartman 2001). Analysis of another cohort of 364 monomer workers, 277 of which worked 
in a U.S. Rubber Reserve plant during World War II, found an SMR of 577 (95% CI=157-1,480) for 
lymphosarcoma and reticulosarcoma (Ward et al. 1995). No significant association was found between
1.3-butadiene monomer exposure and all, lung, or lympho-hematopoietic cancers in a cohort of
614 monomer workers employed between 1948 and 1989 who were exposed to a relatively low mean 
concentration of 3.5 ppm, with many measurements below 1 ppm (Cowles et al. 1994).
The major limitations of the epidemiological studies described so far include the lack of precise historic 
exposure data to 1,3-butadiene, lack of adjustment for smoking, and possible exposure to other chemicals. 
Irons and Pyatt (1998) suggest that dithiocarbamates, such as dimethyldithiocarbamate (DMDTC), used 
in the SBR vulcanization process from 1950 to 1965, may have played a significant role in leukemia 
development that was concentrated in workers employed during this period. However, Santos-Burgoa et 
al. (1992) and Delzell et al. (2001) and HEI (2006) used multivariate analysis to suggest that the estimates 
of 1,3-butadiene exposure provided the best correlation with the rates of leukemia, even in the presence of 
styrene and DMDTC.
Several investigators have evaluated associations between childhood leukemias and ambient
1.3-butadiene emissions. Knox et al. (2005, 2006) associated the occurrence of childhood cancer with 
proximity of birthplace to industrial 1,3-butadiene and benzene emissions, and roads, railways, 
waterways, and bus, ferry, or train stations in Great Britain; however, no actual exposure data or estimates 
were available. Reynolds et al. (2003) calculated leukemia rate ratios (RR), adjusted for age, ethnicity, 
and sex, of 1.21 (95% CI=1.03-1.42) and 1.32 (95% CI= 1.11-1.57) for children in California census 
tracts ranked highest for combined exposure to 25 hazardous air pollutants (HAPs, including
1.3-butadiene) and highest for point-source HAP exposures, respectively. Likewise, Whitworth et al.
(2008) reported a significant association of childhood leukemia incidence with residence in census tracts 
close to the ship channel (which is in close proximity to petrochemical and chemical manufacturing 
facilities) in Houston, Texas. These studies do not indicate strong causality between 1,3-butadiene 
exposure and childhood leukemia, as many chemicals may have contributed to exposure and the actual 
exposure to 1,3-butadiene, if any, is unknown.
The rodent bioassay database corroborates the association of lympho-hematopoietic neoplasms and 
occupational exposure to 1,3-butadiene reported in the epidemiology literature. Mice were clearly more 
sensitive to 1,3-butadiene-mediated tumor development than rats. In rats, increased tumors were not 
observed following intermediate-duration exposures of up to 8,000 ppm 1,3-butadiene 6 hours/day,
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5 days/week for 13 weeks (Crouch et al. 1979). Two-year exposure of rats to 1,000 or 8,000 ppm
6 hours/day, 5 days/week resulted in increased incidences of Leydig cell adenoma, pancreatic exocrine 
adenoma, uterine sarcoma, mammary gland adenoma and carcinoma, Zymbal gland carcinoma, and 
thyroid follicular cell tumors (Owen and Glaister 1990; Owen et al. 1987). In mice, exposure to 200 ppm 
for 40 weeks resulted in increased incidences of lymphocytic lymphoma, histiocytic sarcoma, cardiac 
hemagiosarcoma, alveolar/bronchiolar adenoma/carcinoma, forestomach squamous cell papilloma/ 
carcinoma, hepatocellular adenoma, hardarian gland adenoma/adenocarcinoma, and preputial gland 
carcinoma (NTP 1993). These same tumors developed in mice in as little as 13 weeks after exposure to 
625 ppm 6 hours/day, 5 days/week (NTP 1993). Chronic exposure of mice to lower concentrations of
1,3-butadiene also resulted in multi-target organ neoplasm development. Two-year 6-hour/day, 
5-day/week exposures of 20 ppm for male mice and 6.25 ppm (the lowest exposure level tested) for 
female mice resulted in increased incidences of lymphocytic lymphoma, histiocytic sarcoma, cardiac 
hemagiosarcoma, alveolar/bronchiolar adenoma/carcinoma, forestomach squamous cell papilloma/ 
carcinoma, hepatocellular adenoma, hardarian gland adenoma/adenocarcinoma, mammary gland 
carcinoma, adenocanthoma, malignant mixed tumor, and malignant ovarian granulosa cell tumor.
The cancer effect levels (CELs) are recorded in Table 3-1 and plotted in Figure 3-1.
Using the Poisson regression analysis by Health Canada (2000) of the leukemia risk data from a cohort of
15,000 SBR production workers (Delzell et al. 1996), EPA derived a unit risk for inhalation exposure of 
0.08 ppm-1 (IRIS 2012). This unit risk corresponds to upper bound individual lifetime cancer risks at 
10"4-10"6 for exposure levels of 1x10"3-1x10"6 ppm, which are plotted in Figure 3-1. It should be noted 
that EPA derived the cancer risk levels in 2001, and thus, these values may not reflect the results of more 
recent studies of SBR workers.
The International Agency for Research on Cancer (IARC) has classified 1,3-butadiene as a Group 1 
carcinogen (carcinogenic to humans) (IARC 2009). EPA has classified 1,3-butadiene as carcinogenic to 
humans (EPA 2002; IRIS 2012). The Department of Health and Human Services (NTP 2005) also 
identified 1,3-butadiene as a “known human carcinogen”.
3.2.2 Oral Exposure
No studies were located regarding health effects in humans or animals after oral exposure to 1,3-buta­
diene.
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3.2.3 Dermal Exposure
Dermal contact with liquid 1,3-butadiene causes a sensation of cold followed by a sensation of burning, 
which is the result of rapid expansion of pressurized 1,3-butadiene from liquid to gas states (NIOSH, 
2005). Although this may cause frostbite, it is specific to an unusual exposure scenario and is not a toxic 
endpoint. However, the possible toxic effects from dermal absorption of such a concentrated amount of
1.3-butadine are unknown. High gas concentrations may cause mild skin irritation as well (NIOSH, 
2005). No other studies were located regarding health effects in humans or animals following dermal 
exposure to 1,3-butadiene.
3.3 GENOTOXICITY
1.3-Butadiene has been tested for genotoxicity in a number of in vitro and in vivo studies (Tables 3-2 and 
3-3). Positive results have been found in the reverse mutation assay in Salmonella typhimurium TA1530 
and TA1535 in the absence or in the presence of metabolic activation system (de Meester et al. 1978; 
Madhusree et al. 2002). However, the interpretation of these results was confounded by the fact that the 
Petri dishes not containing S-9 mix were contaminated by volatile active metabolites. It was concluded 
that S-9 mix was necessary to activate 1,3-butadiene into mutagen(s) (De Meester 1988). TA1530 was 
the most sensitive strain, but 1,3-butadiene mutagenicity was detectable only with metabolic activation in 
the subsequent study (de Meester et al. 1980). No significant mutagenic effect on S. typhimurium strain 
TA100 with metabolic activation was observed (Victorin and Stahlberg 1988). A weak genotoxic activity 
was detected in strain TA1535 with rat S-9 (Arce et al. 1989). A weak increase in sister chromatid 
exchanges was observed in Chinese hamster ovary cells, but only with metabolic activation (Sasiadek et 
al. 1991). Increased mutations occurred in the hypoxanthione-guanine phosphoribosyl transferase (hprt) 
and tk gene loci of human TK6 lymphoblastoid cells (Cochrane and Skopek 1993). On the basis of these 
data, 1,3-butadiene appears to require metabolic activation to produce genotoxicity.
The genotoxicity of 1,3-butadiene has been examined in several occupational exposure cohorts. Ward et 
al. (1994) reported a significant increase in hypoxanthine-guanine phosphoribosyltransferase (hprt) 
mutant frequency (measured in peripheral lymphocytes) among eight workers at a Texas 1,3-butadiene 
production plant working in the area of the plant where the highest 1,3-butadiene exposure occurred, as 
compared to levels in five workers in an area with low 1,3-butadiene exposures or in six controls who did 
not work at the 1,3-butadiene production plant. The mean area and personal 1,3-butadiene levels were
3.5 ppm (although most individual samples were <1 ppm) in the high-exposure area and 0.03 ppm in the
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Table 3-2. Genotoxicity of 1,3-Butadiene In Vitro
Species (test system) End point
Results
With Without 
activation activation Reference
Prokaryotic organisms: 
Salmonella typhimurium
TA1530 Gene mutation + - de Meester et al. 1980
TA100 Gene mutation - - Victorin and Stahlberg 1988
TA1535 
Eukaryotic organisms:
Gene mutation + Arce et al. 1989; Madhusree 
et al. 2002
Chinese hamster ovary SCE + - Sasiadek et al. 1991
Human TK6 lymphoblastoid 
cells
hprt and tk loci 
mutations
NA NA Cochrane and Skopek 1993
-  = negative result; + = positive result; NA = not applicable; SCE = sister chromatid exchange
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Table 3-3. Genotoxicity of 1,3 Butadiene In Vivo
Species (test system) End point Results Reference
B6C3F1 mice (inhalation)
Sprague-Dawley rats 
(inhalation)
Bone marrow: Dose-dependent increase 
in SCEs
+ Cunningham et al. 1986
B6C3F1 mice (inhalation) Bone marrow: increase in CAs, SCEs, 
and AGT, and depression of MI
+ Tice et al. 1987
Swiss mice (inhalation) Peripheral blood erythrocytes: induction 
of micronuclei
+ Irons et al. 1986b
B6C3F1 mice (inhalation) Bone marrow: alteration of 
hematopoietic stem cell development
+ Leiderman et al. 1986
B6C3F1 mice (inhalation) Peripheral blood erythrocytes: induction 
of micronuclei
+ Jauhar et al. 1988
B6C3F1 mice (inhalation) Induction of MN; induction of SCEs; CAs + Tice et al. 1988
B6C3F1 mice (inhalation) Sperm abnormalities; dominant lethality + DOE/NTP 1988a
C57B1/6 mice 
(intraperitoneal injection)
Bone marrow increase in CAs and SCEs + Sharief et al. 1986
B6C3F1 mice (inhalation) lacZ mutant frequency in lung + Recio et al. 1992
B6C3F1 mice (inhalation) lacZ mutant frequency in liver and bone 
marrow
- Recio et al. 1992
B6C3F1 mice and F344 
rats (inhalation)
hprt loci mutations in splenic 
T lymphocytes
+ Cochrane and Skopek 
1993; Meng et al. 1999, 
2000,2004, 2007
B6C3F1 mice (inhalation) Peripheral blood erythrocytes and bone 
marrow: induction of micronuclei
+ Autio et al. 1994
Wistar rats Peripheral blood erythrocytes and bone 
marrow: induction of micronuclei
- Autio et al. 1994
C3H mice (inhalation) Heritable spermatid chromosomal 
translocations; dominant lethality
+ Adler et al. 1998
C3H mice (inhalation) Spermatocytes: induction of micronuclei + Xiao and Tates 1995
CD-1 mice (inhalation) Dominant lethality - Brinkworth et al. 1998
CAST/EiJ, NOD/LTj, A/J, 
WSB/EiJ, PWK/PhJ, 
129S/SvlmJ, C57BL/6J 
mice (inhalation)
DNA adduct formation + Koturbash et al. 2011a
C57BL/6J mice 
(inhalation)
DNA adduct formation + Koturbash et al. 2011b
Humans (inhalation) CA; SCE + Sram et al. 1998
Humans (inhalation) CA; SCE - Lovreglio et al. 2006
Humans (inhalation) hprt loci in peripheral lymphocytes - Hayes et al. 1996, 2000
Humans (inhalation) hprt loci in peripheral lymphocytes - Tates et al. 1996
Humans (inhalation) hprt loci in peripheral lymphocytes - Albertini et al. 2001, 
2007; HEI 2003
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Table 3-3. Genotoxicity of 1,3 Butadiene In Vivo
Species (test system) End point Results Reference
Humans (inhalation) hprt loci in peripheral lymphocytes - Liu et al. 2008
hprt exon deletion + Liu et al. 2008
Humans (inhalation) hprt loci in peripheral lymphocytes + Ward et al. 1994
Humans (inhalation) hprt loci in peripheral lymphocytes + Abdel-Rahman et al. 
2001, 2003, 2005; Ma et 
al. 2000; Ward et al. 
1996,2001
Humans (inhalation) hprt loci in peripheral lymphocytes + Wickliffe et al. 2009
C3H mice (inhalation) Induction of spermatid micronuclei + Tommasi et al. 1998
B6C3F1 mice (inhalation) H- and K-ras mutation frequency + Sills et al. 2001
NMRI mice (inhalation) Bone marrow: induction of micronuclei + Vodicka et al. 2006
-  = negative result; + = positive result; AGT = average generation time; CA = chromosomal aberration; MI = mitotic 
index; MN = micronucleated cell; SCEs = sister chromatid exchange
1,3-BUTADIENE
3. HEALTH EFFECTS
51
low-exposure area. A significant correlation between hprt variant frequency and urinary levels of the
1.3-butadiene-specific metabolite, M1, was also found. No significant correlations between hprt variant 
frequency and age or employment length were found. A subsequent study of these workers reported 
2.5-fold higher hprt mutation frequencies in workers exposed to airborne concentrations of 0.3 ppm
1.3-butadiene as compared to workers exposed to mean levels of 0.12 ppm (Ward et al. 1996), indicating 
good correlation between exposure and mutation frequency. Unlike the earlier study, no correlation 
between hprt variant frequency and urinary metabolite levels were found. A follow-up study of the 
southeast Texas SBR workers found a 3-fold increase in hprt mutation frequency in workers exposed to 
1.7 ppm, compared to workers exposed to 0.07 ppm (Ward et al. 2001). A re-analysis of the blood 
samples from the Ward et al. (1996) study using a cloning assay, rather than the autoradiographic assay 
used in the Ward analyses, confirmed the significant difference in hprt variant frequency between high­
exposure workers and the outside controls and found a significant difference in hprt mutation frequency 
between the groups (Ma et al. 2000). However, the investigators did not examine the possible association 
between 1,3-butadiene exposure level and mutation frequency. Neither Ma et al. (2000) nor Ward et al. 
(1994, 1996) provided demographic information on the outside control group, which consisted of workers 
in the Department of Preventive Medicine and Community Health at the University of Texas Medical 
Branch; thus, the appropriateness of this comparison group to the SBR workers cannot be evaluated. A 
more recent study of these SBR workers did not find a significant association between 1,3-butadiene 
exposure level and hprt variant frequency, after removal of an outlier (Wickliffe et al. 2009). The current
1.3-butadiene exposure levels of the 30 subjects examined were low with only six subjects having levels 
of >0.1 ppm. A significant association between employment length and hprt mutant frequency was 
found. Another study conducted by this group (Ammenheuser et al. 2001) at a different SBR facility 
found a 3-fold increase in hprt mutation frequency in 22 workers in the high-exposure group (mean
1.3-butadiene exposure level was 1.48 ppm) compared to low-exposure workers (mean exposure level of 
0.15 ppm). Significant correlations between hprt variant frequency and 1,3-butadiene levels and urinary 
M1 levels were found. Abdel-Rahman et al. (2001, 2003, 2005) examined the association between 
polymorphisms, 1,3-butadiene exposure, and hprt variant frequency among workers at the two Texas 
SBR facilities. Individuals with a polymorphism for microsomal epoxide hydrolase (EH), an enzyme 
important for the hydrolysis of epoxide metabolites of 1,3-butadiene (see Section 3.4.3), exhibited a 
3-fold higher hprt mutation frequency than workers without the polymorphism (Abdel-Rahman et al. 
2001). Further, polymorphisms in the glutathione-S-transferase (another important enzyme in epoxide 
metabolite metabolism) genotypes GSTM1 or GSTT1 did not impact hprt mutation rates, but a 
combination of EH and GST polymorphism did result in an increase in hprt mutation frequency (Abdel- 
Rahman et al. 2001, 2003, 2005). Several studies that examined the possible association between
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1,3-butadiene exposure and the frequency of chromosomal aberrations and/or sister chromatid exchanges 
among Texas 1,3-butadiene workers have not found significant associations (Au et al. 1995; Hallberg et 
al. 1997; Kelsey et al. 1995).
Unlike the results of Texas cohorts, studies of Chinese rubber production workers have not found 
alterations in hprt mutation frequency. No significant difference in hprt gene mutation frequency was 
observed in male and female Chinese polybutadiene rubber production workers exposed to an average of 
1.0-3.5 ppm (median of 2.0 ppm) and unexposed controls (Hayes et al. 1996, 2000, 2001). Additionally, 
no exposure-related significant associations between hprt mutation frequency and 1,3-butadiene exposure 
(as assessed by exposure levels, urinary metabolite levels, or hemoglobin adducts) were found. Similarly, 
no significant alterations in glycophorin A variant frequencies were observed (Hayes et al. 2000). In 
another Chinese study, hprt mutation frequencies in petrochemical workers exposed to mean levels of 
10 ppm were higher, but were not significantly different than unexposed controls, while the percentage of 
workers exhibiting hprt exon deletions (27%) was significantly higher than levels found in controls (13%) 
(Liu et al. 2008).
Several investigators have examined hprt mutation frequency in cohorts of 1,3-butadiene workers in the 
Czech Republic. Tates et al. (1996) did not find significant alterations in hprt mutation frequency among 
male workers from a 1,3-butadiene production plant exposed to a mean concentration of 1.76 ppm, as 
compared to unexposed workers at the plant. However, a significant increase in the percentage of 
lymphocytes with chromosomal aberrations was observed in the exposed workers; increases in DNA 
damage (as assessed using the comet assay) and micronuclei frequency were observed in exposed 
smokers, as compared to unexposed smokers (Sram et al. 1998; Tates et al. 1996). A significant increase 
in the frequency of sister chromatid exchanges was also observed (Sram et al. 1998). When the exposed 
workers and unexposed workers were subdivided based on glutathione-^-transferase polymorphism for 
M1 gene (GSTM1) and glutathione-^-transferase polymorphism for T1 gene (GSTT1) genotypes, a 
significant increase in the frequency of chromosomal aberrations were observed in exposed workers with 
the GSTM1-positive genotype, as compared to exposed workers with GSTM1-null genotype; no effects 
was observed for the GSTT1 genotype. Multifactorial analysis (accounting for 1,3-butadiene exposure, 
smoking, GSTM1, GSTT1, and age) showed a significant association between the frequency of 
chromosomal aberrations and the number of cells with a high frequency of sister chromatid exchanges 
(Sram et al. 1998). However, when 1,3-butadiene exposure was evaluated using N-1-(2,3,4-trihydroxy- 
butyl)adenine adduct levels, there were no significant associations between chromosomal aberration 
frequency, micronuclei formation, or sister chromatid exchange (Zhao et al. 2001). In another study of
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Czech 1,3-butadiene workers, no alterations in chromosome aberrations, sister chromatid exchanges, or 
micronuclei formation were observed in 1,3-butadiene production workers or workers in 1,3-butadiene 
polymer production (Sorsa et al. 1994). However, when workers were subdivided based on GSTM1 and 
GSTT1 genotypes, a significantly higher frequency of chromosomal aberrations were observed in
1,3-butadiene workers lacking the GSTT1 gene (Sorsa et al. 1996). In a larger-scale study of 24 workers 
at a 1,3-butadiene production facility (mean exposure level of 0.64 mg/m3 [0.29 ppm]) and 34 workers at 
a polymerization facility (mean exposure level of 1.76 mg/m3 [0.79 ppm]), no significant association 
between 1,3-butadiene exposure (as assessed using air concentrations, urinary metabolites, or hemoglobin 
adducts) and hprt mutation frequency (assessed using cloning assay) were found; no associations were 
found when workers divided by a number of genotypes including GSTM1 or GSTT1 (Albertini et al. 
2001; HEI 2003). No significant alterations in the frequency of chromosomal aberrations or sister 
chromatid exchanges were found. In a follow-up study at the polymerization facility, male and female 
workers were examined. The mean 1,3-butadiene exposure levels were 0.397 mg/m3 (0.18 ppm) and 
0.808 mg/m3 (0.36 ppm) in the females and males, respectively (Albertini et al. 2007). No significant 
associations between 1,3-butadiene exposure and hprt mutation frequency were found; similarly, there 
were no significant associations between exposure and sister chromatid exchanges or chromosomal 
aberrations.
In a cohort of workers at an Italian petrochemical plant exposed to very low levels of 1,3-butadiene (mean 
concentration of 0.0115 mg/m3 [0.005 ppm]), no significant relationship between 1,3-butadiene exposure 
and alterations in the frequency of chromosomal aberrations or sister chromatid exchanges was observed 
Fustinoni et al. 2004; Lovreglio et al. 2006).
In summary, studies of workers at Texas 1,3-butadiene production facilities or SBR facilities have found 
significantly higher frequencies of hprt variants in the lymphocytes in men working in areas of the facility 
with high 1,3-butadiene exposure levels (Ammenheuser et al. 2001; Ma et al. 2000; Ward et al. 1996, 
2001) However, no significant associations were found in Czech cohorts (Albertini et al. 2001, 2007;
HEI 2003; Tates et al. 1996) or Chinese cohorts (Hayes et al. 1996, 2000, 2001). The reasons for 
dissimilar outcomes in lymphocyte hprt gene mutation frequency between the different cohorts are not 
clear, but may be the result of varying exposure levels, experimental techniques in exposures assessment 
(active vs. passive sampling) and mutation analysis (autoradiography vs. cloning hprt assays). The mean 
exposure levels in the Texas cohort studies tended to be higher than other cohorts; the mean levels in the 
Chinese cohort are elevated due to intermittent high exposures rather than a high TWA level. This is 
supported by a study conducted by Wickliffe et al. (2009) that did not find significant increases in hprt
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frequency in a Texas cohort with low 1,3-butadiene exposure levels (only six subjects were exposed to 
levels >0.1 ppm).
A number of rodent inhalation studies report genotoxic effects. Mice and rats exhibited increased hprt 
locus mutations in splenic T cells (Cochrane and Skopek 1993; Meng et al. 1999, 2000, 2004, 2007). 
Inhaled 1,3-butadiene also induce an increase in micronucleus induction in erythrocytes (Irons et al.
1986b; Jauhar et al. 1988; Tice et al. 1987; Vodicka et al. 2006), spermatocytes (Tommasi et al. 1998; 
Xiao and Tates 1995), and bone marrow cells (Autio et al. 1994), increased frequency of sister chromatid 
exchanges (Tice et al. 1987) and chromosomal aberration frequencies (Cunningham et al. 1986; Tice et al.
1987) in mice. Transgenic B6C3F1 mice exhibited an increased lacZ~ mutant frequency in the lungs 
(Recio et al. 1992). Increased percentages of H- and K-ras proto-oncogene mutations were found in 
forestomach neoplasms from mice inhaling 1,3-butadiene for 2 years (83% in exposed mice compared to 
24% in spontaneous neoplasms from controls) (Sills et al. 2001). Increases in N-7-(2,3,4-trihydroxybut-
1-yl) guanine adduct formation in liver DNA were found in various mouse strains exposed to
1.3-butadiene (Koturbash et al. 2011a, 2011b); the increase DNA adduct formation was concentration- 
related (Koturbash et al. 2011b). No genotoxic effects (micronucleus induction, chromosomal 
aberrations, or sister chromatid exchanges) were found in bone marrow of rats or liver of mice exposed by 
inhalation to 1,3-butadiene (Autio et al. 1994; Cunningham et al. 1986; Recio et al. 1992).
In a dominant lethal study in which male CD-1 mice inhaled 1,3-butadiene for 5 days and were mated to 
nonexposed females, an increased number of dead implantations per pregnancy occurred at 200 and
1,000 ppm, but not at 5,000 ppm during the first 2 weeks postexposure (DOE/NTP 1988b). These results 
were considered to be inconclusive because of the lack of a strict dose-response relationship. Increased 
numbers of dead fetuses were also observed in offspring of CH3 males inhaling 130 ppm (Adler et al. 
1998), but not in CD-1 mice exposed to 125 ppm (Brinkworth et al. 1998). Heritable spermatid 
chromosomal translocations occurred in Fj offspring of male CH3 mice inhaling 1,3-butadiene (Adler et 
al. 1995a, 1998).
Although cytogenetic monitoring of 1,3-butadiene rubber workers for chromosomal aberrations revealed 
no or slight differences between exposed and control groups (Lovreglio et al. 2006; Sram et al. 1998;
Zhou et al. 1986), 1,3-butadiene is clearly genotoxic in mice. As discussed in Section 3.4.3, species 
differences exist in the metabolism of 1,3-butadiene, and data suggest that humans may metabolize this 
compound at different metabolic rates than do rodents. If the genotoxic and clastogenic response of
1.3-butadiene requires activation to an active metabolite that is formed more slowly or deactivated more
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rapidly in humans than in rats and mice, the genotoxicity observed in animals may only be observed after 
much higher exposures in humans. The data in humans are too limited, however, to rule out the 
possibility of a genotoxic potential in humans exposed to 1,3-butadiene.
3.4 TOXICOKINETICS  
3.4.1 Absorption
3.4.1.1 Inhalation Exposure
In human volunteers inhaling 2 ppm 1,3-butadiene for 20 minutes, the absorbed fraction varied from 18 to 
74% (Lin et al. 2001). Neither sex nor age (30±8 years for males, 29±9 years for females) were factors in 
this variation. Fractional absorption in Asian volunteers was about 20% greater than in Caucasians, 
African-Americans, or Hispanics. Blood triglyceride levels may influence absorption, as blood:air 
partition coefficients increased 20-40% in humans having borderline higher triglyceride levels after 
ingestion of fat in the diet (Lin et al. 2002).
In male Sprague-Dawley rats and male B6C3F1 mice exposed to 20 ppm 14C-radiolabeled 1,3-butadiene 
for 6 hours in a dynamic system, the total absorbed radioactivity, as estimated by the sum of 14C in urine, 
feces, carcass, and expired air, was 2.2% in rats and 1.6% in mice (Swain et al. 2003). In close-chamber 
studies, the uptake of inhaled 1,3-butadiene in mice and rats was linear to 2,000 and 1,000 ppm, 
respectively, above which metabolism is saturated (Kohn and Melnick 2001). Absorption of
1.3-butadiene was demonstrated by measurements of the metabolite, 1,2-epoxy-3-butene (EB), in the test 
chamber (due to exhaled air) and measurement of 1,3-butadiene metabolites in blood of male Sprague- 
Dawley rats exposed 1-10,000 ppm and male B6C3F1 mice exposed to 1-6,000 ppm for 6-8 hours in 
closed chambers (Filser et al. 2007). In rats, EB concentrations in the test chamber reached a plateau at 
all exposure concentrations. In mice, chamber concentrations of EB were higher than for rats; EB levels 
reached a plateau at exposure concentrations up to 1,000 ppm, but no plateau was observed at exposure 
concentrations of 2,000-6,000 ppm. The study authors suggest that this concentration-dependence is due 
to “breakdown” of hepatic glutathione-S-transferase mediated 1,3-butadiene conjugation. Filsner et al. 
(2007) did not report an absorption fraction for either species. Absorption of 1,3-butadiene was also 
demonstrated by measurement of metabolites (butadiene monoepoxide and butadiene diepoxide) in blood 
and tissues of male Sprague-Dawley rats and male B6C3F1 mice exposed (nose only) to 62.5 ppm
1.3-butadiene for 2 or 4 hours (Thornton-Manning et al. 1995a). Similar results were observed in male 
and female rats exposed (nose only) to 62.5 ppm 1,3-butadiene for 6 hours (Thornton-Manning et al.
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1995b). The distribution coefficient for 1,3-butadiene between rabbit blood and air was 0.603 in vitro and 
0.654 in vivo, suggesting simple passive diffusion of the gas from the alveoli to the blood (Carpenter et al. 
1944). After 9 minutes of exposure of rabbits to 250,000 ppm, the concentration of 1,3-butadiene was 
0.26 mg/mL in the femoral artery and 0.18 mg/mL in the femoral vein. Pulmonary absorption, therefore, 
appears to be rapid. Distribution studies in rats and mice following inhalation exposure to 1,3-butadiene 
indicate that it is absorbed from the lungs in these species as well (see Section 3.4.2.1). When Macaca 
fascicularis monkeys were exposed to radioactively labeled 1,3-butadiene, the uptake was calculated as 
16.40 ^mol/hour/10 ppm of inhaled and 3.20 ^mol/hour/10 ppm of retained 1,3-butadiene (Dahl et al. 
1990).
3.4.1.2 Oral Exposure
No studies were located regarding absorption in humans or animals after oral exposure to 1,3-butadiene.
3.4.1.3 Dermal Exposure
No studies were located regarding absorption in humans or animals after dermal exposure to 1,3-buta­
diene.
3.4.2 Distribution
In vitro measurements of tissue:blood equilibrium partition coefficients suggest that 1,3-butadiene 
distributes to a variety of tissues. Partition coefficients in humans were highest in fat (18.4) and were 
similar in well- and poorly-perfused tissues (0.69 and 0.72, respectively) (Brochot et al. 2007). In rats, 
partition coefficients were highest for fat (21.9), similar for liver, kidney, muscle, and spleen (0.87-0.94), 
and lowest in brain (0.43) (Johanson and Filser 1993).
3.4.2.1 Inhalation Exposure
In volunteers inhaling 2 ppm 1,3-butadiene for 20 minutes, blood levels approached equilibrium by 
5 minutes (Smith et al. 2001). In mice and rats inhaling up to 625 ppm 1,3-butadiene, equilibrium in 
blood concentrations was reached by 2 hours, with blood levels in mice being three- to 4-fold higher than 
in rats at all times (Himmelstein et al. 1994). The distribution of 1,3-butadiene in several tissues in rats 
was measured following a 1-hour inhalation exposure to 129,000 ppm (Shugaev 1969). Perinephric fat
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contained 152 mg 1,3-butadiene/100 cc tissue, compared to levels of 36-51 mg 1,3-butadiene/100 mL in 
the brain, liver, septum, and kidney.
Species differences in the distribution of inhaled 1,3-butadiene were studied in Sprague-Dawley rats and 
B6C3F1 mice (Bond et al. 1986, 1987). When normalized for amount of inhaled 14C-1,3-butadiene, 
molar tissue concentrations of radioactive material at 1 hour postexposure were 17-fold (thyroid) to 
80-fold higher (lung) in mice than in rats. In blood, the normalized radioactivity concentration was 
57-fold higher in mice than rats, while 110- to 120-fold more radioactivity was found in mouse intestine 
than in rat intestine.
3.4.2.2 Oral Exposure
No studies were located regarding distribution in humans or animals after oral exposure to 1,3-butadiene.
3.4.2.3 Dermal Exposure
No studies were located regarding distribution in humans or animals after dermal exposure to 1,3-buta­
diene.
3.4.3 Metabolism
1,3-Butadiene is metabolized by oxidation, hydrolysis, and conjugation reactions, with oxidation and 
hydrolysis reactions leading to the formation of several reactive epoxide intermediates (Figure 3-2). Of 
the reactive intermediates formed, EB (formed by oxidation of 1,3-butadiene), 1,2:3,4-diepoxybutane 
(DEB; formed by oxidation of EB), and 1,2-dihydroxy-3,4-epoxybutane (EBD; formed by hydrolysis 
reactions of DEB) are reactive electrophilic compounds. Metabolism of 1,3-butadiene appears to follow 
the same enzymatic pathways in all species, including humans, with production of the same reactive 
intermediates. However, important species differences exist in the rates of formation and detoxification 
of reactive metabolites (Kirman et al. 2010a). As a result, rodents, particularly mice, have much higher 
tissue levels of reactive metabolites than nonhuman primates and humans. Evidence for species 
differences in metabolism of 1,3-butadiene is available from in vitro studies, studies using isolated 
perfused livers, and in vivo studies measuring tissue and urine metabolite levels and blood hemoglobin 
adduct levels. Metabolism of 1,3-butadiene exhibits nonlinear kinetics (Kirman et al. 2010a), with both 
dose- and exposure duration-dependent effects. Several processes have been proposed as sources of
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Figure 3-2. Metabolism of 1,3-Butadiene
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□ = boxes indicate biomarkers of exposure that have been measured in exposed workers (Albertini et al. 2003); 
* = monofunctional alkylating agent; ** = bifunctional alkylating agent; ADH = alcohol dehydrogenase;
B-diol = butanediol; b D = 1,3-butadiene; DEB = diepoxybutane; EB = epoxybutene; EBD = epoxybutane diol; 
EH = epoxide hydrolase; GST = glutathione S-transferase; HBVal = W-(2-hydroxy-3-butenyl)-valine;
HMVK = hydroxymethylvinyl ketone; M1 = 1,2-dihydroxy-4-(W-acetylcysteinyl)-butane (urinary metabolite);
M2 = 1-(W-acetylcysteinyl)-2-hydroxy-3-butene (urinary metabolite); P450 = cytochrome P450; 
pyrVal = W,W-(2,3-dihydroxy-1,4-butadiyl)-valine; THBVal = W-(2,3,4-trihydroxybutyl)-valine
Source: Kirman et al. 2010
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nonlinear kinetics; these include inhibition, induction, and saturation of various metabolizing enzymes 
and depletion of glutathione.
The metabolism of 1,3-butadiene has been observed in the liver, lung, and kidneys. The liver is the 
predominant site of 1,3-butadiene metabolism (Elfarra et al. 2001; Schmidt and Loeser 1985, 1986).
1,3-Butadiene is initially oxidized (Figure 3-2) by cytochrome P450 (CYP) to 2-butenal or EB (Bolt et al. 
1983; Csanady et al. 1992; Duescher and Elfarra 1994; Himmelstein et al. 1994, 1995; Kirman et al.
2010; Malvoisin and Roberfroid 1982; Malvoisin et al. 1979; Thornton-Manning et al. 1995b, 1997). 
Metabolism of EB is mediated by three competing oxidative, hydrolytic, or conjugation pathways. The 
flux of 1,3-butadiene through the various pathways is concentration- and species-dependent. Successive 
oxidation steps of EB result in DEB and 3,4-epoxy-1,2-diol (EBdiol). EB can also be conjugated to 
glutathione by glutathione-S-transferase (GST) to form 1-glutathionyl-3-buten-2-ol, or can be hydrolized 
via epoxide hydrolase (EH) to 3-butene-1,2-diol (BDdiol). BDdiol is metabolized via CYP or aldehyde 
dehydrogenase (ADH) to the ketone 1-hydrozy-3-buten-2-one (hydroxymethylvinyl ketone, or HMVK) 
or EBdiol. GST can conjugate glutathione to HMVK and EBdiol to form 4-glutathionyl-1-hydroxy-
2-butanone and 4-glutathionylbutane-1,2,3-triol. Several isoforms of CYP have been implicated in the 
oxidative metabolism of 1,3-butadiene and resulting epoxides in various tissues. In human liver 
microsomes, CYP2E1 dominates metabolism at low concentrations (i.e., 0.16 mM), while CYP2A6 
dominates at higher concentrations (i.e., 4.4 mM) (Elfarra et al. 1996). In mice, CYP2E1 and 2A5 are 
active in 1,3-butadiene oxidation in lung and liver microsomes, but CYP4B1 dominates metabolism in the 
kidneys (Elfarra et al. 2001).
Examination of blood levels of 1,3-butadiene metabolites in male Sprague-Dawley rats exposed to 1­
10,000 ppm and male B6C3F1 mice exposed to 1-6,000 ppm for 6-8 hours in closed chambers indicates 
species differences in the predominance of metabolic pathways (Filsner et al. 2007). In rats and mice,
EB, EBD, and 3-butene-1,2-diol concentrations in blood increased with increasing exposure 
concentrations. Ratios of mouse:rat EB blood levels ranged from 2.0 to 8.6 over 1,3-butadiene exposure 
concentrations of 1-1,250 ppm. DEB was detected in blood of mice, but not in rats. Similar results were 
observed in male Sprague-Dawley rats and male B6C3F1 mice exposed (nose only) to 62.5, 625, or 
1,250 ppm 1,3-butadiene for 6 hours; DEB was detected in mouse, but not rat, blood, and higher levels of 
butadiene monoepoxide were present in mouse blood, compared to rat blood (Himmelstein et al. 1994). 
Results of these studies are consistent with enhanced formation and/or lower metabolism of DEB in mice 
compared to rats. Differences also were noted between rodents and monkeys in 1,3-butadiene 
metabolism (Dahl et al. 1990; Sun et al. 1989a). At 10 ppm, blood levels of EB, DEB, and EBdiol were
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lower in monkeys inhaling 10 ppm than in rodents. The difference was not so great at 8,000 ppm (Sun et 
al. 1989a). Similar exposures of 10 ppm 1,3-butadiene resulted in blood concentrations of total 1,3-buta­
diene metabolites in monkeys that were about 5-50 times lower than in mice and about 4-14 times lower 
than in rats (Dahl et al. 1991). The results indicated possible lower susceptibility to toxic effects of low 
levels of 1,3-butadiene in primates.
Species differences in metabolism are also supported by results of studies examining tissue levels of 
metabolites (Filser et a;. 2007; Himmelstein et al. 1995; Thorton-Manning et al. 1995a, 1995b). 
Comparison of butadiene epoxide levels in livers and lungs of male Sprague-Dawley rats and male 
B6C3F1 exposed (nose only) to 62.5, 625, 1,250, or 8,000 (rats only) ppm 1,3-butadiene shows higher 
levels of butadiene monoepoxide in mice compared to rats, and the presence of butadiene diepoxide in 
mice, but not rats (Himmelstein et al. 1995). In male Sprague-Dawley rats and male B6C3F1 mice 
exposed to 62.5 ppm 1,3-butadiene for 4 hours, tissue levels of butadiene monoepoxide were higher in 
tissues (blood, heart, lung, liver, fat, spleen, and bone marrow) of mice compared to rats, with mouse:rat 
ratios ranging from 3.0 (heart) to 11.5 (bone marrow); butadiene diepoxide was not detected in lung or 
liver of rats (Thorton-Manning et al. 1995a). In mice, butadiene diepoxide levels were similar to 
monoepoxide levels in blood, heart, thymus and bone marrow; diepoxide levels in mouse lung, liver, and 
spleen were higher than monoepoxide levels, but were lower in fat. Butadiene diepoxide levels in rats 
were very low compared to levels in mice, and diepoxide was not detected in liver or bone marrow. 
Comparison of butadiene epoxide levels in tissues of male and female Sprague-Dawley rats exposed to
1.3-buradiene for 6 hours (nose only) suggests gender differences in metabolism (Thorton-Manning et al. 
1995b). Butadiene monoepoxide levels in lung were approximately 5-fold higher in males compared to 
females; whereas similar monoepoxide levels for males and females were observed for blood, femur, and 
fat.
Results of studies using isolated perfused livers provide additional evidence of species differences in 
metabolism of 1,3-butadiene. Following single pass, isolated perfusion of livers from male Sprague- 
Dawley rats and male B6C3F1 mice with 1,3-butadiene (at concentrations that approached saturation of
1.3-butadiene metabolism), differences were observed in 1,3-butadiene metabolites in liver effluent 
(Filser et al. 2001). In mice, three epoxides (EB, DEB, and EBD) and 3-butane-1,2-diol (B-diol) were 
detected, whereas only EB and B-diol were detected in effluent from rat livers. Furthermore, the 
concentration of EB in effluent from rat livers was approximately 8.5-fold less than that in effluent from 
mouse livers. Additional species differences were observed in a study evaluating single-pass perfusion of 
the 1,3-butadiene metabolites, EB, DEB and B-diol (Filser et al. 2010). For perfusion with EB, EBD,
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DEB, and B-diol were formed in rats and mice, with an approximately 4-fold higher percentage of DEB 
in mice compared to rats. The major metabolite of DEB in rats and mice was EBD. For perfusion with 
B-diol, EBD was detected in effluent of rats, but not in mice. Results of studies using hepatic 
microsomes from mice and rats indicate differences in stereochemistry of 1,3-butadiene metabolites 
(Nieusma et al. 1997). Mouse microsomes form more (S)-EB than (R)-EB; rat microsomes initially 
formed more (S)-EB than (R)-EB, although the S:R fell below 1.0 as incubation time increased to 
30 minutes. For DEB formation, mice microsomes formed more DEB when starting with (S)-EB 
compared to when starting with (R)-EB; the opposite was observed with rat microsomes.
In vitro studies indicate that mouse lung and liver have a higher capacity than other species, including 
humans, to oxidize 1,3-butadiene to EB and DEB, but have much less ability to detoxify the epoxides via 
the EH pathway (Jackson et al. 2000b). Female mouse tissue homogenates resulted in higher EB 
generation than in males or in rat, human, or monkey tissues, while human and monkey tissues 
hydrolyzed the epoxides to diols approximately 20-fold more extensively than rodents (Schmidt and 
Loeser 1985, 1986). In studies of liver microsomes, mice had intrinsic clearance (Vmax/Km) values of
57.5 and 0.77 minute-1 for oxidation of 1,3-butadiene to EB and EB to DEB, respectively. These values 
are 3-4-fold higher than the respective rat values of 1,637 and 0.21 minute-1 (Elfarra et al. 2001). 
Conversely, intrinsic clearance via EH-mediated hydrolysis of EB was 34.4 minute-1 in rats, compared to 
12.4 minute-1 in mice. Clearance by EB conjugation with GSH was similar (21.0 and 22.0 minute-1) in 
both species. These in vitro findings comport with metabolic differences observed between rats and mice 
after inhalation exposure to EB (Kreiling et al. 1987; Laib et al. 1990). A limited rate of EB removal and 
its subsequent accumulation was observed in mice at 500 ppm exposure, but not in rats at exposures up to
5,000 ppm. This may partially account for the differing levels of toxicity and carcinogenicity between 
rats and mice in long-term studies. For additional information, see Section 3.5 (Mechanisms of Action).
Based on evaluation of hemoglobin adduct biomarkers (adducts formed by interaction of 1,3-butadiene 
metabolites with hemoglobin), mice appear to have higher DEB levels than rats and much higher levels 
than humans (Swenberg et al. 2007). Analysis of hemoglobin adducts in mice and rats exposed to
1,3-butadiene by inhalation show much higher levels of the hemoglobin adducts, pyr-Val and THB-Val 
(formed by interaction of DEB with hemoglobin), in mice than in rats (Boysen et al. 2004). Results are 
consistent with results of studies showing higher levels of DEB in tissues of mice compared to rats. In 
polymerization workers exposed to 0.81 ppm 1,3-butadiene, THB-Val was the predominant hemoglobin 
adduct, comprising 99.6% of the total; the mean percent of HB-Val was 0.33% and the mean percent of 
pyr-Val was 0.05% (Boysen et al. 2012). In monomer workers exposed to lower concentrations of
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1,3-butadiene (0.29 ppm), lower levels of HB-Val (0.26%) and higher levels of pyr-Val (0.11%) were 
found; the decrease in pyr-Val levels was significantly related to the increasing 1,3-butadiene 
concentrations. The lower percentage of pyr-Val formed in the workers exposed to higher 1,3-butadiene 
levels may be suggestive of saturation of the formation of pyr-Val in humans (Boysen et al. 2012).
As noted in the introduction to Section 3.4.3, metabolism of 1,3-butadiene exhibits nonlinear kinetics 
(Kirman et al. 2010a), with both dose- and exposure duration-dependent effects. Glutathione deletion and 
saturable kinetics have been proposed as possible sources of nonlinear kinetics. Studies evaluating effects 
of hepatic glutathione levels show that gluthione depletion exhibited concentration-dependence and was 
greater in mice than in rats (Deutschman and Laib, 1989; Kreiling et al. 1988). Glutathione depletion was 
also observed in livers and lungs of rats and mice exposed to 1,3-butadiene, with more extensive 
depletion in mice than in rats (Himmelstein et al. 1995). Regarding saturable kinetics, blood levels of EB 
reached a plateau in rats, but not mice (Filser et al. 2007). The study authors suggested that the results are 
consistent with competitive inhibition of CYP450 isozymes.
3.4.4 Elimination and Excretion
3.4.4.1 Inhalation Exposure
The monoepoxide metabolite, EB, can be conjugated to glutathione by GST to form 
monohydroxybutenylmercaptic acid (MHBMA, or M2), a mixture of N-acetyl-S-([1-hydroxymethyl]-
2-propenyl)cysteine and N-acetyl-S-([2-hydroxymethyl]-3-propenyl)cysteine. EBdiol, formed by 
hydrolysis of EB, may also be conjugated by GST to glutathione to form N-acetyl-S-(3,4-dihydroxy- 
butyl)cysteine (DHBMA, or M1). Both mercaptic acids are excreted in the urine (Boogaard et al. 2001a; 
McDonald et al. 2004). These excretion products have been used as biomarkers of 1,3-butadiene 
exposures in both environmental and occupational settings (Albertini et al. 2001, 2007; Ammenheuser et 
al. 2001; Boogaard et al. 2001a) (see Section 3.8). The relative abundance of MHBMA and DHBMA in 
urine indicates the flux of EB through the competing GST and EH metabolic pathways. In humans,
>97% of urinary mercaptic acid measured following 1,3-butadiene inhalation is DHBMA, indicating that 
most EB proceeds to hydrolysis via EH rather than to formation of the diepoxide (Henderson et al. 1996). 
Albertini et al. (2007) showed that women excrete lower levels of both mercaptic acids than men per unit 
of 1,3-butadiene exposure; however, they maintain the ratio of M1 and M2, suggesting sex differences in 
metabolic activity, but not pathway flux.
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In rats exposed to 1,3-butadiene, 1,2-epoxybutene-3 and acetone were exhaled as suspected metabolites of 
the administered compound (Bolt et al. 1983). The pharmacokinetic profile of inhaled 1,3-butadiene was 
studied in mice (Kreiling et al. 1986b) and in rats (Bolt et al. 1984; Filser and Bolt 1984). Following 
exposure of mice and rats to 14C-1,3-butadiene, the elimination of radioactivity was rapid, and 77-99% of 
the initial tissue amount was eliminated with half-lives of between 2 and 10 hours (Bond et al. 1987). At 
concentrations of approximately <1,000 ppm, the elimination of 1,3-butadiene followed first-order 
kinetics in both species. The first-order metabolic clearance of inhaled 1,3-butadiene per kg body weight 
was 4,500 mL/hour for rats (Laib et al. 1988) and 7,300 mL/hour for mice (Kreiling et al. 1986b). The 
maximal metabolic elimination rate was calculated as 220 ^mol/hour/kg for rats (Laib et al. 1988) and 
400 ^mol/hour/kg for mice (Kreiling et al. 1986b). With increasing concentrations of 14C-1,3-butadiene, 
exhalation of radiolabeled carbon was a major pathway for elimination of 14C in mice and rats (Bond et al. 
1986). Similar results were observed in mice and rats following inhalation of 62.5 ppm 1,3-butadiene for 
6 hours (Himmelstein et al. 1996). Blood 1,3-butadiene concentrations in mice fell from about 3 ^M at 
the end of exposure to 0.03 ^M 15 minutes later. Rat elimination of 1,3-butadiene from blood was 
slower, falling from a post-exposure maximum of about 1.5-0.1 ^M 30 minutes later.
About 2% of the total inhaled amount of 1,3-butadiene was excreted as metabolites in Cynomolgus 
monkeys (Sun et al. 1989a). Carbon dioxide was the major exhalation product at 10 ppm, while epoxy­
metabolites (specific compounds not determined) were predominant in exhaled breath at 300 and
8,000 ppm. Urinary excretion of total metabolites was not influenced by exposure levels. In Macaca 
fascicularis monkeys, about 39% of metabolite radioactivity (specific compounds not determined) were 
eliminated in the urine, 0.8% in feces, and 56% were exhaled as carbon dioxide during the first 70 hours 
postexposure (Dahl et al. 1990).
3.4.4.2 Oral Exposure
No studies were located regarding excretion in humans or animals after oral exposure to 1,3-butadiene.
3.4.4.3 Dermal Exposure
No studies were located regarding excretion in humans or animals after dermal exposure to 1,3-butadiene.
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3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
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many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-3 shows a conceptualized representation of a PBPK model.
Literature on PBPK modeling of 1,3-butadiene is extensive (Beaudouin et al. 2010; Bois et al. 1999;
Bond et al. 1996; Brochot et al. 2007; Csanady et al. 1996; Evelo et al. 1993; Filser et al. 1993; Johanson 
and Filser 1993, 1996; Kohn 1997; Kohn and Melnick 1993, 1996, 2000, 2001; Leavens and Bond 1996, 
Pery and Bois 2009; Seilken et al. 1996; Smith et al. 2001; Sweeney et al. 1996, 1997, 2001). Models 
have been developed to simulate 1,3-butadiene kinetics in mice (Bond et al. 1996; Csanady et al. 1996; 
Johanson and Filser 1993, 1996; Kohn and Melnick 1993, 1996, 2000, 2001; Leavens and Bond 1996; 
Sweeney et al. 1996, 1997, 2001), rats (Bond et al. 1996; Csanady et al. 1996; Johanson and Filser 1993, 
1996; Kohn and Melnick 1993, 1996, 2000, 2001; Sweeney et al. 1996, 1997, 2001), and humans 
(Beaudouin et al. 2010; Bond et al. 1996; Brochot et al. 2007; Csanady et al. 1996; Evelo et al. 1993; 
Johanson and Filser 1996; Pery and Bois 2009). Model structures differ with respect to the number of 
physiological compartments simulated, the extent to which secondary and tertiary metabolites are 
simulated, and in which tissue compartments metabolism is assumed to occur. Selected examples are 
described in greater detail in the sections that follow.
Johanson and Filser 1996
Description of the Model. The Johanson and Filser model (Filser et al. 1993; Johanson and Filser 
1993, 1996) model simulates absorption and disposition of 1,3-butadiene and the metabolite, 3,4-epoxy- 
1-butene, in the mouse, rat, and human. The hepatic conjugation of 3,4-epoxy-1-butene to GSH is also 
simulated. Tissue compartments include the blood/lung, liver, fat, and muscle/richly-perfused tissues.
1,3-BUTADIENE
3. HEALTH EFFECTS
66
Figure 3-3. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
Inhaled c h e m ica l  ^ |------► Exhaled chem ical
C hem ica ls  
contacting skin
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: Adapted from Krishnan and Andersen 1994
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Model parameters are presented in Table 3-4. Both the exchange of 1,3-butadiene and 3,4-epoxy- 
1-butene between blood and tissue or lung air is assumed to be first-order and flow-limited. In vitro 
derivation of tissue:air and tissue:blood partition coefficients was performed by the model authors and 
reported in the study. Michaelis-Menten expressions were included for 1,3-butadiene oxidation,
3,4-epoxy-1-butene hydrolysis, and 3,4-epoxy-1-butene conjugation to GSH, all occurring in the liver 
compartment. Values for physiological (alveolar, pulmonary, and tissue perfusion rates, organ weights) 
and metabolic parameters (Vmax, Km, and GSH content and elimination rates) were taken from the 
literature, except for the affinity constant (Km) for 1,3-butadiene oxidation, which was fit to chamber air
1.3-butadiene timecourse data from rat and mouse closed chamber experiments. Elimination of
1.3-butadiene and 3,4-epoxy-1-butene was represented as either metabolism or as exchange passage back 
to the lung air.
Risk Assessment. This model has not been used in risk assessment. The model predicts that steady- 
state blood concentrations of 3,4-epoxy-1-butene resulting from continuous inhalation exposures to
1.3-butadiene would be higher in mice compared to rats or humans. At non-saturating conditions (e.g., 
exposures <1,000 ppm), the ratio of blood 3,4-epoxy-1-butene concentrations predicted from the model 
were: 1.6:1.0:0.3 for mouse:rat:human (Johanson and Filser 1996).
Validation of the Model. The Km for 1,3-butadiene oxidation and 3,4-epoxy-1-butene hydrolysis 
were the only parameters optimized against close-chamber gas uptake data for 1,3-butadiene or
3.4-epoxy-1-butene (1,000-5,000 ppm) in rats (Filser and Bolt 1984) and mice (Kreiling et al. 1987). 
Model predictions were evaluated against the concentration of 3,4-epoxy-1-butene appearing in the 
chambers (due to metabolism and exhalation from the animals) during the 1,3-butadiene exposures, and 
were found to predict 3,4-epoxy-1-butene levels that were similar to observations.
Target Tissues. The model simulates concentrations of 1,3-butadiene and 3,4-epoxy-1-butene in 
liver, a target tissue for 1,3-butadiene metabolites, as well as in blood, fat, and a lumped compartment for 
muscle and richly-perfused tissues.
Species Extrapolation. The model has been developed for simulations of rats, mice, and humans. 
Extrapolation to other species would require species-specific physiological and metabolism parameter 
values and blood-tissue partition coefficients.
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Table 3-4. Physiological and Chemical Parameters Used in the Johanson and
Filser (1993) PBPK Model for 1,3-Butadiene
Mouse Rat
Physiological data
Body weight (bw) Standard animal 25 250
(g) Simulations 27.5 157.5-217.5
Alveolar ventilation Standard animal 15 70.2
(mL/minute)
2/3proportional to bw 2 /3proportional to bwSimulations
Cardiac output Standard animal 17 83 2 /3Simulations proportional to bw2/3 proportional to bw2 /3
Blood flows Muscle and vessel-rich group aa aa
(percent of cardiac (VRG)
output) Fat 9 9
Liver 25 25
Compartment Lung and arterial 1 1
volumesa (percent Muscle and VRG 75 80
of body weight) Fat 10 7
Liver 5.5 4
Tissue:air partition coefficients
Butadiene Lung and arterial, muscle and 
VRG, liver
0.76 0.76
Fat 21.9 21.9
Blood 3.03 3.03
Epoxybutene Lung and arterial, muscle and 
VRG, liver
58.9 58.9
Fat 1 55 1 55
Blood 83.4 83.4
Water 43.0 43.0
Metabolic constants
Butadiene oxidation Microsomal protein (mg/g liver) 30 30
Vm a x (nmol minute-1 mg-1) 3.22 2.17
Km (pmol/L air) 5 5
Epoxybutene Microsomal protein (mg/g liver) 30 30
hydrolysis Vm a x (nmolminute-1 mg-1) 19 17
Apparent Km (mmol/L) 1.5 0.7
Intrinsic Km (percent of apparent 2 0% 2 0%
Km)
Epoxybutene Cytosolic protein (mg/g liver) 95 95
conjugation Vm a x/Km of epoxybutene 
(pLminute- 1 mg-1)
15 11
Km towards epoxybutene 100 100
(mmol/L)
Km towards glutathione (mmol/L) 0.1 0.1
Glutathione kinetics Initial steady-state concentration 
(mmol/L)
5.5 4.2
Elimination rate constant (hour-1) 0.15 0.15
aDensity was set to 1 for all organs
Source: Johanson and Filser 1993 (although simulations from a human model were reported in Johanson and Filser 
1996, parameter values were not reported)
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High-low Dose Extrapolation. The model has been evaluated for simulating inhalation exposures in 
mice and rats ranging from 500 to 5,000 ppm.
Interroute Extrapolation. The model simulates inhalation exposures only and would require 
additional parameterization to simulate exposures by other routes.
Strengths and Limitations. Strengths of the model are that it simulates disposition and clearance of 
inhaled 1,3-butadiene, as well as production and clearance of 3,4-epoxy-1-butene, the major oxidative 
metabolite formed in rodents. Limitations include: (1) the model has not been evaluated for inhalation 
exposures below 500 ppm; (2) the model does not simulate the appearance and disposition of other 
metabolites, such as the diepoxide, diols, and GSH-conjugate products eliminated in the urine; and (3) the 
model does not simulate 1,3-butadiene disposition in humans.
Kohn and Melnick 2001
Description of the Model. The Kohn and Melnick model (Kohn and Melnick 1993, 1996, 2000, 
2001) simulates absorption of 1,3-butadiene and the disposition of 1,3-butadiene and the metabolite,
3.4-epoxy-1-butene, in the mouse and rat. Model parameters are presented in Tables 3-5, 3-6, and 3-7. 
The body is represented by discrete compartments for venous and arterial blood, lung, liver, kidney, fat, 
the gastrointestinal tract, and lumped compartments for richly- and poorly perfused tissues (viscera and 
muscle, respectively). Values for physiological flow rates, tissue volumes, and tissue:blood partition 
coefficients were taken from the literature. 1,3-Butadiene is eliminated by exhalation to lung air or 
oxidative metabolism to 3,4-epoxy-1-butene and its oxidation metabolites (3,4-epoxy-1-butene, DEB,
3.4-epoxy-1,2-diol, 3-butene-1,2-diol) and glutathione conjugates. All of these pathways are described as 
saturable Michaelis-Menten processes, with Vmax and Km values optimized against published closed- 
chamber 1,3-butadiene and 3,4-epoxy-1-butene uptake data (Bolt et al. 1984; Filser and Bolt 1984; 
Kreiling et al. 1986b, 1987). Epoxide hydrolysis was modeled such that dissociation of the diepoxide 
from P450 in the microsome is followed by preferential binding of the epoxide hydrolase, replicating the 
so-called privileged access model for epoxide hydrolysis. The model simulates production and utilization 
of glutathione in kidney, liver, and lung, with the assumption that glutathione production is limited by 
availability of cysteine for the first step in glutathione synthesis (y-glutamylcysteine synthetase).
Risk Assessment. This model has not been used in risk assessment.
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Table 3-5. Physiological Parameter Values Used in the Kohn and Melnick (2001)
PBPK Model for 1,3-Butadiene
Mouse (percent) Rat (percent)
Tissue compartment volumes, percent body weight
Liver 5.5 3.7
Lung 0.6 0.52
Alveolar 0.5 0.515
Kidney 1.67 1.48
Gastrointestinal tract 7.5 7.5
Viscera 3.93 14.3
Fat 6 7
Muscle and skin 64.5 54.2
Blood 6 5.4
Capillary blood volume, percent tissue volume
Liver 11 13.8
Lung 11 18
Kidney 10.2 16
Gastrointestinal tract 2.9 2.65
Viscera 7.1 7.1
Fat 3 2
Muscle and skin 1.3 2
Blood flow rate, percent cardiac output
Liver (hepatic artery only) 4.4 3.9
Kidney 16.3 13.3
Gastrointestinal tract 18.1 18.1
Viscera 22.4 24.8
Fat 5 6.5
Muscle and skin 33.8 33.4
Source: Kohn and Melnick 2001
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Table 3-6. Chemical Partition Coefficients Parameter Values Used in the Kohn 
and Melnick (2001) PBPK Model for 1,3-Butadiene
Butadiene Epoxybutane Butenediol Epoxybutanediol Diepoxybutane
Blood:air 1.95 56.8 - - -
Liver 0.595 0.984 1.04 0.903 1.41
Lung 0.615 0.977 1.107 0.958 1.41
Kidney 0.472 0.842 0.962 0.833 1.54
Gastrointestinal tract 0.446 0.908 1.22 1.06 1.41
Viscera 0.446 0.908 1.22 1.06 1.41
Fat 10.8 2.25 0.573 0.496 2.19
Muscle and skin 0.564 0.736 1.139 0.986 1.82
Source: Kohn and Melnick 2001
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Table 3-7. Chemical Metabolism Parameter Values Used in the Kohn and Melnick
(2001) PBPK Model for 1,3-Butadienea
Liver Lung K idney
Butadiene metabolism
V m a x 155, 130 139, 9.6 1,430, 30
I / - P 4 5 0
Km 0.002, 0.00375 0.00501, 0.00775 0.00501, 0.00216
Epoxybutene metabolism
V m a x 45.1, 24.3 10.2, 9.84 48.6, 12.6
i x P 4 5 0
Km 0.0156, 0.145 0.0156, 0.145 0.0156, 0.145
V EHm 3 4 7 ,584 34.8, 42.8 113, 14.7
K e hKm 1.59, 0.26 1.59, 0.7 1.59, 0.7
VGSTm a x 6,420, 4,260 720, 196 960, 494
Adjusted k G T 3.59, 2.59 3.59, 4.94 3.59, 4.39
Butenediol metabolism
VP 4 5 0  
V m a x 16.3, 67.1 1.0, 31.5 1.0, 85.0
P 4 5 0
Km 0.0156, 0.145 0.0156, 0.145 0.0156, 0.145
VGSTm a x 3,480, 1,230 491, 276 1,070, 658
k g s t
m x 34, 34 34, 34 34, 34
Epoxybutanediol metabolism
c n
V m a x 363, 1,150 69.5, 169 10.0, 152
K E HKm 8.1, 2.76 7.5, 7.1 7.5, 7.1
VGSTm a x 2,260, 271 50.0, 100 50.0, 138
KGS T
m x
6.40, 4.17 6.40, 4.17 6.40, 4.17
Diepoxybutane metabolism
V Enm a x 1,920, 3,170 10.0, 1,160 35.2, 1,000
K E n
Km 8.1, 2.76 7.5, 7.1 7.5, 7.1
VGS T
m a x 9,720, 1,940 100, 100 100, 100
Adjusted k E T 6.40, 4.17 6.40, 4.17 6.40, 4.17
Cysteine metabolism
Tissue cysteine 0.193, 0.195 0.171, 0.127 0.280, 0.326
V Y 'G C S  
v  m a x 4 2 0 ,396 54, 50 7,920, 6,080
EH = epoxide hydrolase; y-GCS = gamma-glutamylcysteine synthesase; GST = glutathione S-transferase
aNon-bold values for mouse; bold values for rat; values in italics were estimated by formal optimization; entries in 
italics indicate optimized parameter values; Vmax values in nmol/hour/mg of protein; Km values and tissue cysteine 
concentrations in mM.
Source: Kohn and Melnick 2001
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Validation of the Model. The model predicted similar profiles of 1,3-butadiene and 3,4-epoxy- 
1-butene uptake data (100-4,000 ppm) in mice and rats against which it was optimized. Further, it 
predicted single time point concentrations of 1,3-butadiene in mice and rats similar to observations from 
nose-only exposures to 7-1,250 ppm (Bond et al. 1986; Himmelstein et al. 1994). Additionally, it 
predicted similar percentages of GSH depletion in mouse and rat lung and liver observed following 
7-hour 1,3-butadiene exposures of 50-2,000 ppm (Deutschmann and Laib 1989).
Target Tissues. The model simulates concentrations of 1,3-butadiene and 3,4-epoxy-1-butene in 
lung, liver, and kidney, all target tissues for 1,3-butadiene metabolite intoxication, as well as in blood, fat, 
gastrointestinal tract, and lumped compartments for muscle and viscera.
Species Extrapolation. The model has been developed for simulations of rats and mice. 
Extrapolation of predictions to humans would require additional species-specific values for physiology 
and metabolism, as well as human data to verify the accuracy of the predictions.
High-low Dose Extrapolation. The model has been evaluated for simulating inhalation exposures 
ranging from 7 to 4,000 ppm.
Interroute Extrapolation. The model simulates inhalation exposures only and would require 
additional parameterization to simulate exposures by other routes.
Strengths and Limitations. Strengths of the model are that it simulates disposition and clearance of 
inhaled 1,3-butadiene, as well as production and clearance of the major oxidative metabolites of
1,3-butadiene in kidney, liver, and lung, including 3,4-epoxy-1-butene, 1,2:3,4-diepoxybutane, 3,4-epoxy-
1,2-diol, and 3-butene-1,2-diol. It also simulates production and utilization of GSH in the kidney, lung, 
and liver, which allows prediction of glutathione depletion resulting from 1,3-butadiene metabolism. 
Limitations include: (1) the model has not been evaluated against data for inhalation exposures in 
humans, and (2) the model does not simulate the appearance and disposition of other metabolites, such as 
the diepoxide, diols, and GSH-conjugate products eliminated in the urine.
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Brochot et al. 2007
Description of the Model. The Brochot model (Brochot and Bois 2005; Brochot et al. 2007) 
simulates absorption of 1,3-butadiene and the disposition of 1,3-butadiene, 1,2-epoxy-3-butene, and 
1,2:2,3-diepoxybutane in the blood, fat, and lumped compartments for richly- and poorly-perfused tissues 
in humans. Model parameters are presented in Table 3-8. In addition, the disposition and clearance of 
3-butene-1,2-diol and 3,4-epoxy-1,2-butanediol was modeled for the blood and richly- and poorly- 
perfused tissues. Tissue:blood partition coefficients were taken from the literature. 1,3-Butadiene is 
eliminated by exhalation to lung air or oxidative metabolism, epoxide hydrolysis, or GSH conjugation in 
the richly-perfused tissues to mono- and diepoxide and the two diols. Since the model was intended to 
direct further study design for low-ppm human exposures, all of the metabolic steps are described as 
1st-order processes, governed by a rate constant for each pathway. The metabolic rate constants and 
physiological parameters were optimized using Bayesian techniques against 133 datasets from individual 
subjects inhaling 2 ppm 1,3-butadiene for 20 minutes (Lin et al. 2001). Several extensions of the Brochot 
et al. (2007) model have been reported. A 23-compartment model was developed for simulating
1,3-butadiene and 1,2-epoxy-3-butene kinetics in humans (Pery and Bois 2009). The model simulates 
flow-limited distribution to each tissue with partitioning assumed to occur predominantly into tissue fat 
(estimated from the fat:blood partition coefficient and fat content of each tissue). Beaudouin et al. (2010) 
further extended this model to a generic human lifetime PBPK model that included growth and 
transplacental transfer to the fetus.
Risk Assessment. This model has not been used in risk assessment.
Validation of the Model. The model fit well against the human data from which it was calibrated. Its 
performance has not been evaluated against other independent human inhalation data.
Target Tissues. The model predicts parent compound, mono- and diepoxide, and viscinal thiol 
(including the epoxydiol) concentrations in the blood, but not in other tissues.
Species Extrapolation. The model was optimized for humans. Extrapolation of predictions to 
animals would require additional species-specific values for physiology and metabolism, as well as 
animal data (available in the literature) to verify the accuracy of the predictions.
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Table 3-8. Physiological and Chemical Parameters Used in the Brochot et al.
2007 PBPK Model for 1,3-Butadiene Humans
Parameter Meana Standard deviationa
Body weight (kg) 70
Sex M
Metabolic activity in liver (mg protein/kg liver)
Microsomal protein 14,500
Cytosolic protein 45,000
Relative weight (percent of body weight)
Liver 0.026
Relative volumes (percent of body weight)
Well-perfused tissues 0.10 0.02
Fat 0.21 0.05
Relative flows (percent of total blood flow)
Poorly perfused tissues 0.26 0.06
Fat 0.05 0.01
Pulmonary characteristics
Minute volume (L/minute) 7.5 1.87
Ventilation perfusion ratio 1.0 0.25
Dead space fraction 0.33 0.08
Partition coefficients for BD
Blood:air 1.22 0.30
Poorly perfused tissues:blood 0.72 0.18
Well-perfused tissues:blood 0.69 0.17
Fat:blood 18.4 4.6
Partition coefficients for EB
Blood:air 93.3 23.3
Poorly perfused tissues:blood 0.49 0.12
Well-perfused tissues:blood 0.59 0.15
Fat:blood 1.80 0.45
Partition coefficients for DEB
Poorly perfused tissues:blood 1.98 0.49
Well-perfused tissues:blood 1.53 0.38
Fat:blood 2.20 0.55
Partition coefficients for BDD
Poorly perfused tissues:blood 1.00 0.25
Well-perfused tissues:blood 1.00 0.25
Partition coefficients for EBD
Poorly perfused tissues:blood 1.00 0.25
Well-perfused tissues:blood 1.00 0.25
Metabolic constants (minute-1)
BD ^  EB 0.119 0.06
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Table 3-8. Physiological and Chemical Parameters Used in the Brochot et al.
2007 PBPK Model for 1,3-Butadiene Humans
Parameter Meana Standard deviation0
Metabolic constants
EB ^  DEB 0.020 0.01
EB ^  BDD 0.511 0.25
DEB ^  EBD 0.471 0.23
BDD ^  EBD 0.00B 0.01
Other transformations (L/kg liver/minute)
EB by GSH 0.195 0.10
DEB by GSH 0.113 0.06
EBD by GSH 0.056 0.03
EBD by hydrolysis 0.235 0.12
BDD by ADH 0.045 0.02
aMean and standard deviation of lognormal distributions, reflecting variability in the human population.
ADH = alcohol dehydrogenase; BD = 1,3-butadiene; BDD = 3-butene-1,2-diol; DEB = 1,2:3,4-diepoxybutane; 
EB = 1,2-epoxy-3-butene; EBD = 3,4-epoxy-1,2-butanediol; GSH = glutathione
Source: Brochot et al. 2007
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High-low Dose Extrapolation. The model was calibrated for low (2 ppm) exposures in humans. 
Extrapolation to higher doses will require that the metabolic expression be modified to account for 
saturation of the oxidative, hydrolytic, and conjugating pathways described.
Interroute Extrapolation. The model was designed to simulate inhalation exposures. Additional 
parameters and absorption expressions must be added (and optimized with oral or dermal data) in order to 
extrapolate internal dosimetry from inhalation exposures across other routes of exposure. Parameters for 
gastrointestinal absorption of 1,3-butadiene were reported for use in a generic lifetime model (Beaudouin 
et al. 2010).
Strengths and Limitations. The model is the first PBTK model to simultaneously predict blood 
levels of 1,3-butadiene and its epoxide and viscinal diol metabolites in humans. Limitations include:
(1) the model has not been evaluated against data for inhalation exposures in animals, and (2) the model 
does not account for saturation of metabolic pathways that may occur in humans (and have been observed 
in rodents) exposed to higher inhalation concentrations of 1,3-butadiene.
Sweeney et al. 2001
Description of the Model. The Sweeney et al. (1996, 1997, 2001) model simulates inhalation 
absorption of 1,3-butadiene and the disposition of 1,3-butadiene, 1,2-epoxy-3-butene, and 
1,2:2,3 diepoxybutane in mice, rats, and humans. Blood, fat, liver, and lumped compartments for richly- 
and poorly-perfused tissues are simulated. Model parameters are presented in Table 3-9, 3-10, 3-11, 3-12,
3-13, 3-14, and 3-15. 1,3-Butadiene is eliminated by exhalation to lung air or oxidative metabolism to
1,3-epoxide-3-butene or to other products (e.g., aldehydes) in liver. The monoepoxide (1,3-epoxide-
3-butene) undergoes further oxidative metabolism to the diepoxide (DEB) and both the mono- and 
diepoxide undergo epoxide hydrolysis, GSH conjugation, or nonenzymative degradation. Enzymatic 
reactions are simulated as saturable reactions (Km, Vmax) and non-enzymatic elimination reactions are 
simulated as first-order reactions. Production and utilization of glutathione in liver are simulated, which 
allows prediction of glutathione depletion resulting from 3,4-epoxy-1-butene metabolism.
Risk Assessment. This model has not been used in risk assessment.
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Table 3-9. Physiological Parameters Used in Sweeney et al. (1997) 1,3-Butadiene
PBPK Model
Parameter Rat Mouse
Alveolar ventilation3 (Qpu) (L/hour/kg) 17 41
Cardiac outputa (Qt) (L/hour/kg) 17 41
Body weight (BW) (kg) 0 .215-0.475 0.028-0.035
Blood flowb (Qi) (fraction of cardiac output) (Fi) (dimensionless)
Lung 1.0 1.0
Fat 0.09 0.09
Slowly perfused tissues 0.15 0.15
Richly perfused tissues 0.51 0.51
Liver 0.25 0.25
Organ volumesc (Vi) (fraction of body weight) (dimensionless)
Lung 0.0053 0.005
Fat 0.09 0.10
Slowly perfused tissues 0.71 0.7
Richly perfused tissues 0.0347 0.0226
Liver 0.05 0.0624
aAlveolar ventilation and cardiac output are given for a hypothetical 1 -kg animal. In the model simulations, the 
parameter is multiplied by the body weight of the animal (in kg) to calculate the ventilation rate and cardiac output (in 
L/hour) for that individual animal.
bTissue blood flows are calculated by multiplying the total cardiac output by the fractional flow: Qi = Fi x Qt. 
cTissue volumes are calculated by multiplying the body weight by the fractional volume: Vi = Fi x BW.
Source: Sweeney et al. 1997
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Table 3-10. Partition Coefficients Used in Sweeney et al. (1997) PBPK Model for
1,3-Butadiene
Tissue
Butadienea Epoxybutenea Diepoxybutaneb
Rat Mouse Rat Mouse Mouse
Blood 1.49 1.34 50.4 36.6 0.437
Liver 1.19 1.35 72.0 42.1 0.615
Lung 0.92 1.47 54.7 56.3 ND
Kidney ND ND ND ND ND
Muscle 1.47 4.01 19.8 23.6 0.795
Fat 22.2 19.2 138.0 91.2 0.959
Saline 0.088 44.3 0.723
Oil 23.2 164 ND
aTissue:air partition coefficients. 
bTissue:hexane partition coefficient.
ND = not determined
Source: Sweeney et al. 1997
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Table 3-11. Nonenzymatic Reaction Rate Constants Used in Sweeney et al. (1997)
PBPK Model for 1,3-Butadiene
Tissue
Epoxybutene Diepoxybutane
Rat Mouse Rat Mouse
Blood 0.582 0.558 ND 0.189
Liver 4.94 4.14 ND 3.15
Lung 6.07 2.70 ND 4.1
Fat 1.72 1.56 ND 2.8
Muscle 0 0 ND 0
ND = not determined
Source: Sweeney et al. 1997
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Table 3-12. Metabolism Rate Constants Used in the Sweeney et al. (1997) PBPK
Model for 1,3-Butadiene
Parameter value
Substrate Tissue Pathway Units Rat Mouse
Butadiene Liver Oxidation ^mol/kg/hour 62 338
(to all products) ^mol/L 3.75 2.0
Oxidation ^mol/kg/hour 8.2 97
(to epoxybutene only) ^mol/L 1.54 0.88
Oxidation ^mol/kg/hour 54 243
(to other volatiles) ^mol/L 4.36 2.72
Lung Oxidation ^mol/kg/hour 1.01 21.6
(to all products) ^mol/L 7.75 5.01
Oxidation ^mol/kg/hour 0.13 6.4
(to epoxybutene only) ^mol/L 3.18 1.6
Oxidation ^mol/kg/hour 0.88 16.1
(to other volatiles) ^mol/L 9.14 9.5
Epoxybutene Liver Oxidation ^mol/kg/hour 57.1 176.6
(one enzyme) ^mol/L 141 145
Oxidation ^mol/kg/hour 10 32.5
(two enzymes) ^mol/L 141 15.6
^mol/kg/hour 47.1 144.1
^mol/L 141 145
Hydrolysis ^mol/kg/hour 260 754
^mol/L 260 1,590
Glutathione conjugation ^mol/kg/hour 78,100 154,000
^mol/L 13,800 35,300
^mol/L 100 100
Lung Glutathione conjugation ^mol/kg/hour 819 4,088
^mol/L 17,400 36,500
Diepoxybutane Liver Hydrolysis ^mol/kg/hour 5,555 4,193
^mol/L 2,700 8,100
Glutathione conjugation ^mol/kg/hour 60,264 50,342
^mol/L 24,000 6,400
Lung Hydrolysis ^mol/kg/hour 122.7 466.1
^mol/L 7,100 7,500
Glutathione conjugation ^mol/kg/hour 332 577
^mol/L 4,170 1,700
Source: Sweeney et al. 1997
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Table 3-13. Physiological Parameters Used in the Sweeney et al. (2010) PBPK
Model for 1,3-Butadiene in Humans
Parameter Value Units Comment
Alveolar ventilation rate (QPC) 4.3 L/hour/kg body weight QP = QPC x BW
Cardiac output (QCC) 4.5 L/hour/kg body weight QC = QCC x BW
Fractional blood flow to liver 0.227 Dimensionless QR = 0.76 x QC-QL
Fractional blood flow to fat 0.052 Dimensionless QS = 0.24 x QC-QF
Fractional weight of liver 0.027 Dimensionless
Fractional weight of lung 0.0076 Dimensionless VR = 0.09-VL-VLU
Fractional weight of fat 0.2142 Dimensionless VS = 0.81 -VF
Body weight 70 kg
Cytosolic protein content of liver 89,000 mg protein/kg liver Rat value
Microsomal protein content of liver 77,000 mg protein/kg liver Human value
Source: Sweeney et al. 2001
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Table 3-14. Chemical Partition Coefficients Used in the Sweeney et al. (2010)
PBPK Model for 1,3-Butadiene in Humans
Parameter Value Comment
1,3-Butadiene
Blood:air 1.22 Average of individual values for humans
Liver:air 0.68 Human tissue
Fat:air 22.5 Human tissue
Lung:air 0.48 Human tissue
Slowly perfused tissue:air 0.88 Value for human muscle
Richly perfused tissue:air 0.84 Values for human kidney, brain, and 
liver weighted by contribution to body 
weight
Butadiene monoepoxide
Blood:air 93.3 Human tissue
Liver:air 55.3 Human tissue
Fat:air 168 Human tissue
Lung:air 55.3 Value measured for human liver
Slowly perfused tissue:air 45.8 Value measured for human muscle
Richly perfused tissue:air 55.3 Value measured for human liver
Butene diol
Liver:blood 1 Volume of distribution=0.87 L/kg in 
mouse; mouse model has perfused 
tissues=0.9 kg/kg total body weight
Rest of body:blood 1 Volume of distribution=0.87 L/kg in 
mouse; mouse model has perfused 
tissues=0.9 kg/kg total body weight
Butadiene diepoxide
Liver:blood 1.53 Rat tissue
Fat:blood 2.2 Rat tissue
Lung:blood 1.53 Rat liver value
Slowly perfused tissue:air 1.82 Rat muscle value
Richly perfused tissue:air 1.41 Rat kidney value
Epoxybutane diol
Liver:blood 1 Assumption based on butene diol and 
butadiene diepoxide partition 
coefficients
Rest of body:blood 1 Assumption based on butene diol and 
butadiene diepoxide partition 
coefficients
Source: Sweeney et al. 2001
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Table 3-15. Chemical Metabolism Parameters Used in the Sweeney et al. (2010)
PBPK Model for 1,3-Butadiene in Humans
Parameter (units) Baseline valuea
VGax for epoxidation of 1,3-butadiene to butadiene monoepoxide (^mol/mg 
protein/hour)
0.0132
Kg for epoxidation of 1,3-butadiene to butadiene monoepoxide (^M) 0.7
VGax for epoxidation of butadiene monoepoxide to butadiene diepoxide (^mol/mg 
microsomal protein/hour)
0.031
Kg for epoxidation of butadiene monoepoxide to butadiene diepoxide (^M) 880
VGax for hydrolysis of butadiene monoepoxide to butene diol 1.4
Kg for hydrolysis of butadiene monoepoxide to butene diol 540
VGax for conjugation of butadiene monoepoxide and glutathione (^mol/mg cytosolic 
protein/hour)
2.7
Kg for conjugation of butadiene monoepoxide and glutathione (^M) 10,400
VGax for conjugation of butadiene diepoxide and glutathione (^mol/mg cytosolic 
protein/hour)
0.4
Kg for conjugation of butadiene diepoxide and glutathione (^M) 3,390
VGax for epoxidation of butene diol to epoxybutane diol (^mol/mg microsomal 
protein/hour)
0.031
Kg for epoxidation of butene diol to epoxybutane diol (^M) 880
VGax for hydrolysis of butadiene diepoxide to epoxybutane diol (^mol/mg microsomal 
protein/hour)
9.2
Kg for hydrolysis of butadiene diepoxide to epoxybutane diol (^M) 4,605
VGax for metabolism of butene diol by alcohol dehydrogenase (^mol/mg cytosolic 
protein/hour)
0.64
Kg for metabolism of butene diol by alcohol dehydrogenase (^M) 10,600
VGax for hydrolysis of epoxybutane diol to erythritol (^mol/mg microsomal protein/hour) 4.6
Kg for hydrolysis of epoxybutane diol to erythritol (^M) 4,605
VGax for conjugation of epoxybutane diol and glutathione (^mol/mg cytosolic 
protein/hour)
0.2
Kg for conjugation of epoxybutane diol and glutathione (^M) 3,390
aMedian or average parameter values. 
Source: Sweeney et al. 2001
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Validation of the Model. The model was calibrated and evaluated against data from intravenous 
studies in rats and inhalation exposures of mice and rats (Sweeney et al. 1997) and humans (Sweeney et 
al. 2001).
Target Tissues. The model has been used to predict parent compound, monoepoxide, and diepoxide 
concentrations in the blood.
Species Extrapolation. Mouse, rat, and human models have been developed. Extrapolation of 
predictions to animals would require additional species-specific values for physiology and metabolism, as 
well as animal data (available in the literature) to verify the accuracy of the predictions.
High-low Dose Extrapolation. The model has been evaluated for simulating inhalation exposures in 
mice and rats ranging from 60 to 1,250 ppm in rodents and 5 ppm in humans.
Interroute Extrapolation. The model was designed to simulate inhalation exposures. Additional 
parameters and absorption expressions must be added (and optimized with oral or dermal data) in order to 
extrapolate internal dosimetry from inhalation exposures across other routes of exposure.
Strengths and Limitations. Strengths of this model include simulation of an alternative oxidative 
pathway for 1,3-butadiene (other than leading to 1,2-epoxy-3-butene); simulations of both enzymatic and 
nonenzymatic elimination of 1,3-butadiene metabolites; and simulation of production and utilization of 
glutathione.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Formation o f Reactive Metabolites. The role of metabolism of 1,3-butadiene to reactive metabolites and 
the importance of species differences in metabolism of 1,3-butadiene to human health risk assessment 
were recently reviewed by Kirmam et al. (2010a). As discussed in Section 3.4.3 (Toxicokinetics/ 
Metabolism; also see Figure 3-2), 1,3-butadiene is metabolized by oxidation, hydrolysis, and conjugation 
reactions, with oxidation and hydrolysis reactions leading to the formation of several reactive epoxide 
intermediates. Of the reactive intermediates formed, EB (formed by oxidation of 1,3-butadiene), DEB 
(formed by oxidation of EB), and EBD (formed by hydrolysis reactions of DEB) are reactive electrophilic
1,3-BUTADIENE
3. HEALTH EFFECTS
86
compounds that have been shown to interact with DNA. The order of genotoxic potency of the epoxide 
metabolites is DEB >> EB > EBD. The higher genotoxic potency of DEB may be due to its ability to 
bind to two molecules or two places in the molecule at the same time (e.g., DNA-protein cross-links or 
DNA cross-links) (see discussion below in Section 3.5.2 on mechanisms of genotoxicity) (Albertini et al. 
2010). Thus, the formation of reactive metabolites is critical to the genotoxic activity of 1,3-butadiene. 
Although little information was identified regarding the role of reactive metabolites in the development of 
other adverse effects of 1,3-butadiene (e.g., nongenotoxic, noncancer), given their reactive nature, it is 
likely that reactive epoxide metabolites play an important role in the development of other adverse 
effects.
Species Differences in Metabolism. Metabolism of 1,3-butadiene appears to follow the same enzymatic 
pathways in all species, including humans, with production of the same reactive intermediates. However, 
as discussed below, important species differences exist in the rates of formation and detoxification of 
reactive metabolites (Bond et al. 1993; Csanady et al. 1992; Dahl et al. 1991; Filser et al. 2001, 2007, 
2010; Himmelstein et al. 1997; Henderson et al. 1996, 2001; Kirman et al. 2010a; Krause and Elfarra 
1997; Schmidt and Loeser 1985; Thornton-Manning et al. 1995a). As a result, rodents, particularly mice, 
have much higher tissue levels of reactive metabolites than nonhuman primates and humans. Therefore, 
based on the assumption that the same mechanism of action is involved in the development of 1,3-buta­
diene-induced toxicity (i.e., interaction of the reactive metabolites with DNA and other cellular 
macromolecules) is the same for all species, mice are expected to be much more sensitive to 1,3-buta­
diene than other rats, nonhuman primates, and humans.
As reviewed by Kirman et al. (2010a), evidence for species differences in metabolism of 1,3-butadiene is 
available from in vitro studies, studies using isolated perfused livers, and in vivo studies measuring tissue 
and urine metabolite levels and blood hemoglobin adduct levels. Results of in vitro studies using hepatic 
microsomal fractions isolated from mice, rats, and humans show that conversion of EB to DEB in mice is
3.3-fold greater than in rats and 2.4-61-fold greater than in humans. Studies in isolated perfused livers 
show differences in metabolism of 1,3-butadiene in mice and rats. In livers perfused with 1,3-butadiene, 
three epoxide metabolites (EB, DEB, and EBD) were identified in perfusion effluent in mice, whereas 
only one epoxide metabolite (EB) was identified in rats. Effluent concentrations of EB in mice were
8.5-fold greater than in rats. For perfusion studies with EB (which is oxidized to form DEB), DEB 
formation was greater in mice than in rats. Metabolite levels in tissues following inhalation exposure of 
mice and rats to 1,3-butadiene also provide evidence of species differences. Compared to rats, EB and 
DEB levels in blood and tissues of mice were from approximately 2-15- and >100-fold higher,
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respectively, with levels exhibiting dose- and time-dependence (see discussion below on nonlinear 
kinetics) (Filser et al. 2007). Based on evaluation of hemoglobin adduct biomarkers (adducts formed by 
interaction of 1,3-butadiene metabolites with hemoglobin), mice appear to have higher DEB levels than 
rats and much higher levels than humans (Swenberg et al. 2011). However, quantitative measurements of 
differences in hemoglobin adduct profiles show considerable variability, possibly due to differences in 
exposure conditions. Comparison of urinary excretion profiles of 1,3-butadiene metabolites in mice, rats, 
and humans also shows that species differences exist in the detoxification pathways. Findings suggest 
that humans and rats are more “efficient” at detoxification of reactive metabolites than mice. Taken 
together, results of in vitro and in vivo studies showing that mice have higher levels of reactive 
metabolites, particularly the highly reactive DEB, than other species suggest that mice may be uniquely 
sensitive to toxic effects of 1,3-butadiene and, therefore, may not be an appropriate animal model for use 
in human health risk assessment of 1,3-butadiene.
Nonlinear Toxicokinetics (Metabolism). Metabolism of 1,3-butadiene exhibits nonlinear kinetics 
(Kirman et al. 2010a), with both dose- and duration-dependent effects (see discussion in Section 3.4.3 
Toxicokinetics/Metabolism). Because the formation of reactive metabolites are critical in the 
development of 1,3-butadiene toxicity, nonlinearity in metabolic processes has the potential to affect 
dose-response extrapolation from animals to humans. Several processes have been proposed as sources 
of nonlinear kinetics; these include inhibition, induction and saturation of various metabolizing enzymes 
and depletion of glutathione (as reviewed by Kirman et al. 2010a).
3.5.2 Mechanisms of Toxicity
Genotoxicity. The genotoxicity of 1,3-butadiene and its electrophilic metabolites have been extensively 
studied. A comprehensive review of the genotoxicity of 1,3-butadiene metabolites, focusing primarily on 
EB, DEB, and EDB, was recently published (Albertini et al. 2010). The weight of evidence strongly 
suggests that 1,3-butadiene metabolites, rather than 1,3-butadiene itself, are responsible for genotoxic 
effects, due to their highly reactive nature. Of these metabolites, the order of potency for mutagenicity is 
DEB >> EB > EDB. Results of in vitro studies in bacterial and mammalian cells (including human cells) 
show that the electrophilic metabolites of 1,3-butadiene form DNA adducts, induce DNA strand breaks, 
increase unscheduled DNA synthesis and DNA excision repair, induce sister-chromatid exchange, induce 
micronucleus formation, and produce mutations, chromosome aberrations (including breaks), and 
aneuploidy (as reviewed by Albertini et al. 2010). Results of in vivo studies in animals show that
1,3-butadiene metabolites form adducts with DNA (Koturbash et al. 2011a, 2011b). Other studies 
evaluating genotoxicity following inhalation exposure to 1,3-butadiene provide indirect evidence of
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genotoxicity of 1,3-butadiene metabolites (Cunninham et al. 1986; Jauhar et al. 1988; Lovreglio et al. 
2006; Sharief et al. 1986; Sram e tal. 1998; Tice et al. 1987).
Carcinogenicity. As discussed in Section 3.2.1.7, chronic exposure to 1,3-butadiene is associated with an 
increased risk of mortality due to leukemia in styrene-butadiene workers and the development of multisite 
cancers in laboratory rodents. The mode of action for carcinogenicity of 1,3-butadiene was recently 
assessed by Kirman et al. (2010b). As discussed above (Mechanism of Toxicity, Genotoxicity), the 
genotoxicity of electrophilic metabolites of 1,3-butadiene (DEB, EB, and EBD) have been extensively 
studied. Results show that DEB, EB, and EBD react with DNA and are mutagenic. Based on the weight 
of evidence for genotoxicity, it is likely that the carcinogenic mode of action of 1,3-butadiene is 
mutagenic activity of the electrophilic 1,3-butadiene metabolites.
Ovarian atrophy. Intraperitoneal studies in mice suggest that 1,3-butadiene metabolites are the causative 
agent for the ovarian effects observed in intermediate- and chronic-duration inhalation studies (NTP 
1993). Dose-related decreases in ovarian and uterine weights, number of small (primordial) ovarian 
follicles, and number of growing (primary to pre-antral) ovarian follicles were observed following a 
30-day intraperitoneal exposure to EB or DEB (Doerr et al. 1996). The ED50 (i.e., the effective dose that 
reduces the number of follicles to 50% of controls) values for small and growing follicles were 0.29 and 
0.40 mmol/kg, respectively, for EB and 0.10 and 0.14 mmol/kg, respectively, for DEB. Similarly, 
decreases in ovarian or uterine weight and the number of ovarian follicles were also observed in rats 
similarly exposed to DEB (Doerr et al. 1996). However, no alterations were observed in rats 
administered EB at doses as high as 1.43 mmol/kg. These data strongly suggest that DEB is the causative 
agent of the ovarian atrophy.
Although similar effects were observed in rats and mice administered DEB, mice appear to be more 
sensitive to its toxicity than rats. Administration of 0.14 mmol/kg resulted in 83 and 52% depletion of 
small and growing follicles, respectively, in mice and only 31 and 40% reductions in rats. When the 
dose-response plot for ovarian weight is based on area under the blood EB or DEB concentration-time 
curve (estimated using PBPK modeling), the curves are similar for both species (Sweeney et al. 2001). 
Sweeney et al. (2001) also used PBPK modeling to estimate the blood area under the DEB concentration- 
response curve using the data from the NTP (1993) study, which found ovarian effects in mice exposed to 
>6.25 ppm, and from the Owen study (Owen and Glaister 1990; Owen et al. 1987), which did not find 
ovarian effects in rats exposed to <8,000 ppm. In mice, the blood area under the DEB curve was 
consistent with the results of the Doerr et al. 1996) intraperitoneal study. The blood DEB area under the
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curve for rats exposed to 8,000 ppm 6 hours/day, 5 days/week for 105 weeks would be 189 ^M-hour; this 
value lies between the predicted NOAEL and LOAEL for ovarian effects in rats administered DEB via 
intraperitoneal injection.
3.5.3 Animal-to-Human Extrapolations
Comparison of rat and mouse data identify large differences in sensitivity to 1,3-butadiene, which are due 
to metabolic differences between species. Humans, rats, and mice metabolize 1,3-butadiene using the 
same enzymatic pathways resulting in the production of the same reactive metabolites, in particular, EB, 
DEB, and EBD. However, quantitative differences in the rate of formation and detoxification of reactive 
metabolites have been found that result in higher tissue levels of reactive metabolites in rodents, 
particularly mice, than in humans (Bond et al. 1993; Csanady et al. 1992; Dahl et al. 1991; Filser et al. 
2001, 2007, 2010; Henderson et al. 1996, 2001; Himmelstein et al. 1997; Kirman et al. 2010a; Krause and 
Elfarra 1997; Schmidt and Loeser 1985; Thornton-Manning et al. 1995b). In vitro and perfusion data 
show that mice are more efficient than rats at oxidizing 1,3-butadiene to form EB, and the conversion of 
EB to DEB in mice is 3.3-fold greater than in rats and 2.4-61-fold greater than in humans (Kirman et al. 
2010a). In addition, mice have a higher ratio of 1,3-butadiene activation to detoxification than rats or 
humans; the ratio of activation to detoxification was 74:1 in mouse, 6:1 in rat, and 6:1 in human liver 
tissues (Bond et al. 1993).
Following inhalation exposure to 1,3-butadiene, blood and tissue levels of EB and DEB were 2-15- and 
>100-fold higher, respectively, in mice as compared to rats (Filser et al. 2007). At equivalent inhalation 
concentrations, the total amount of 1,3-butadiene metabolites were 5-50 times lower in cynomolgus 
monkeys than in mice and 4-14 times lower in monkeys compared to rats (Dahl et al. 1991). Swenberg et 
al. (2011) estimated DEB blood levels measured 1,3-butadiene-derived hemoglobin adducts levels in rats, 
mice, and humans exposed to approximately 1 ppm 1,3-butadiene. The estimated DEB doses were 0.02, 
0.42, and 24 nM-hour/ppm-hour in humans, rats, and mice, respectively. Thus, the extrapolation of 
rodent data to humans would require the use of an internal dose metric to account for these species 
differences in the metabolism of 1,3-butadiene. Although PBPK models have been developed in rodents 
(Johanson and Filser 1993; Kohn and Melnick 1993, 1996, 2000) and a preliminary model has been 
developed in humans (Brochot et al. 2007), the models are limited in their ability to predict internal doses 
for key metabolites (Kirman and Grant 2012). An alternative approach to using PBPK models would be 
to use a biomarker of exposure to the reactive metabolites. Several biomarkers of exposure have been 
identified for reactive 1,3-butadiene metabolites including MHB-Val hemoglobin adducts, N-(2,3,4-tri-
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hydroxybutyl)valine (THB-Val) hemoglobin adducts, and pyr-Val hemoglobin adducts, which have been 
shown to be good surrogate biomarkers for EB, EBD, and DEB, respectively (Georgieva et al. 2010; 
Slikker et al. 2004).
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
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No in vivo or in vitro studies were located regarding endocrine disruption in humans and/or animals after 
exposure to 1,3-butadiene.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the
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child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
No human data are available to determine whether children are more sensitive than adults to 1,3-buta­
diene toxicity. Mechanistic data in animals suggest that the ratio of 1,3-butadiene oxidation:epoxide 
hydrolysis may be a significant determinant of 1,3-butadiene sensitivity (see Sections 3.5.1 and 3.5.2). It 
is not known if  the ratio of 1,3-butadiene oxidation:epoxide hydrolysis is different in children than adults. 
Unborn children may be more sensitive to 1,3-butadiene toxicity than adults, as changes in fetal body 
weight and developmental effects have been identified at the lowest LOAELs in mice exposed to acute- 
and intermediate-duration inhalation exposures (Anderson et al. 1996; DOE/NTP 1987b). Several studies 
have associated the development of childhood leukemia to close proximity of birthplace to industrial 
point sources of 1,3-butadiene (and other high-volume industrial chemicals, including benzene) (Knox et 
al. 2005, 2006; Reynolds et al. 2003; Whitworth et al. 2008). Although these study authors suggest that 
in utero exposure to 1,3-butadiene may have significantly contributed to cancer risks in these populations, 
there are no estimates of actual prenatal or postnatal exposures of mothers or children, respectively.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).
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A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment 
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several 
factors can confound the use and interpretation of biomarkers of exposure. The body burden of a 
substance may be the result of exposures from more than one source. The substance being measured may 
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from 
exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken. It may be difficult to 
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids 
(e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 1,3-buta­
diene are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused 
by 1,3-butadiene are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to 1,3-Butadiene
Two urinary metabolites of 1,3-butadiene have been identified in tollbooth workers. Sapkota et al. (2006) 
measured 258-378 ng/mL 1,2-dihydroxy-4-(N-acetylcysteinyl)-butane and 6-9.7 ng/mL of the isomeric 
mixture of 1-hydroxy-2-(N-acetylcysteinyl)-3-butene and 1-(N-acetylcysteinyl)-2-hydroxy-3-butene in
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workers’ urine following average ambient 1,3-butadiene exposures of 0.4-1 ppb. These biomarkers are 
quite specific to 1,3-butadiene exposure, but the measured levels were not significantly associated with 
exposure, although this may have been due to the small sample size used or the low (0.0005 ppm) 
exposure levels studied. N-acetyl-S-((1-hydroxymethyl)-2-propenyl)cysteine and N-acetyl-
S-((2-hydroxymethyl)-3-propenyl)cysteine, the isomeric mixture known as MHBMA (or M2), are the 
GST conjugation products of EB found in human urine following 1,3-butadiene exposure. Another 
urinary metabolite, N-acetyl-S-(3,4-dihydroxybutyl)cysteine, or DHBMA (M1), is formed by EBdiol 
conjugation with glutathione via GST (Boogaard et al. 2001a; McDonald et al. 2004). These urinary 
metabolites have been used as biomarkers of 1,3-butadiene exposures in several human studies (Albertini 
et al. 2001, 2007; Ammenheuser et al. 2001; Boogaard et al. 2001a; Fustinoni et al. 2004).
Protein adducts have been widely used to monitor the formation of alkylating metabolites and can be used 
as dose metrics to compare species differences in metabolism. Hemoglobin adducts accumulate over the 
lifespan of the erythrocyte and they represent cumulative exposure since they are not removed by 
enzymatic repair systems (Georgieva et al. 2010). Three N-terminal valine hemoglobin adducts have 
been identified for 1,3-butadiene: MHB-Val, THB-Val, and pyr-Val. MHB-Val, THB-Val, and pyr-Val 
are formed when EB, DEB, and EB-diol, respectively, react with hemoglobin (Georgieva et al. 2010; 
Slikker et al. 2004). A linear accumulation of MHB-Val and THB-Val was observed in B6C3F1 mice 
and Sprague-Dawley rats after intraperitoneal (Sun et al. 1989b) and inhalation (HEI 2000) exposures. 
Species differences have been detected in the amount of adducts formed at a given 1,3-butadiene 
concentration. Higher levels of MHB-Val and pyr-Val adducts were found in mice compared to rats 
(Albrecht et al. 1993; Boysen et al. 2004). Concentration-response studies have shown that the formation 
of pyr-Val hemoglobin adducts is saturable. In rats, the formation of pyr-Val adducts plateaus at 
inhalation exposures of >200 ppm (Georgieva et al. 2010). In mice, the formation of pyr-Val adducts did 
not plateau; however, the rate of formation decreased below 1.5 ppm (Georgieva et al. 2010). MHB-Val 
and THB-Val hemoglobin adduct levels were well correlated with 1,3-butadiene exposure in
1,3-butadiene monomer workers (Albertini et al. 2001, 2007; Begemann et al. 2001a, 2001b; Osterman- 
Golkar et al. 1996) and Chinese polymer workers (Hayes et al. 2000; HEI 2000). .Pyr-Val was not 
detected in blood of male and female Czech workers exposed to 0.2-0.4 ppm (Albertini et al. 2007). 
Pyr-Val adducts were detected in the blood of workers not occupationally exposed to 1,3-butadiene, in 
monomer workers and polymerization workers (Boysen et al. 2012); the levels in the polymerization 
workers (mean 1,3-butadiene exposure level of 0.81 ppm) were significantly higher than in the control 
and monomer workers (mean 1,3-butadene exposure levels of 0.01 and 0. 29 ppm, respectively). When 
the three groups of workers were combined, a significant association between pyr-Val adduct levels and
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individual 1,3-butadiene exposure levels was found. Using levels of these hemoglobin adducts,
Swenberg et al. (2011) estimated metabolite levels in rats, mice, and humans, which allowed for a species 
comparison of reactive metabolite levels at a given 1,3-butadiene concentration.
Zhao et al. (2000) found a significant linear relationship of DNA adduction and 1,3-butadiene exposure 
between 1,3-butadiene workers and controls. The levels of N1-(2,3,4-trihydroxybutyl)adenine adduct in 
lymphocytes of 1,3-butadiene workers (mean exposure: 0.3 ppm; range: <0.005-7.7 ppm) were 5-fold 
higher than controls (mean exposure: 0.01 ppm; range: <0.001-0.07 ppm). 1,3-Butadiene-specific 
urinary metabolites and hemoglobin and DNA adducts have also been observed in animals. Excretion of
1.3-butadiene metabolites was reported to be high in the urine of exposed monkeys (Dahl et al. 1990). 
DNA adducts were detected in the livers of mice and rats exposed to radiolabeled 1,3-butadiene (Kreiling 
et al. 1986b). In mice exposed to 1,3-butadiene by nose-only inhalation, the N7-guanine adduct 
(^7-(1-(hydroxymethyl)-2,3-dihydroxypropyl)guanine) from interaction with 3,4-epoxy-1,2-diol, was the 
major DNA adduct measured (Boogaard et al. 2001b).
1.3-Butadiene has been measured in expired air of forestry workers living in mountain villages (Perbellini 
et al. 2003); however, the levels measured (median of 1.2 ng/L) were not correlated with any exposure to
1.3-butadiene.
3.8.2 Biomarkers Used to Characterize Effects Caused by 1,3-Butadiene
Dermal, ocular, and/or upper respiratory irritation can occur following 1,3-butadiene exposure (NIOSH 
2005) and may alert the exposed individual. However, the effects are not specific for 1,3-butadiene 
exposure and may be caused by several other chemicals.
Given the genotoxic (Section 3.3) and carcinogenic (Section 3.2.1.7) activity of 1,3-butadiene, a useful 
biomarker of effect would correlate a quantifiable measure of genetic mutation with 1,3-butadiene 
exposure. 1,4-Bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD) and 1-(guan-7-yl)-4-(aden-1-yl)-
2.3-butanediol (N7G-N1A-BD) are DEB-specific DNA-DNA cross-links identified in rats and mice 
inhaling up to 625 ppm 1,3-butadiene (Goggin et al. 2009, 2011). Mice exhibited 4-10-fold higher levels 
than rats of these cross-links. Further, higher levels of bis-N7G-BD were measured in females, compared 
to males. The sensitivity of female mice to these biomarkers and to 1,3-butadiene-induced 
carcinogenicity suggests that: (1) DEB is the putative carcinogenic metabolite of 1,3-butadiene, and
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(2) bis-N7G-BD and N7G-N1A-BD levels may quantitatively inform on genotoxicity leading to tumor 
development.
Another biomarker of genetic change is the mutation frequency of the hprt gene locus in human 
peripheral lymphocytes, which has been used in multiple studies of 1,3-butadiene SBR, monomer, and 
polymer workers in the United States, China, and Czech Republic. These studies are discussed in detail 
in Section 3.3. Several of these studies demonstrated good correlation between the increase in hprt 
mutation frequency and 1,3-butadiene exposure (Abdel-Rahman et al. 2001, 2003, 2005; Ammenheuser et 
al. 2001; Ma et al. 2000; Ward et al. 1994, 1996, 2001), as well as correlation with urinary and 
hematological biomarkers of exposure. Others did not find a significant correlation between exposure 
and mutation frequency (Albertini et al. 2001, 2007; Hayes et al. 1996, 2000; HEI 2003; Liu et al. 2008; 
Tates et al. 1996). The reasons for the differences in sensitivity of the hprt mutation as a biomarker may 
include the very low exposures that were studied and differences in assay procedures (as discussed in 
Section 3.3). It is unclear at this time which hprt mutation frequency assay is most adequate for risk 
assessment.
Two biomarkers for carcinogenic effect have been consistently found in multiple tumors sites in rodent 
chronic bioassays. A number of malignant gliomas and neuroblastomas in mice chronically inhaling
1,3-butadiene exhibited mutations of the p53 gene and H- and K-ras oncogenes (Kim et al. 2005), which 
have also been observed in forestomach tumors (Sills et al. 2001), hemagiosarcomas (Hong et al. 2000), 
and lymphomas (Zhuang et al. 1997) of chronically exposed mice.
3.9 INTERACTIONS WITH OTHER CHEMICALS
In addition to 1,3-butadiene, workers in the rubber industry are exposed to other chemicals, including 
styrene and its mutagenic metabolite, styrene oxide (Loprieno et al. 1978; Norppa et al. 1980; Pohlova 
et al. 1985; Watabe et al. 1978), as well as dithiocarbamates (Irons and Pyatt 1998). It is unclear whether 
these other chemicals or their active metabolites have a synergistic harmful effect in humans, but a 
multivariate analysis of an SBR worker cohort (HEI 2006) did not detect interactive effects of co­
exposure to 1,3-butadiene, styrene, and dimethyldithiocarbamate (DMDTC). Animal studies have found 
that DMDTC can qualitatively and quantitatively effect the metabolism of 1,3-butadiene. In vitro studies 
show that DMDTC treatment decreases the metabolism of 1,3-butadiene to EB and the metabolism of 
epoxybutene to DEB in rats and mice (Green et al. 2001). Styrene has been shown to inhibit the 
metabolism of 1,3-butadiene in rats simultaneously exposed to both compounds (Laib et al. 1992;
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Leavens et al. 1996). The inhibition was only observed at 1,000 ppm 1,3-butadiene concentration and not 
at 100 ppm (Leavens et al. 1996). However, blood levels of EB increased and the blood levels of DEB 
were unaffected by styrene co-exposure, as compared to exposure to 1,3-butadiene only (Leavens et al.
1996). Thus, co-exposure to styrene may not affect the toxicity of 1,3-butadiene. Inhalation exposure to
1,3-butadiene and styrene did not affect the genotoxic potential of 1,3-butadiene in mice (Leavens et al.
1997).
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to 1,3-butadiene than will most 
persons exposed to the same level of 1,3-butadiene in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters result in reduced detoxification or excretion of 1,3-butadiene, or compromised function 
of organs affected by 1,3-butadiene. Populations who are at greater risk due to their unusually high 
exposure to 1,3-butadiene are discussed in Section 6.7, Populations with Potentially High Exposures.
The human and animal data do not identify a gender-specific susceptibility to 1,3-butadiene. Human in 
vivo data do not identify specific populations that may be sensitive to the effects of 1,3-butadiene. 
Polymorphisms in metabolic enzymes may affect the toxicokinetics of 1,3-butadiene and render some 
individuals more sensitive to toxicity, based on increased sensitivity to genetic changes seen in these 
groups. Lymphocytes from GSTT1-null 1,3-butadiene workers in Texas had higher induction of sister 
chromatid exchange following in vitro DEB exposure (Kelsey et al. 1995), while GSTT1-null Czech 
workers exhibited higher rates of chromosomal aberrations (Sorsa et al. 1996). However, no such effects 
were observed in other Czech (Sram et al. 1998) or Chinese (Hayes et al. 2000) workers that were GSTT1 
or GSTM1 deficient. Increased hprtmutation frequencies have been reported in U.S. 1,3-butadiene 
workers with various polymorphisms in EH (Abdel-Rahman et al. 2001, 2003, 2005). In in vitro studies 
with human lymphocytes, EB induced higher levels of sister chromatid exchanges in GSTM1-null 
samples, as compared to GSTM1 samples (Uuskula et al. 1995), suggesting that the clastogenic change 
may the result of less EB being detoxified via GSTM1-mediated glutathione conjugation. Similarly, EB 
induced higher levels of sister chromatid exchanges in lymphocytes from GSTT1-null individuals, as 
compared to GSTT1-positive individual (Bernardini et al. 1998).
The relationship between polymorphisms and the urinary excretion of M1 and M2 metabolites has been 
exposed in studies of Czech 1,3-butadiene workers. GST polymorphisms resulted in shifts in the mean
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ratio of M2/(M1 + M2) (indicative of the activity of EB glutathione conjunction pathway), which was 
significantly lower in GSTM1-null workers, as compared to GSTM1-positive workers (HEI 2003); a 
lower ratio was also found in the GSTT1-null workers, but it was not significantly different from the 
GSTT1-positive workers. No significant alterations in M1 or M2 concentrations or the ratio were found 
for workers genotyped for CYP2E1, EH, and ADH polymorphisms. Regression analysis revealed that the 
slopes of the 1,3-butadiene concentration-M2 levels and concentration-M2/(M1+M2) was significantly 
different in CYO2E1 D/D intron 6 polymorphism compared to workers who were heterozygous for C/D 
(HEI 2003). In a subsequent study by this group, a significant difference in M2/(M1+M2) ratio was 
observed in the GSTT1-null workers (Albertini et al. 2007). When different EH genotypes were 
combined into high, intermediate, and low activity phenotypes, significantly higher M2 levels were 
observed in the low activity genotype group (Albertini et al. 2007).
Animals studies indicate that the predominant factor in species sensitivity is related to the toxicokinetics 
of 1,3-butadiene, specifically, the ratio of P450-mediated oxidation:epoxide hydrolase activity (see 
Section 3.4.3). Human populations that have a higher ratio of 1,3-butadiene oxidation:hydrolysis 
metabolism may also be more sensitive, although such populations have not been identified. In terms of 
absorption capacity, Asian volunteers had about 20% greater fractional absorption of inhaled
1,3-butadiene than did Caucasians, African-Americans, or Hispanics (Lin et al. 2001). However, it is not 
known if this results in higher internal doses of the putative epoxide toxicants.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to 1,3-butadiene. However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to 1,3-butadiene. When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.
3.11.1 Reducing Peak Absorption Following Exposure
No specific antidotes for 1,3-butadiene are available; however, recommendations have been made for 
general treatment of intoxicated persons (Bronstein and Currance 1988; Stutz and Janusz 1988). First, the 
exposed individual should be removed from the contaminated area and contaminated clothing should be 
taken away (Currance et al. 2007; Leikin and Paloucek 2002). It has been suggested that exposed skin 
should be washed with soapy water and contaminated eyes should be flushed with water. Inhalation
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exposure to high 1,3-butadiene concentrations may result in narcosis leading to respiratory paralysis and 
death. Data have shown that neurological effects, including anesthesia have been observed in animals 
exposed to 250,000 ppm (Carpenter et al. 1944). Therefore, administration of oxygen has been used and 
ventilation has been assisted as needed in cases of 1,3-butadiene poisoning.
3.11.2 Reducing Body Burden
No information is available regarding displacing or removing absorbed 1,3-butadiene prior to metabolism 
to reactive metabolites.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
Toxicity studies found mice to be extremely sensitive (DOE/NTP 1987b; Melnick et al. 1989, 1990b;
NTP 1993). Studies on the metabolism of 1,3-butadiene demonstrated that the chemical is converted to 
its epoxy derivatives by P450 isoforms in lung, liver, kidney (see Section 3.4.3), and possibly other 
tissues. The epoxides may be responsible for most toxic and carcinogenic effects caused by 1,3-butadiene 
exposure. The epoxides are detoxified by hydrolysis or conjugation with glutathione (Kreiling et al.
1988). A higher rate of epoxide formation and a greater depletion of hepatic nonprotein sulfhydryl 
content in mice is probably responsible for their higher susceptibility to 1,3-butadiene toxicity. Since the 
macromolecular covalent binding is enhanced only after a substantial decrease of glutathione levels 
(Kreiling et al. 1988), sufficient availability of glutathione should mitigate the effects of 1,3-butadiene 
exposure.
Interference with the oxidative metabolism of 1,3-butadiene may also be effective in allowing pulmonary 
clearance of the parent compound to occur before reactive epoxides are formed. In mice, a 30-56% 
reduction in induction of erythrocyte micronuclei was observed in mice pretreated with various P450 
inhibitors (Jackson et al. 2000b). However, the side effects of systemically inhibiting P450s in humans 
are unknown.
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of 1,3-butadiene is available. Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure
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the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of 1,3-butadiene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of 1,3-Butadiene
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
1,3-butadiene are summarized in Figure 3-4. The purpose of this figure is to illustrate the existing 
information concerning the health effects of 1,3-butadiene. Each dot in the figure indicates that one or 
more studies provide information associated with that particular effect. The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
As seen from Figure 3-4, information regarding acute systemic effects (respiratory tract irritation and 
narcotic effect), chronic systemic effects (respiratory irritation), genotoxicity, and cancer exists for 
inhalation exposure in humans. No information was located regarding oral or dermal exposure of humans 
to 1,3-butadiene.
Inhalation studies in animals provide data on death, systemic effects, immunologic effects, neurologic 
effects, reproductive and developmental effects, genotoxicity, and carcinogenicity. No information was 
located regarding effects in animals after oral or dermal exposure to 1,3-butadiene.
3.12.2 Identification of Data Needs
No studies were located regarding effects following oral or dermal exposure, and no pharmacokinetic 
studies by the oral or dermal routes were located; therefore, it is not possible to predict if effects
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following oral or dermal exposure would be similar to those observed after inhalation exposure. Because
1.3-butadiene exists primarily as a gas and has been detected in soil off-gases at hazardous waste sites, 
inhalation exposure appears to be the greatest concern. However, it is not known if 1,3-butadiene is 
present in groundwater or soil at these hazardous waste sites because it is difficult to analyze these media 
for the compound. 1,3-Butadiene has been detected in industrial waste water and drinking water, and is 
poorly soluble in water (735 ppm). Therefore, oral and dermal routes of exposure cannot be ruled out. 
Information concerning 1,3-butadiene toxicity by these routes of exposure would be useful.
Acute-Duration Exposure. Acute inhalation exposure to very high concentrations (>25,000 ppm) of
1.3-butadiene may lead to narcosis and death by respiratory paralysis in animals (Carpenter et al. 1944). 
Data in humans are limited to a study of two men exposed to various concentrations of 1,3-butadiene for
6-8 hours that examined clinical signs and psychomotor function (Carpenter et al. 1944). No studies 
were located that correlated the level of exposure with the first signs of toxicity in humans or animals. 
Developmental effects were seen in mice after exposure to concentrations as low as 40 ppm (DOE/NTP 
1987b; Irvine 1981). Although the available animal data identify critical targets of toxicity following 
acute-duration inhalation exposure, the database lacks adequate toxicokinetic and PBPK modeling data, 
which could be used to account for species differences in the metabolism of 1,3-butadiene; thus, an acute- 
duration MRL was not derived. Additionally, there are limited data on the potential effects of the parent 
compound, such as neurotoxicity, which may be a more sensitive target of toxicity in humans. Because 
people living at or near these hazardous waste sites may be exposed for brief periods of time, more dose- 
response data for acute exposures by oral and inhalation routes is considered to be important.
Intermediate-Duration Exposure. No information is available regarding effects of 1,3-butadiene 
during intermediate-duration exposure in humans. No studies were located regarding effects in humans 
or animals following oral or dermal exposure to 1,3-butadiene, and pharmacokinetic data for these routes 
of exposure are insufficient to predict whether the disposition or toxicity of 1,3-butadiene following oral 
or dermal exposure would be similar to that following inhalation exposure. Therefore, information 
regarding the toxicity of 1,3-butadiene by the oral route of exposure would be useful. Several studies on 
intermediate-duration inhalation exposure to 1,3-butadiene have been conducted in animals (Anderson et 
al. 1996, 1998; Crouch et al. 1979; Irons et al. 1986a; NTP 1984, 1993; Thurmond et al. 1986). Atrophy 
of reproductive organs, anemia, precancerous hyperplasia in multiple organs, and cancer occurred in mice 
exposed to >200 ppm (Irons et al. 1986a; NTP 1984, 1993). The observed hematological changes 
(macrocytic megaloblastic anemia) were similar to those found in human preleukemic syndrome (Biemer 
1983), suggesting that 1,3-butadiene exposure might interfere with normal bone marrow cell
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development. Further investigation of this topic could be valuable since epidemiological studies in 
humans indicate that hematopoietic tissue may be a possible target for 1,3-butadiene toxicity (Checkoway 
and Williams 1982). Several studies have identified potential targets of toxicity following intermediate- 
duration exposure; however, the available toxicokinetic and PBPK modeling data do not allow for 
adequate adjustment for species differences in the metabolism of 1,3-butadiene. Thus, intermediate- 
duration inhalation MRLs were not derived.
Chronic-Duration Exposure and Cancer. Possible risk for hematological disorders was reported 
in humans after chronic inhalation exposure to 1,3-butadiene in occupational settings, but exposure levels 
are lacking, and exposure to other chemicals occurs in these settings (Checkoway and Williams 1982). 
However, other studies (Cowles et al. 1994; Tsai et al. 2005) that monitored 1,3-butadiene levels have not 
found hematological alterations. Well-conducted inhalation studies identified respiratory effects, liver 
necrosis, gonadal atrophy, multi-site cancer, and increased mortality in mice at exposures as low as
6.25 ppm (Melnick et al. 1989, 1990a; NTP 1984, 1993), while renal pathology, cancer, and increased 
mortality were observed in rats exposed to >1,000 ppm (Owen et al. 1987). Because a serious LOAEL of 
severe ovarian atrophy (with complete destruction of oocytes, follicles, and corpora lutea) was found at
6.25 ppm, with no associated NOAEL, no chronic MRL has been derived. Chronic-duration studies are 
needed that identify a NOAEL in mice for gonadal atrophy. Oral studies are lacking, and toxicokinetic 
data are insufficient to predict toxicity across routes of exposure. Therefore, information concerning the 
possible toxicity of 1,3-butadiene by this route would be useful to identify the target organs and the 
thresholds for toxic effects.
Epidemiological studies in humans indicate a possible increase in risk of leukemia from occupational 
exposure to 1,3-butadiene (Cheng et al. 2007; Delzell et al. 1996; Divine 1990; Divine and Hartman 
2001; Divine et al. 1993; Downs et al. 1987; Macaluso et al. 1996; Matanoski and Schwartz 1987; 
Matanoski et al. 1982, 1989a, 1989b, 1990; McMichael et al. 1974, 1975, 1976; Meinhardt et al. 1982; 
Ward et al. 1995). This is supported by the information about mutagenic activity of 1,3-butadiene 
metabolites (de Meester 1988) and by well-conducted chronic inhalation studies that provide information 
on carcinogenic effects of 1,3-butadiene in mice and rats (Melnick et al. 1989; NTP 1984, 1993; Owen et 
al. 1987). IARC (2009) and EPA (EPA 2002; IRIS 2012) concluded that there is sufficient evidence for 
the carcinogenicity of 1,3-butadiene in animals. IARC has classified 1,3-butadiene in group 1, 
carcinogenic to humans. EPA has classified 1,3-butadiene as a human carcinogen. The Department of 
Health and Human Services (NTP 2011) also identified 1,3-butadiene as a “known human carcinogen”. 
Further epidemiological investigations that examined additional potential targets of 1,3-butadiene toxicity
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would be useful. Also, data are needed on 1,3-butadiene exposure to urban populations living in close 
proximity to major roadways and intersections, as well as on long-term follow-up of health effects, 
particularly the detection of diminishment in reproductive capability and prevalence of lympho- 
hematopoietic cancers.
No chronic oral or dermal carcinogenicity studies in animals were located, and pharmacokinetic data are 
insufficient to predict a carcinogenic potential of 1,3-butadiene by these routes.
Genotoxicity. Studies of chromosomal aberrations, sister chromatid exchanges, and hprt mutation 
frequencies among petrochemical and 1,3-butadiene monomer workers exposed to low levels (<2 ppm) 
provide conflicting results (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Hayes et al. 1996,
2000; HEI 2003; Lovreglio et al. 2006; Sram et al. 1998; Tates et al. 1996; Ward et al. 1996, 2001; Zhou 
et al. 1986). 1,3-Butadiene has caused increases in micronuclei induction, chromosomal aberration 
frequency, and mutations of proto-oncogenes in in vivo studies of rats and mice following inhalation 
exposure (Autio et al. 1994; Cochrane and Skopek 1993; Cunningham et al. 1986; Irons et al. 1987b; 
Jauhar et al. 1988; Meng et al. 1999, 2000, 2004, 2007; Recio et al. 1992; Sills et al. 2001; Tice et al.
1987; Vodicka et al. 2006). Information on the genotoxic effects of 1,3-butadiene was also obtained from 
in vitro studies in prokaryotic (Arce et al. 1989; de Meester 1988, de Meester et al. 1980; Victorin and 
Stahlberg 1988) and eukaryotic (Cochrane and Skopek 1993; Sasiadek et al. 1991) organisms. These data 
sufficiently characterize the mutagenic potential of 1,3-butadiene metabolites.
Reproductive Toxicity. The atrophy of gonads in mice after chronic inhalation exposures as low as
6.25 ppm 1,3-butadiene was reported (Melnick et al. 1989; NTP 1984, 1993). The fertility of rats, guinea 
pigs, or rabbits was reported to be unaltered by acute- and intermediate-duration inhalation exposure to
1,3-butadiene (Anderson et al. 1996, 1998; Carpenter et al. 1944). Sperm head abnormalities were found 
in male mice exposed to 1,3-butadiene by inhalation (DOE/NTP 1988b). Further information regarding 
the reproductive effects of 1,3-butadiene in animals such as multigeneration studies would be useful to 
estimate the possible risk for reproductive effects in humans. An epidemiological study among exposed 
populations concentrating on reproductive effects would be useful.
No studies were located regarding reproductive toxicity of 1,3-butadiene by the oral or dermal routes in 
humans or animals, and pharmacokinetic data were insufficient to suggest the potential for 1,3-butadiene 
to cause reproductive effects by these routes of exposure. The potential for exposure of humans by the 
oral and dermal routes, however, is not known.
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Developmental Toxicity. No information on developmental toxicity in humans was located. A 
developmental study by the inhalation route indicated growth retardation in rat fetuses and an increase in 
major skeletal abnormalities at a concentration of 1,000 ppm of 1,3-butadiene (Irvine 1981).
Furthermore, fetotoxicity was observed in mice at acute-duration exposures of 40 ppm and intermediate- 
duration exposures of 12.5 ppm 1,3-butadiene (DOE/NTP 1987b). More data on developmental toxicity 
in other species (at least one of them nonrodent) would be useful to identify the possible developmental 
risk for humans. The developmental effects following other routes of exposure have not been studied, 
and pharmacokinetic data are insufficient to predict that responses would be similar to those by the 
inhalation route. Therefore, studies of oral exposures in animals to determine the possible developmental 
effects of 1,3-butadiene and the thresholds for these effects would be useful.
Immunotoxicity. Reduction in thymus weight and lymphoid histopathology was seen after the 
intermediate-duration exposure of mice to >625 ppm 1,3-butadiene (NTP 1993; Thurmond et al. 1986). 
The indications of disturbances in hemato- and lymphatopoietic stem cell regulations were observed after 
inhalation exposure of mice to 1,3-butadiene (Liederman et al. 1986). The high incidence of lymphoma 
among mice after the chronic exposure (NTP 1984, 1993) also indicates that the immune system is a 
target. A battery of immune function tests has not been performed in humans or animals. More data 
regarding humans and animals would be useful for determining potential human immunotoxicity of
1,3-butadiene. Studies regarding skin sensitization with 1,3-butadiene are lacking.
Neurotoxicity. Narcosis has been demonstrated in animals after acute inhalation exposure to very high 
levels of 1,3-butadiene (250,000 ppm) (Carpenter et al. 1944). No reliable information was located 
regarding neurotoxicity due to chronic inhalation exposure or to oral or dermal exposure for any duration. 
Information regarding early, subtle signs of possible neurological effects with correlation to the exposure 
levels is lacking. A battery of neurological and neurobehavioral tests would be useful to better define the 
neurological end points.
Epidemiological and Human Dosimetry Studies. Several epidemiological studies on health 
effects of 1,3-butadiene have been conducted (Case and Hosker 1954; Fox et al. 1974; Matanoski and 
Schwartz 1987; Matanoski et al. 1989a, 1989b; McMichael et al. 1974, 1975, 1976; Meinhardt et al.
1982). The limitation of these studies is that the cohorts of exposed workers were recruited from the 
rubber industry, in which the people were exposed to a mixture of various chemicals. Some genotoxicity 
studies have been conducted among 1,3-butadiene manufacturing workers and petrochemical workers
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exposed to low (<2 ppm) exposures, but have reported conflicting results (Albertini et al. 2001, 2007; 
Ammenheuser et al. 2001; Hayes et al. 1996, 2000; HEI 2003; Kelsey et al. 1995; Lovreglio et al. 2006; 
Tates et al. 1996; Ward et al. 1996, 2001; Wickliffe et al. 2009; Zhou et al. 1986). Reliable dosimetry 
data on the exposed populations would be useful for good epidemiological comparisons. Efforts to 
improve estimates of past exposures and to more accurately define current exposure levels to 1,3-buta­
diene would be valuable. Epidemiological studies should concentrate on the possible carcinogenic effect 
of 1,3-butadiene in humans and on changes in hemato- and lymphatopoietic systems as possible targets 
for 1,3-butadiene induced toxicity. The data obtained from workers exposed occupationally to low 
concentrations of 1,3-butadiene could possibly be extrapolated to populations living near hazardous waste 
sites.
Biomarkers of Exposure and Effect.
Exposure. The determination of 1,3-butadiene-derived urinary metabolites (Albertini et al. 2001, 2007; 
Ammenheuser et al. 2001; Bechtold et al. 1994; Dahl et al. 1990; Hayes et al. 1996, 2000; Sapkota et al. 
2006; Ward et al. 1994, 1996), DNA adducts (Kreiling et al. 1986b; Sun et al. 1989b; Zhao et al. 2001), 
and hemoglobin adducts (Albertini et al. 2001, 2007; Begemann et al. 2001a, 2001b; Boogaard et al. 
2001b; Hayes et al. 2000; HEI 2000; Osterman-Golkar et al. 1996) of rats, mice, and humans exposed to
1,3-butadiene has been performed. Data are needed that accurately correlate the level of biomarkers 
measured in the body, particularly for pyr-Val hemoglobin adducts with the exposure to 1,3-butadiene, as 
well as the variability in this correlation between sexes and ethnicity.
Effect. Conflicting data exist for the sensitivity of human lymphocyte hprt mutation frequencies resulting 
from occupational exposures (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Hayes et al. 1996, 
2000; HEI 2003; Kelsey et al. 1995; Lovreglio et al. 2006; Tates et al. 1996; Ward et al. 1996, 2001; 
Wickliffe et al. 2009; Zhou et al. 1986). In mice and rats, levels of DEB-specific DNA-DNA cross-links 
correlated well with 1,3-butadiene inhalation and relative sensitivity of female mice to toxicity (Goggin et 
al, 2009). Two biomarkers for carcinogenic effect have been consistently found in multiple tumors sites 
in rodent chronic bioassays. A number of malignant gliomas and neuroblastomas in mice chronically 
inhaling 1,3-butadiene exhibited mutations of the p53 gene and H- and K-ras oncogenes (Kim et al.
2005), which have also been observed in forestomach tumors (Sills et al. 2001), hemagiosarcomas (Hong 
et al. 2000), and lymphomas (Zhuang et al. 1997) of chronically exposed mice. Data for reliable and 
specific biomarkers indicating onset of developmental effects in animals would be useful to determine if 
comparable exposure may lead to these effects in humans.
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Absorption, Distribution, Metabolism, and Excretion. The timecouse of 1,3-butadiene and its 
primary metabolite, EB, in human blood has been investigated in volunteers inhaling 2 ppm for 
20 minutes (Lin et al. 2001). In vitro studies have characterized some of the metabolism dynamics of
1,3-butadiene in animals (Bolt et al. 1983; Csanady et al. 1992; Duescher and Elfarra 1994; Elfarra et al. 
1996, 2001; Himmelstein et al. 1994, 1995; Jackson et al. 2000a; Kreiling et al. 1987; Laib et al. 1990; 
Malvoisin and Roberfroid 1982; Malvoisin et al. 1979; Schmidt and Loeser 1985, 1986; Thornton- 
Manning et al. 1995b, 1997). Several toxicokinetic studies on 1,3-butadiene metabolism in vivo have 
been conducted in rats and mice following inhalation exposure (Bolt et al. 1983; Bond et al. 1987; 
Himmelstein et al. 1994; Kohn and Melnick 2001; Kreiling et al. 1986b; Shugaev 1969), but not 
following exposure by other routes. Thus, further studies in animals by the oral route to determine 
possible target organs by this route could be useful. Ethical considerations limit the testing of humans, 
but the development of methods to determine urinary and breath excretion of 1,3-butadiene and its 
metabolites by humans with known exposure to 1,3-butadiene may provide a means of monitoring 
humans for exposure.
Comparative Toxicokinetics. The study by Schmidt and Loeser (1985) indicated that there is a 
difference between the capability of mouse and rat liver postmitochondrial fractions to produce
1,2-epoxybutene-3 after incubation with 1,3-butadiene. Furthermore, monkey and human postmito­
chondrial liver preparations catalyzed the formation of only a small amount of the epoxide. Higher levels 
of the toxic epoxides were found in blood of mice following 1,3-butadiene exposure as compared to 
monkeys (Bolt et al. 1983; Csanady et al. 1992; Dahl et al. 1990; Duescher and Elfarra 1994; Elfarra et al. 
1996, 2001; Jackson et al. 2000a; Sun et al. 1989a). Species differences in the toxicokinetics of a 
chemical may account for differences in toxic responses. Analysis of the blood, breath, and urine of 
humans exposed to 1,3-butadiene for parent compound and metabolites over time would provide a greater 
knowledge of the human metabolic pathways. Qualitative and quantitative comparison of human 
metabolites with those of animals could help identify the most appropriate species to serve as a model for 
predicting toxic effects and mechanisms of action in humans.
Methods for Reducing Toxic Effects.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
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The sensitivity of children to 1,3-butadiene toxicity, if any, is unknown. In mice, acute- and intermediate- 
duration inhalation exposures resulted in in utero fetal effects at exposure levels of 21.5-40 ppm 
(Anderson et al. 1996; DOE/NTP 1987b). No information is available for interfering with effects of
1.3-butadiene toxicity in utero.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: 
Exposures of Children.
3.12.3 Ongoing Studies
The following ongoing studies were identified in the Federal Research in Progress database (FEDRIP 
2009).
E. Struble is being funded by EPA National Health and Environmental Effects Research Laboratory 
(HEERL) to use environmental irradiation chambers (smog chambers) to induce the natural 
photochemically stimulated transformations of environmental pollutants. The synthetic urban smog 
mixture is composed of 55 hydrocarbon species representative of the ambient air of an average city in the 
United States. In this study, A549 cells were exposed simultaneously to irradiated and non-irradiated 
chamber mixtures for 5 hours. Post exposure, adverse health effects were determined by measures of 
increased cellular stress cytokine release and cytotoxicity. Exposure to the photochemically-generated 
products of 1,3-butadiene, toluene, and methanol induced increases in both cytotoxicity and IL-8 gene 
expression compared to 1,3-butadiene, toluene, or methanol alone. The exposure design was used to 
investigate the toxicity of chemicals after photochemical reactions and interactions with the urban 
atmosphere on healthy and susceptible individuals using representative in vitro samples. This research 
informs the toxicity from exposures to multiple environmental pollutants found in urban settings.
James A. Swenberg is being funded by the National Institute of Environmental Health Sciences (NIEHS) 
to examine the molecular dose of previously unexplored DNA adducts in rodents exposed to
1.3-butadiene and 3-butene-1,2-diol (BD-diol). The data will be compared with mutation frequencies and 
mutational spectra to determine (1) if a particular adduct could be used as a mutagenic indicator, and
(2) to determine the effects of exposure on gene expression. First, it will be determined if 
hydroxymethylvinyl ketone (HMVK) is formed in vivo during exposure to 1,3-butadiene and BD-diol in 
a sex-, species-, and exposure concentration-dependent manner, resulting in mutagenicity. Secondly,
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promutagenic N 1 adenine adducts will be observed to see if they are converted to more stable inosine 
adducts, which may accumulate in tissues during chronic exposures. Several specific aims will be 
accomplished while addressing these questions. Specific Aim 1 is to examine the formation of potentially 
mutagenic DNA adducts (specifically 1, N2-propanodeoxyguanosine) by HMVK in vivo. Specific Aim 2 
is to determine the utility of the N-terminal valine adduct of HMVK (HMVK-Val) as a biomarker of 
HMVK formation by BD and BD-diol. Specific Aim 3 is to develop methods for detecting N1- inosine, 
N1- and N6-adenine adducts derived from BD metabolites in vivo. Specific Aim 4 is to determine the 
mutagenic responses induced by BD exposures and characterize the impact of BD-diol-derived 
metabolites on the spectra of mutations induced by BD exposure in the B6C3F1 mouse and F344 rat to 
identify which adducts studied in Aims 1 and 3 are quantitative indicators of mutagenesis. Specific Aim 
5 will examine the effects of exposure to BD and BD-diol on gene expression and DNA repair pathways. 
Collectively, these experiments have been designed to inform on adduct formation, DNA repair, 
mutagenicity, and genomic alterations in rodents exposed to 1,3-butadiene and BD-diol, as well as the 
impact of glutathione depletion and DNA repair deficiency.
Elaine Symanski is being funded by the National Cancer Institute (NCI) to evaluate an association 
between lymphohematapoietic (LH) cancer incidence and air pollution in the Houston metropolitan area, 
with particular emphasis on three compounds: benzene, 1,3-butadiene, and styrene. Data from the Texas 
Cancer Registry (TCR) from 1995 to 2005 and the Texas Commission on Environmental Quality (TCEQ) 
from 1992 to 2003 will be analyzed to: (1) investigate the spatial and temporal distribution of LH cancer 
incidence in Harris and surrounding counties; (2) evaluate the association between distance from 
industrial sources and LH cancer incidence; (3) identify optimal methods for assessing ambient levels of 
benzene, 1,3-butadiene, and styrene using existing TCEQ monitoring data; and (4) evaluate the 
association between ambient levels of benzene, styrene, and 1,3-butadiene and LH cancer incidence using 
Poisson regression in single and multi-pollutant models. This will be the first study to examine this 
association in Harris and seven surrounding counties (Texas) and is among the first to utilize monitored 
levels of HAPs to assess increased risks of LH cancer associated with air pollution. This work will also 
correlate cancer rates with proximity to industrial facilities as well as ambient levels of benzene, styrene, 
and 1,3-butadiene. This study will address a gap in the literature by examining the association between 
HAPs and cancer incidence in Harris County, Texas and will further explore innovative methods to 
evaluate this association utilizing existing data sources.
Natalia Y. Tretyakova is being funded by the National Cancer Institute to evaluate the role of DNA-DNA 
cross-linking in the genotoxicity of diepoxybutane and 1,3-butadiene. DEB-DNA cross-links will be
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structurally characterized and formation sequence preferences will be determined. The hydrolytic 
stability of DEB-DNA cross-links will be evaluated for their recognition by the E. coli UvrABC repair 
complex. DEB-DNA cross-links in rodent tissues will be quantified by capillary high performance liquid 
chromatography-electrospray tandem mass spectrometry (HPLC-ESI-MS/MS) methods. This research 
will provide valuable information on the molecular mechanisms underlying the genotoxic activity of 
diepoxybutane.
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4. CHEM ICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Information regarding the chemical identity of 1,3-butadiene is located in Table 4-1. This information 
includes synonyms, chemical formula and structure, and identification numbers.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Information regarding the physical and chemical properties of 1,3-butadiene is located in Table 4-2.
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Table 4-1. Chemical Identity of 1,3-Butadienea
C h arac te ris tic In form ation
Chemical name 1,3-Butadiene
Synonyms and trade names Butadiene; buta-1,3-diene; biethylene; bivinyl; divinyl; 
vinylethylene; erythrene; alpha,-gam m a-butadiene; pyrrolyleneb
Chemical formula C4H6
Chemical structure 
Identification numbers:
h 2c ^ ^ CH2
CAS registry 106-99-0
N IO SH  R TEC S E I9275000c
EPA hazardous waste R 0377-0754d
D O T/U N /N A /IM D G  shipping 1010
E IN EC S 203-450-8
HSDB 181
NCI C 50602
aAll information obtained from HSDB 2009 and ChemID Plus Advanced 2009 except where noted. 
bO'Neil et al. 2006. 
cNIOSH 2005. 
dMiller 1978.
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EINECS = European Inventory of Existing Commercial 
chemical Substances; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank;
NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; RTECS = Registry 
of Toxic Effects of Chemical Substances
1,3-BUTADIENE 113
Table 4-2. Physical and Chemical Properties of 1,3-Butadiene
P ro perty 1 ,3 -B u ta d ie n e R e fe re n c e
Molecular weight 54.09 O ’Neil et al. 2006
Color Colorless Lewis 2007
Physical state Gas Lewis 2007
Melting point -108 .966  °C O ’Neil et al. 2006
Boiling point -4 .5  °C O ’Neil et al. 2006
Density:
at 25 °C (g/cm3) 0 .6149 Lide 2008
Vapor density 1.88 (air=1) N IO SH  2005
Odor Mildly aromatic; gasoline-like Lewis 2007
W ater Not applicable3 Amoore and Hautala 1983
Air 1.6 ppm Amoore and Hautala 1983
Odor threshold
Solubility:
W ater at 25 °C 735 mg/L McAuliffe 1966
Organic solvent(s) Soluble in ether, ethanol and 
benzene; very soluble in acetone
Lide 2008
Partition coefficients:
Log Kow 1.99 Hansch et al. 1995
K o o 288 (estim ated)13 H SDB 2009
Vapor pressure at 25 °C 2 .11x103 mm Hg A IC hE 2000
Henry's law constant at 25  °C 7.4x10 -2 atm -m 3/mol (estim ated)c H SDB 2009
Autoignition tem perature 414 °C Lewis 2007
Flashpoint C
o
67- Lewis 2007
Explosive limits 2 .0-11.5% O ’Neil et al. 2006
Conversion factors 1 ppm=2.21 mg/m3 
1 m g/m3=0.452 ppm
N IO SH  2005
aAmoore and Hautala (1983) reported an odor threshold of 0.0014 ppm for 1,3-butadiene in water; however, these 
authors state that this solution lacks enough persistence for this value to be used for reference purposes. 
bThis Koc value was estimated using the measured log Kow value (1.99) and a regression derived equation. 
cThis Henry's Law constant value was calculated from the measured vapor pressure (2.11x103 mm Hg at 25 °C) and 
water solubility (735 mg/L).
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
1.3-Butadiene was discovered in the nineteenth century and its use in the development of rubber-like 
polymers was explored during the early 1900s (Grub and Loser 2005; Sun and Wristers 2002). Large 
volume production of 1,3-butadiene in the United States began during World War II as a result of the 
nation’s synthetic rubber program (American Chemical Society 2007; Dolnick and Potash 1948).
U.S. production rose to 2.7 billion pounds in 1965 as new plants were started to meet the increasing 
butadiene-rubber demand of the auto industry (Chemical Market Reporter 2006; Grub and Loser 2005; 
Kirshenbaum 1978). Production reached 3.7 billion pounds (1,674 metric tons) by 1974 and then 
fluctuated through the 1980s as a response to market pressures (Grub and Loser 2005; Kirshenbaum 
1978; Sun and Wristers 2002). Production growth resumed during the 1990s, reaching 4.5 billion pounds 
(2,020 metric tons) in 1998 (Grub and Loser 2005). Actual production volumes of 1,3-butadiene 
manufactured in the United States during more recent years are not available; however, the annual
U.S. production capacity was reported to be 6 billion pounds (2,800 metric tons) during 2008 (Chemical 
Week 2008; SRI 2008).
The 1,3-butadiene market is heavily dependent on the synthetic rubber demand of the auto industry, 
which accounts for approximately 60% of the total consumption of this substance (Chemical Market 
Reporter 2006). Also, since most 1,3-butadiene is produced through steam cracking, the supply of this 
chemical has been largely influenced by the demand for ethylene, the primary product from steam 
cracking (Sun and Wristers 2002).
The companies that produced 1,3-butadiene in the United States, their production sites, and their annual 
capacities during 2008 (the most recent year for which figures are available) are shown in Table 5-1 (SRI
2008). Table 5-2 summarizes the number of facilities in each state that manufactured or processed
1.3-butadiene in 2007, the ranges of maximum amounts on site, if reported, and the activities and uses as 
reported in the Toxics Release Inventory (TRI) (TRI09 2011). The data listed in this table should be used 
with caution since only certain types of facilities are required to report. This is not an exhaustive list.
Except for a small amount of 1,3-butadiene produced by the oxydehydrogenation of n-butene, all the
1.3-butadiene produced in the United States is a co-product of ethylene manufacture (Chemical Market 
Reporter 2006; Sun and Wristers 2002). In this process, feed streams ranging from light hydrocarbons to 
heavy gas oils are cracked in the presence of steam at 700-900 °C (Grub and Loser 2005; Kirshenbaum
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Table 5-1. Companies that Produce 1,3-Butadiene in the United States and
Annual Capacities During 2008
C o m p a n y Location
C a p a c ity  (m illion  
p o u n d s /year)
C a p a c ity  
(m e tric  tons)
Equistar Chemicals, LP Alvin, Texas 150 68,060
Channelview, Texas 865 392,500
Corpus Christi, Texas 200 90,740
ExxonMobil Chemical Company Baton Rouge, Louisiana 385
INEOS Americas, LLC
Baytown, Texas 325 147,500
INEOS Olefins & Polymers USA Alvin, Texas 235 106,600
Sabina Petrochemicals LLC Port Arthur, Texas 900
Shell Chemical LP Deer Park, Texas 360 163,300
Norco, Louisiana 575 260,900
Texas Petrochemicals, Inc. Houston, Texas 1,080 490,000
Port Neches, Texas 925 419,700
Total 6,000 2,722,000
Source: SRI 2008
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
1,3-BUTADIENE 117
Table 5-2. Facilities that Produce, Process, or Use 1,3-Butadiene
S ta te 8
N u m b e r of 
facilities
M in im um  
a m o u n t on site  
in p o u n d sb
M a x im u m  
a m o u n t on site  
in p ou n d sb A ctiv ities  an d  u sesc
AL 8 0 9,999 ,999 1, 3, 5, 6, 8, 13, 14
AR 6 1,000 999,999 1, 2, 3, 6, 9, 12
A Z 1 10,000 99,999 9
CA 73 0 999,999 ,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
CO 13 0 9,999 ,999 1, 3, 5, 6, 8, 12, 13
C T 3 1,000,000 9,999 ,999 2, 3, 6
DE 11 1,000 9,999 ,999 1, 2, 3, 5, 6, 7, 9, 12, 13
GA 4 100,000 9,999 ,999 1, 5, 6
HI 7 1,000 99,999 1, 3, 5, 6, 13, 14
IA 5 100,000 9,999 ,999 1, 3, 4, 5, 6
IL 39 0 49,999 ,999 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14
IN 24 0 9,999 ,999 1, 3, 4, 5, 6, 7, 8, 12, 13, 14
KS 11 0 499,999 ,999 1, 3, 6, 10, 13
KY 16 10,000 9,999 ,999 1, 3, 4, 5, 6, 7, 9, 12, 13
LA 106 0 10,000 ,000 ,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
MI 28 0 49,999 ,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13
MN 10 0 9,999 ,999 1, 2, 3, 5, 6, 7, 12, 13
MO 6 0 9,999 1, 5, 7, 12, 14
MS 12 1,000 499 ,999 ,999 1, 2, 3, 4, 5, 6, 7, 9, 13, 14
M T 19 100 999,999 1, 3, 5, 6, 8, 12, 13, 14
NC 9 0 49,999 ,999 2, 3, 6, 7, 8, 10
ND 4 0 9,999 1, 2, 3, 4, 6
NE 2 0 9,999 3, 8, 11 , 12
NH 1 1,000 9,999 6
NJ 16 0 99,999 1, 3, 4, 5, 6, 7, 12, 13
NM 2 0 9,999 1, 3, 5, 7, 11
N Y 7 10,000 999,999 2, 3, 4, 6, 8, 11
OH 33 0 49,999 ,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
OK 21 0 9,999 ,999 1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13
PA 20 0 9,999 ,999 1, 2, 3, 5, 6, 7, 8, 12, 13, 14
PR 1 10,000,000 49,999 ,999 1, 5, 7
SC 3 0 99,999 1, 5, 6, 13, 14
TN 21 0 9,999 ,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14
TX 234 0 10,000 ,000 ,000 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 15 100 999,999 1, 3, 4, 5, 6, 7, 8, 9, 12
VA 7 0 9,999 1, 3, 4, 5, 6, 13
VI 5 100 99,999 1, 2, 3, 6, 13
W A 27 0 9,999 ,999 1, 2, 3, 4, 5, 6, 7, 11, 12, 13, 14
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Table 5-2. Facilities that Produce, Process, or Use 1,3-Butadiene
S ta te a
N u m b e r of 
facilities
M in im um  
a m o u n t on site  
in p o u n d sb
M a x im u m  
a m o u n t on site  
in p ou n d sb A ctiv ities  an d  u sesc
W I 2 100,000 9,999 ,999 6
W V 10 0 99,999 ,999 1, 5, 6, 7, 8, 12
W Y 5 0 99,999 1, 3, 4, 6
Post office state abbreviations used.
’Amounts on site reported by facilities in each state. 
:Activities/Uses:
b
1. Produce
2. Import
3. Onsite use/processing
4. Sale/Distribution
5. Byproduct
6. Impurity
7. Reactant
8. Formulation Component
9. Article Component
10. Repackaging
11. Chemical Processing Aid
12. Manufacturing Aid
13. Ancillary/Other Uses
14. Process Impurity
Source: TRI09 2011 (Data are from 2009)
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1978; Sun and Wristers 2002). The fraction of 1,3-butadiene produced by this process varies widely with 
the type of feedstock used and is lowest with low-boiling input streams (Grub and Loser 2005; 
Kirshenbaum 1978).
Purification of the crude C4 stream resulting from the steam cracking process cannot be achieved by a 
simple distillation due to the close boiling point of the various products and the fact that 1,3-butadiene 
forms an azeotrope with butane (Grub and Loser 2005; Kirshenbaum 1978). 1,3-Butadiene can be 
removed from the hydrocarbon stream by liquid-liquid extraction or extractive distillation. The selective 
solvents used in these processes include aqueous cupric ammonium acetate, acetonitrile, furfural, 
dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidinone (Grub and Loser 2005; Sun and 
Wristers 2002).
The oxidative dehydrogenation of n-butene, used in the production of 1,3-butadiene, is a highly selective, 
irreversible process that involves heating the starting material, air, and a suitable catalyst together at 400­
450 °C (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). The hydrogen released in the 
dehydrogenation step combines with oxygen, producing large amounts of heat, which makes this process 
energy-efficient (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). As indicated above, 
oxidative dehydrogenation of n-butene has not been competitive with the steam cracking process for 
manufacture of 1,3-butadiene (Chemical Market Reporter 2006; Grub and Loser 2005). Rather, this 
method has been used on a campaign basis when there is a large enough differential between feedstock 
and 1,3-butadiene prices (Grub and Loser 2005).
5.2 IMPORT/EXPORT
Large amounts of 1,3-butadiene are imported into the United States as consumption typically exceeds 
production (Chemical Market Reporter 2006; Chemical Week 2008; Sun and Wristers 2002). U.S. 
imports of 1,3-butadiene in 2005 were approximately 600 million pounds (Chemical Market Reporter
2006). More recent import data are not available. U.S. Exports of 1,3-butadiene are considered to be 
negligible (Chemical Market Reporter 2006).
5.3 USE
1.3-Butadiene is used as a monomer in the production of rubber and plastics; approximately 60% of the
1.3-butadiene consumed in the United States is used in the production of synthetic rubbers (Chemical 
Market Reporter 2006). 1,3-Butadiene uses can be broken down into the following categories: synthetic
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rubber, 61% (styrene butadiene rubber [SBR], 30%; polybutadiene elastomer, 25%; polychloroprene 
elastomer, 4%; nitrile elastomer, 2%) adiponitrile/hexamethylene diamine (HMDA), 11%; styrene- 
butadiene latex, 12%; ABS resins, 5%; and other uses, 11% (Chemical Market Reporter 2006). 
Automobile tires are the major end-use product (Chemical Market Reporter 2006). Both styrene 
butadiene rubber and polybutadiene are used heavily for this purpose. 1,3-Butadiene is also used for 
other automotive applications such as high-impact polystyrene and ABS resin plastics (Chemical Market 
Reporter 2006). 1,3-Butadiene is a precursor in the production of adiponitrile (used to make nylon) and 
chloroprene (used to make neoprene) (Chemical Market Reporter 2006).
5.4 DISPOSAL
The recommended method of disposal of 1,3-butadiene is by incineration within a suitable combustion 
chamber or in a safe area (HSDB 2009). Gaseous 1,3-butadiene can be burned directly; however, 
liquefied 1,3-butadiene (in a compressed cylinder) must be atomized before burning (HSDB 2009). 
Kennedy et al. (2009) report that burning off 1,3-butadiene, also referred to as flaring, is commonly 
practiced at facilities where excess amounts of this substance need to be destroyed (Kennedy et al. 2009).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
1.3-Butadiene has been identified in at least 13 of the 1,699 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number 
of sites evaluated for 1,3-butadiene is not known. The frequency of these sites can be seen in Figure 6-1.
1.3-Butadiene is a high-volume, volatile hydrocarbon used in the production of commercial plastics and 
synthetic rubbers (Chemical Market Reporter 2006). The chemical reactivity of this monomer is utilized 
in its transformation into polymeric materials (Sigsby et al. 1987).
1.3-Butadiene may be released to the environment as an intentional or fugitive emission during its 
production, use, storage, transport, or disposal. Large amounts (1.17 million pounds) of this hydrocarbon 
are released to the atmosphere from commercial processes (TRI09 2011). Data on the detection of
1.3-butadiene in soil and water are scarce. In the past, it has been qualitatively detected in drinking water 
(EPA 1978; Kraybill 1980); however, more recent measurements are not available.
1.3-Butadiene is a highly volatile gas; therefore, it is expected to partition predominantly to the 
atmosphere. In the atmosphere, 1,3-butadiene is expected to undergo rapid destruction, primarily by 
photo-initiated reactions. The reaction with photochemically produced hydroxyl radicals has a calculated 
half-life of approximately 6 hours and is expected to be the dominant pathway for atmospheric removal 
(Atkinson 1989). Destruction of atmospheric 1,3-butadiene by the gas-phase reaction with tropospheric 
ozone and by the night-time reaction with nitrate radicals in urban areas is also expected to be significant 
(Atkinson and Carter 1984; Atkinson et al. 1984).
Limited data have been located on the fate of 1,3-butadiene in soil or water. Based on its physical 
properties, rapid volatilization of 1,3-butadiene from either soil or water to the atmosphere is expected to 
dominate over all other potential environmental processes. Based on estimated soil adsorption coefficient 
values, 1,3-butadiene is not expected to adsorb significantly to soil or sediment, nor is it expected to 
bioconcentrate in fish or aquatic organisms based on estimated bioconcentration and bioaccumulation 
factors.
Although 1,3-butadiene undergoes rapid photooxidation in the atmosphere, it is almost always present at 
very low concentrations in urban and suburban areas (Curren et al. 2006; Grant et al. 2007; Oguz et al.
Figure 6-1. Frequency of NPL Sites with 1,3-Butadiene Contamination
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2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004). Automobile exhaust is a constant source of
1.3-butadiene release to the atmosphere. Because of the compound's ubiquity in the urban/suburban 
atmosphere, the general population is exposed to low ppb levels of 1,3-butadiene through inhalation 
(Higashino et al. 2007; Hughes et al. 2003). Exposure to 1,3-butadiene may also occur from the 
inhalation of cigarette smoke or the smoke from wood fires (Adam et al. 2006; Bartle et al. 1969; 
Blomberg and Widmark 1975; Brunnemann et al. 1990; Carmella et al. 2009; Counts et al. 2006; 
Gustafson et al. 2007; Lofroth et al. 1989; Pankow et al. 2004, 2007; Penn and Snyder 2007; Stump et al. 
1989; Thweatt et al. 2007; Vainiotalo et al. 2008). Ingestion of contaminated food or drinking water may 
also lead to low levels of exposure, although current levels of this compound in food and water samples 
are not known, nor is there a good understanding of their frequency of detection (EPA 1978; Hughes et al. 
2003; Kraybill 1980; Leber 2001; McNeal and Breder 1987; Startin and Gilbert 1984). The levels of
1.3-butadiene in soil are not known. Elevated levels of exposure for the general population may occur for 
those near its site of manufacture or facilities where it is made into polymeric materials.
Occupational exposure to 1,3-butadiene is expected to be limited to those working at facilities that 
manufacture 1,3-butadiene or convert it into commercial polymers (Anttinen-Klemetti et al. 2006; 
Begemann et al. 2001a; Fustinoni et al. 2004; Jones and Harris 1983; Lovreglio et al. 2006; Meinhardt 
et al. 1982; Sathiakumar et al. 2007; Tsai et al. 2001, 2005; Ward et al. 2001). Exposure by inhalation is 
expected to be the dominant pathway for exposure. Dermal exposure to liquified 1,3-butadiene could 
occur during an explosion of a pressurized storage tank or some other catastrophic event.
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005). This is not an exhaustive list. Manufacturing and processing 
facilities are required to report information to the TRI only if they employ 10 or more full-time 
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20-39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
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imports, or processes >25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI 
chemical in a calendar year (EPA 2005).
6.2.1 Air
Estimated releases of 1.17 million pounds (530 metric tons) of 1,3-butadiene to the atmosphere from 
193 domestic manufacturing and processing facilities in 2009 accounted for about 99% of the estimated 
total environmental releases from facilities required to report to the TRI (TRI09 2011). These releases are 
summarized in Table 6-1.
The dominant sources for the release of 1,3-butadiene to the atmosphere are fugitive or accidental 
emissions during its manufacture, use, transport, and storage. Low levels of 1,3-butadiene are 
continuously emitted to the atmosphere from many sources including exhaust from motor vehicle engines 
using petroleum-based fuels.
EPA's National Emission Inventory database (NEI) contains detailed information about sources that emit 
criteria air pollutants and their precursors, and hazardous air pollutants for the 50 United States, 
Washington DC, Puerto Rico, and the U.S. Virgin Islands. Emission data for 1,3-butadiene in 2005 is 
presented in Table 6-2 and suggest that automobile usage accounts for approximately one-third of all 
emissions.
1,3-Butadiene was measured in the exhaust of typical automobiles and light trucks using both winter and 
summer gasoline formulations and accounted for up to 0.12% of total hydrocarbon emissions (Stump 
et al. 1989). An earlier study determined that the concentration of 1,3-butadiene in automobile exhaust 
was 20-60 ppb (Neligan 1962). 1,3-Butadiene has also been detected in the exhaust of diesel engines 
(Hayano et al. 1985) and high-altitude jet aircraft engines operating under simulated conditions (Katzman 
and Libby 1975).
There are several minor sources for the release of 1,3-butadiene to the atmosphere, all of which involve 
the thermal breakdown of other materials. 1,3-Butadiene has been detected as a component of the 
sidestream smoke from cigarettes (Adam et al. 2006; Bartle et al. 1969; Blomberg and Widmark, 1975; 
Carmella et al. 2009; Penn and Snyder 2007; Vainiotalo et al. 2008). The average amount of 1,3-buta­
diene in sidestream cigarette smoke is 205-361 ^g/cigarette (Brunnemann et al. 1990), with an average 
airborne yield of 400 ^g/cigarette (Lofroth et al. 1989).
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or 
Use 1,3-Butadienea
R e p o rte d  am o u n ts  re le a s e d  in pounds p e r y e a rb
To ta l re le a s e
S ta te c R F d A ire W a te rf U Ig L a n d h O th e r1 O n-site* O ff-s ite k O n - and  o
AL 2 3,069 0 0 47 0 3,069 47 3,116
AR 1 1,140 0 0 0 0 1,140 0 1,140
AZ 1 1,460 0 0 0 0 1,460 0 1,460
CA 17 6,116 0 0 8 0 6,116 8 6,124
CO 3 776 0 0 0 0 776 0 776
CT 1 32 0 0 0 0 32 0 32
DE 1 534 0 0 0 0 534 0 534
GA 2 3,732 0 0 0 0 3,732 0 3,732
HI 1 401 0 0 0 0 401 0 401
IA 1 4,766 0 0 0 0 4,766 0 4,766
IL 7 43,415 10 0 44 0 43,425 44 43,469
IN 5 3,859 5 0 0 0 3,864 0 3,864
KS 3 120 0 0 0 0 120 0 120
KY 5 15,246 0 0 726 0 15,246 726 15,972
LA 23 110,511 574 0 65 0 111,085 65 111,150
MI 2 3,585 0 0 0 0 3,585 0 3,585
MN 1 3,983 2 0 0 0 3,985 0 3,985
MS 1 809 0 0 0 0 809 0 809
MT 3 903 0 0 0 0 903 0 903
NC 3 858 0 0 0 0 858 0 858
ND 1 89 0 0 0 0 89 0 89
NJ 4 102 0 0 0 0 102 0 102
OH 13 35,145 6 0 4,161 5 39,311 6 39,317
OK 4 6,981 0 0 0 0 6,981 0 6,981
PA 4 2,258 0 0 0 0 2,258 0 2,258
SC 1 5,520 0 0 0 0 5,520 5,520
TN 4 4,648 0 0 0 0 4,648 0 4,648
TX 67 902,132 49 2,266 10 6 904,446 17 904,463
UT 2 1,069 0 0 0 0 1,069 0 1,069
VA 1 962 0 0 0 0 962 0 962
VI 1 1,039 0 0 0 0 1,039 0 1,039
W A 4 292 0 0 0 0 292 0 292
WI 1 156 0 0 0 0 156 0 156
W V 1 2,100 0 0 13 0 2,113 0 2,113
1,3-BUTADIENE
6. POTENTIAL FOR HUMAN EXPOSURE
126
Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use 1,3-Butadienea
R e p o rte d  am o u n ts  re le a s e d  in pounds p e r y e a rb
To ta l re le a s e
S ta te c R F d A ire W a te rf U Ig L a n d h O th e r1 O n-site* O ff-s ite k O n - and  o ff-s ite
W Y 2 500 0 0 0 0 500 0 500
Total 193 1,168,307 646 2,266 5,074 11 1,175,391 913 1,176,304
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI09 2011 (Data are from 2009)
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C a te g o ry  n a m e  T y p e  A n n u a l em iss io n s  (tons) P e rc e n ta g e
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Fuel comb, residential fireplaces Nonpoint 3,352.17 6.35
On-road vehicles, gasoline Onroad 16,008.77 30.32
Miscellaneous sources Nonpoint 17,627.65 33.39
On-road vehicles, diesel Onroad 1,058.86 2.01
Agricultural field burning Nonpoint 339.31 0.64
Fuel comb, residential woodstoves Nonpoint 315.31 0.60
Graphic arts Point 0.00 0.00
Gas stations Point 0.01 0.00
Wildfires Nonpoint 3,340.53 6.33
Bulk gasoline term inals Point 5.11 0.01
Fuel comb, commercial/institutional Nonpoint 0.07 0.00
Planes, trains, and ships Nonroad 109.07 0.21
Prescribed fires Nonpoint 164.95 0.31
Industrial process, storage and transfer Nonpoint 2.61 0.00
Industrial process, NEC Point 129.88 0.25
Surface coating, industrial Point 16.81 0.03
Non-road equipment, diesel Nonroad 364.74 0.69
Non-road equipment, gasoline Nonroad 8,062.72 15.27
Industrial process, petroleum refineries Nonpoint 1.30 0.00
Industrial process, petroleum refineries Point 22.15 0.04
Industrial process, cement manufacturing Point 64.37 0.12
Logging slash burning Nonpoint 211.34 0.40
Fuel comb, e lectric utility Point 2.30 0.00
Waste disposal, open burning Point 0.03 0.00
Waste disposal, open burning Nonpoint 123.52 0.23
Fuel comb, commercial/institutional Point 0.78 0.00
Industrial process, oil and gas production Point 7.71 0.01
Waste disposal Nonpoint 1.52 0.00
Industrial process, chemical manufacturing Point 603.65 1.14
Degreasing Point 0.01 0.00
Industrial process, chemical manufacturing Nonpoint 1.44 0.00
Solvent, NEC Point 0.24 0.00
Planes, trains, and ships Point 323.90 0.61
Fuel comb, industrial boilers, ICEs Nonpoint 2.86 0.01
Fuel comb, industrial boilers, ICEs Point 111.72 0.21
Waste disposal Point 37.16 0.07
Industrial process, oil and gas production Nonpoint 0.18 0.00
Industrial process, storage and transfer Point 217.59 0.41
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Table 6-2. 1,3-Butadiene Emission Data for 2005a
C a te g o ry  n a m e T y p e A n n u a l em iss io n s  (tons) P e rc e n ta g e
Industrial process, pulp and paper Point 0.30 0.00
Industrial process, metals Point 161.81 0.31
aEmission estimates are subject to updates for subsequent revised versions of the 2005 National Emissions 
Inventory data. These numbers may be different than values published for previous versions of the 2005 data and 
may also be different than values for subsequent revisions of the data as generated by EPA.
ICEs = internal combustion engines; NEC = not elsewhere classified
Source: EPA 2008
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The burning of plastics or rubber has been shown to release small amounts of 1,3-butadiene (Miller 
1978). In a test designed to simulate a real-life electrical overload condition, 1,3-butadiene was detected 
when polyurethane coated wire was heated to 250 °C for 40 minutes (Rigby 1981). 1,3-Butadiene has 
also been measured as a component of the smoke from brush fire (Stephens and Burleson 1969), and as a 
stack emission from waste incinerators (Junk and Ford 1980). The concentrations of 1,3-butadiene were 
not presented in these studies. The mean, minimum, and maximum concentrations of 1,3-butadiene 
measured in the air of nine municipal structural fires were 1.03, 0.03, and 4.84 ppm, respectively (Austin 
et al. 2001). The sources of 1,3-butadiene were considered to be both the combustion of wood and the 
thermal degradation of polymeric materials. Forest fires are considered to be a natural source of 1,3-buta­
diene in the atmosphere (Curren et al. 2006). Detection of 1,3-butadiene while heating rapeseed oil 
indicates that the heating of cooking oils may be a source of 1,3-butadiene in indoor air (Pellizzari et al. 
1995).
1,3-Butadiene has been identified in air samples collected at 8 of the 13 NPL hazardous waste sites where 
it was detected in some environmental media (HazDat 2007).
6.2.2 W ater
Estimated releases of 646 pounds (0.29 metric tons) of 1,3-butadiene to surface water from 193 domestic 
manufacturing and processing facilities in 2009, accounted for about 0.05% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI09 2011). An additional 
913 pounds (0.08 metric tons) were transferred off-site which includes releases to publicly owned 
treatment works (POTWs) (TRI09 2011). These releases are summarized in Table 6-1.
Additional information regarding the release of 1,3-butadiene to water was not located in the available 
literature. 1,3-Butadiene has been identified in groundwater samples collected at 1 of the 13 NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 2007). It was not 
identified in surface water at any of the NPL sites.
6.2.3 Soil
Estimated releases of 5,074 pounds (2.3 metric tons) of 1,3-butadiene to soils from 193 domestic 
manufacturing and processing facilities in 2009, accounted for about 0.43% of the estimated total 
environmental releases from facilities required to report to the TRI (TRI09 2011). An additional
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2,266 pounds (1.03 metric tons), constituting about 0.19% of the total environmental emissions, were 
released via underground injection (TRI09 2011). These releases are summarized in Table 6-1.
Additional information regarding the release of 1,3-butadiene to soil was not located in the available 
literature. 1,3-Butadiene has been identified in soil samples collected at 2 of the 13 NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2007). It was not identified in 
sediment at any of the NPL sites.
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
1.3-Butadiene’s high volatility suggests that it will partition predominantly to the atmospheric 
compartment, where it is not expected to be adsorbed to particulate matter to any significant extent 
(Eisenreich et al. 1981).
Based on the calculated Henry’s Law constant of 7.4x10-2 atm-m3/mol, the half-life for volatilization of
1.3-butadiene is 2.2 hours from a model river (1 m deep, flowing at 1 m/second, with a wind velocity of
3 m/second) and 2.9 days from a model lake (1 m deep, flowing at 0.05 m/second, with a wind velocity of 
0.5 m/second) (Lyman et al. 1990). Based on an experimental log octanol/water partition coefficient of 
1.99 (Hansch et al. 1995), a calculated soil adsorption coefficient of 288 (Lyman et al. 1990) suggests that 
adsorption to sediment and suspended organic matter will not be a significant fate process. From the log 
octanol/water partition coefficient, a calculated bioconcentration factor of 19 (Lyman et al. 1990) 
indicates that 1,3-butadiene will not bioconcentrate in fish and aquatic organisms to any significant 
extent. However, no experimental data have been located to verify these theoretical values.
If released to soil, 1,3-butadiene is expected to volatilize rapidly from either moist or dry soil to the 
atmosphere. This follows from the estimated lack of any appreciable adsorption to soil, and consideration 
of 1,3-butadiene's calculated Henry's law constant for moist soil or its vapor pressure, 2,100 mm Hg at 
25 °C (AIChE 2000), for dry soil. Both values suggest a rapid rate of volatilization from their respective 
media.
The calculated soil adsorption coefficient of 288 (Hansch et al. 1995; Lyman et al. 1990) suggests that
1.3-butadiene may display moderate mobility in soil (Swann et al. 1983). However, the expected rapid 
rate of volatilization and the possibility of rapid degradation in soil suggest that there is little potential for
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1.3-butadiene to leach into groundwater. But until adequate groundwater monitoring for 1,3-butadiene 
has been performed, the partitioning of 1,3-butadiene in soil cannot be adequately addressed.
6.3.2 Transformation and Degradation
6.3.2.1 Air
Butadiene is a reactive, electron-rich chemical that is expected to undergo rapid reactions with the 
electrophilic oxidants typically present in the atmosphere: ozone, photochemically produced hydroxyl 
radicals, nitrate radicals, and molecular oxygen. Among these, the most rapid reaction in the atmosphere 
is with photochemically produced hydroxyl radicals.
The atmospheric degradation of 1,3-butadiene by photo-initiated processes has been established 
empirically by early studies. These studies typically involved irradiating urban air samples in 
atmospheric chambers of varying complexity and monitoring the disappearance of each constituent.
Using this technique, 1,3-butadiene, at an average concentration of 12.4 ppb, disappeared in 6 hours when 
irradiated with natural sunlight during October (Kopczynski et al. 1972). In another study, a half-life of 
2 hours was determined for the atmospheric removal of 1,3-butadiene using natural sunlight in October or 
November (Altshuller et al. 1970). In smog chamber studies, the sunlight oxidation of 1,3-butadiene led 
to the formation of fairly potent eye irritants, suggesting destruction of this compound with concomitant 
formation of oxygenated species (Dimitriades et al. 1975; Heuss and Glasson 1968). It is believed that 
the destruction of 1,3-butadiene occurs by photo-initiated bimolecular processes rather than direct 
photochemical degradation (Kopczynski et al. 1972). It is important to note that the rate of destruction of
1.3-butadiene when it was irradiated with natural light depended on the time of day in which the 
irradiation occurred. Furthermore, these studies were performed in October and November, when the 
amount and the intensity of available sunlight is diminished over that of summer months; thus, these 
values probably represent the high end of the compound's atmospheric lifetime. The individual processes 
responsible for the destruction of 1,3-butadiene in the atmosphere are discussed below.
Numerous studies have determined the rate constant for the gas-phase reaction of 1,3-butadiene with 
photochemically produced hydroxyl radicals (Atkinson 1985; Atkinson and Aschmann 1984; Atkinson 
et al. 1977, 1979; Maldotti et al. 1980). The experimental rate constant 6.85x10-11 cm3/molecule-second 
at 26 °C (Atkinson et al. 1977) is representative. Given an average hydroxyl radical concentration of 
5x105 molecule/cm3 (Atkinson 1985), the half-life for this second-order process is 5.6 hours. Major 
products of this reaction include acrolein and formaldehyde (Baker et al. 2005).
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Gas-phase 1,3-butadiene also reacts with ozone in the atmosphere. Rate constants ranging from 
6.7x10-18 to 8.4x10-18 cm3/molecule-second at 25 °C have been published in the literature (Atkinson and 
Carter 1984; Jaspar et al. 1974). Using an average atmospheric ozone concentration of 7x10n molecules/ 
cm3 (Atkinson and Carter 1984), half-lives ranging from 1.4 to 1.7 days can be calculated for this second- 
order process. Therefore, the reaction of 1,3-butadiene with ozone is expected to contribute to the overall 
destruction of atmospheric 1,3-butadiene. The initial products from the reaction of 1,3-butadiene with 
ozone are acrolein, formaldehyde, acetylene, ethylene, and formic anhydride (Niki et al. 1983). All of 
these products are susceptible to secondary reactions with ozone and other atmospheric oxidants.
The night-time degradation of 1,3-butadiene is also expected to occur via the gas-phase reaction with 
nitrate radicals; this tends to be significant in urban areas, where the concentration of this oxidant is 
typically higher than in rural areas (Altshuller and Cohen 1964; Gay and Bulfalini 1971; Maldotti et al. 
1980). A rate constant of 5.4x10-14 cm3/molecule-second at 22 °C has been determined for this reaction. 
This corresponds to a half-life of 14.9 hours using an average atmospheric nitrate radical concentration of 
2.4x108 molecule/cm3 (Atkinson et al. 1984), typical of mildly polluted urban centers. Acrolein has been 
identified as a primary product of this reaction.
In summary, there are three gas-phase pathways that degrade 1,3-butadiene in the troposphere.
Depending on local conditions, any one or all of these reactions may occur. Destruction of atmospheric
1,3-butadiene by the gas-phase reaction with photochemically produced hydroxyl radicals is expected to 
be the dominant photo-initiated pathway. Degradation via nitrate radicals is expected to be a significant 
night-time process in urban areas.
6.3.2.2 W ater
Data on the degradation of 1,3-butadiene in aquatic systems are limited. Experimental data are restricted 
to microbial degradation studies performed under aerobic conditions. The bulk of these data were 
obtained from isolated bacterial strains (pure cultures), not with mixed microbial populations typically 
found in natural systems, and are not considered to be representative of the biodegradation of 1,3-buta­
diene in the environment. However, results from these studies suggest that biodegradation of 1,3-buta­
diene proceeds through oxidation to form 3,4-expoxybutene (Hou et al. 1979, 1980, 1983; Patel et al. 
1982a; Watkinson and Somerville 1976). Watkinson and Somerville (1976) reported further degradation.
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6.3.2.3 Sediment and Soil
As is the case for the degradation of 1,3-butadiene in water, very limited data on the destruction of this 
compound in soil could be located in the available literature. Results from pure culture studies suggest a 
similar aerobic biodegradation pathway for 1,3-butadiene in soil compared to the pathway in water (Hou 
et al. 1979; Patel et al. 1979, 1982a, 1982b; VanGinkel et al. 1987; Watkinson and Somerville 1976).
6.3.2.4 Other Media
Specific information regarding the transformation or degradation of 1,3-butadiene in other environmental 
media was not located.
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to 1,3-butadiene depends in part on the reliability 
of supporting analytical data from environmental samples and biological specimens. Concentrations of
1.3-butadiene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the 
limits of current analytical methods. In reviewing data on 1,3-butadiene levels monitored or estimated in 
the environment, it should also be noted that the amount of chemical identified analytically is not 
necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring
1.3-butadiene in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
1.3-Butadiene is widely detected at low ppb levels in urban air samples. Reported average concentrations 
range from 0.1 to 2 ^g/m3 (0.04-0.9 ppb) (Curren et al. 2006; Grant et al. 2007; Oguz et al. 2003; Reiss 
2006; Reiss and Griffin 2004; Sax et al. 2004). A major source of 1,3-butadiene in urban air is 
automobile engine exhaust (Broderick and Marnane 2002; Sigsby et al. 1987; Stump and Dropkin 1985; 
Stump et al. 1989). Atmospheric emissions from industrial facilities that produce or use 1,3-butadiene are 
another major source of the compound in areas located near these facilities. Concentrations as high as
40 ^g/m3 (18 ppb) have been measured in the air near industrial sites (highest 24-hour level measured 
downwind from a major industrial source) (Grant et al. 2007). Curren et al. (2006) analyzed 3,267 air 
samples collected at eight rural locations in Canada and reported a mean 1,3-butadiene concentration of 
0.02 ^g/m3 (0.009 ppb) at these sites. EPA (2003a) estimated that the average background concentration 
of 1,3-butadiene in the air of the United States is 0.13 ^g/m3 (0.058 ppb). McCarthy et al. (2006)
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provided a lower estimate (<0.02 ^g/m3; 0.009 ppb) of 1,3-butadiene in the background air of North 
America. Table 6-3 lists reported concentrations of 1,3-butadiene measured in outdoor air.
1.3-Butadiene has also been detected in indoor air samples. Mean concentrations of 1,3-butadiene 
measured in indoor air of homes in New York were 1.0 ^g/m3 (0.5 ppb) during the winter and 1.2 ^g/m3 
(0.54 ppb) during the summer (Sax et al. 2004). In Los Angeles, mean concentrations were 0.5 ^g/m3 
(0.2 ppb) during the winter and 0.2 ^g/m3 (0.09 ppb) during the fall. The concentrations of 1,3-butadiene 
measured in a tavern were 11 and 19 ^g/m3 (5.0 and 8.6 ppb) in two separate studies, while the outside air 
concentration was <1 ^g/m3 (0. 5 ppb) at the same time (Lofroth et al. 1989). The difference in the indoor 
versus outdoor concentration may be ascribed to the presence of 1,3-butadiene in cigarette smoke. The 
concentration of 1,3-butadiene in a smoke-filled bar was 2.7-4.5 ^g/m3 (1.2-2.0 ppb) (Brunnemann et al. 
1990). Higher 1,3-butadiene levels have been observed in air samples collected from the smoking areas 
of restaurants and pubs than in air samples collected from the nonsmoking areas of these buildings (Kim 
et al. 2001; Vainiotalo et al. 2008). Mean 1,3-butadiene concentrations measured in the indoor air of
32 smoking homes and 32 nonsmoking homes were 1.7 and 0.5 ^g/m3 (0.77 and 0.23 ppb), respectively 
(Kim et al. 2001). Mean 1,3-butadiene levels were 0.31-0.38 ^g/m3 (0.14-0.17 ppb) in the air of wood 
burning homes and 0.114 ^g/m3 (0.0515 ppb) in non-wood burning homes in Hagfors, Sweden 
(Gustafson et al. 2007). Table 6-4 lists reported concentrations of 1,3-butadiene measured in indoor air.
6.4.2 W ater
No current information on the occurrence of 1,3-butadiene in water was located in the available literature.
1.3-Butadiene was found in 1 of 204 water samples taken in 1975-1976 from surface waters near known 
industrialized areas across the United States. The single positive sample was obtained in the Carquinez 
Strait, Posta Corta, California, at an approximate concentration of 2 ppb (Ewing et al. 1977).
No specific data on its presence in drinking water, such as monitoring dates or concentration, were 
located; however, 1,3-butadiene has been qualitatively detected in U.S. drinking water in the past (EPA 
1978; Kraybill 1980).
6.4.3 Sediment and Soil
No data on the occurrence of 1,3-butadiene in soil were located in the available literature.
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Table 6-3. 1,3-Butadiene Concentrations in Outdoor Air
C o n cen tra tio n  (^ g /m 3)
Location n > L O D L O D M e a n M e d ia n M a x im u m R e fe re n c e
Urban
New York City Sax et al. 2004
W inter 31 14% 0.06 0.1 ND 0.7
Sum mer 
Los Angeles
27 11% 0.06 0.1 ND 2.0
Sax et al. 2004
W inter 35 24% 0.06 0.2 ND 1.7
Fall
Houston
32 3% 0.06 0.01 ND 0.3
Reiss 2006
16 Locations 
Texas
4,374 61% 0.02a 1.3 — 7.2
Grant et al. 2007
47 Urban/ 
industrial sites
Baltimore
<30-74% 0.61 0.5 40
Sapkota and
Toll booth 
Baltimore
56 100% 0.46 — 2 -1 3 .5 b 19 Buckley 2003 
Kim et al. 2007
Parking garage 
Canada
2 o 0 .2 -0 .5d 8
Curren et al. 
2006
30 Locations
Rural
Canada
5,160 0.001-0 .02 0.22 0.17 2.58
Curren et al. 
2006
8 Locations 
Background estimate
3,267 — 0.001-0 .02 0.02 — —
United States — — — 0.13 0.10 2.2 EPA 2003a
North America — — — <0.02 <0.02 <0.02 M cCarthy et al. 
2006
aValue is referred to as the reporting limit.
bLower and upper median values correspond to measurements taken during 12-3 a.m. and 6 -9  a.m., respectively. 
cSeven-hour samples were collected on 18 week days and 6 weekend days.
dLower and upper median values correspond to measurements taken on weekends and weekdays, respectively. 
LOD = limit of detection; n = number of samples; ND = not detected
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Table 6-4. 1,3-Butadiene Concentrations in Indoor Air
C o n cen tra tio n  (^ g /m 3)
Location n > L O D L O D M e a n M e d ia n M ax im u m R e fe re n c e
New York City 
W inter 36 64% 0.06 1.0 0.7 5.8
Sax et al. 2004
Sum mer 30 44% 0.06 1.2 ND 12
Los Angeles 
W inter 40 60% 0.06 0.5 0.5 1.8
Sax et al. 2004
Fall 32 38% 0.06 0.2 ND 1.5
Arizona NHEXAS 
Home indoor 24 4% 0.38 ND ND 0.6
Gordon et al. 
1999
Home outdoor 14 0% 0.38 ND ND ND
Ottawa, Canada 
House background 17 65% 0.1 0.51 0.36 1.63
Graham et al. 
2004
Cold-start housea 17 100% 0.1 5.76 2.69 28.6
Cold-start garage3 17 100% 0.1 82.8 84.7 166
Birmingham, United 
Kingdom
6 smoking homes 32 100% 0.11 1.7 0.7 10.8
Kim et al. 2001
6 nonsmoking homes 32 <100% 0.11 0.5 0.4 1.1
Restaurants 6 — 0.11 1.5 — —
Pubs 6 — 0.11 3.0 — —
O ther indoorb 43 — 0.11 0 .2-0 .9 — —
Helsinki, Finland 
10 Restaurants 
Smoking area 20 100% 0.02 4.3 10.1
Vainiotalo et al. 
2008
Non-smoking area 20 100% 0.02 1.1 — 3.9
Hagfors, Sweden 
Wood burning homes 14 NR 0.03-0 .15 0.31-0 .38 0.20-0 .23 0 .90 -1 .54c
Gustafson et 
al. 2007
Reference homes 10 NR 0.03-0 .15 0.11 0.10-0.11 0 .18 -0 .24c
Area outdoor 9 NR 0.03-0 .15 0.12 0.11 —
C oncentrations measured in the house and garage after a cold vehicle engine was started in the attached garage. 
bIncludes offices, department stores, cinemas, perfume shop, libraries, and laboratories. 
c90th percentile values.
LOD = limit of detection; n = number of samples; ND = not detected; NHEXAS = National Human Exposure 
Assessment Survey; NR = not reported
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1.3-Butadiene is used to manufacture synthetic rubber and plastics that are frequently used for food 
packaging. Because residual 1,3-butadiene may be present in the polymers used to make the containers, 
both the packaging and the food contained therein have been analyzed. In one study, 1,3-butadiene at a 
concentration of 8-9 ng/g (ppb) was detected in three of three brands of olive oil packaged in 1,3-buta­
diene rubber-modified acrylonitrile-acrylic bottles (McNeal and Breder 1987). Analysis of the bottles 
themselves found 1,3-butadiene residues as high as 6,600 ng/g (ppb). Soft-plastic packaging tubs used as 
containers for potato salad, cottage cheese, and yogurt had residual 1,3-butadiene levels in the range of 
21-1,700 ng/g (ppb). However, no 1,3-butadiene was detected in any of the food packed in these 
containers (detection limit 1 ppb). Chewing gum made with a 1,3-butadiene rubber base did not show 
residual traces of this diene (McNeal and Breder 1987). Soft-plastic margarine tubs from five major 
name brands in the United Kingdom contained 1,3-butadiene residues ranging from 5 to 310 ^g/kg (ppb), 
but none of the monomer was detected in the margarine samples themselves (detection limit 0.2 ^g/kg) 
(Startin and Gilbert 1984). The authors concluded that migration of the 1,3-butadiene monomer from 
plastic packaging to food is unlikely to present a problem. Residual levels of 1,3-butadiene in food 
containers are closely regulated by the Food and Drug Administration.
Pellizzari et al. (1995) measured 0.1 mg of 1,3-butadiene in rapeseed oil emissions during 20 minutes of 
heating the oil in a wok at 260 °C. The presence of 1,3-butadiene was attributed to the pyrolytic 
decomposition of unsaturated fatty acids in the oil.
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
1.3-Butadiene is almost always present in the air at low levels due to its emission from motor vehicles. 
Therefore, the general population is probably routinely exposed to ppb levels of this compound.
Exposure to 1,3-butadiene by the general population is expected to be dominated by inhalation 
(Higashino et al. 2007; Hughes et al. 2003). Reported mean concentrations of 1,3-butadiene measured in 
urban air generally range from 0.1 to 2 ^g/m3 (0.4-0.9 ppb) (Curren et al. 2006; Grant et al. 2007; Oguz et 
al. 2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004). Sapkota et al. (2006) measured mean
1.3-butadiene personal air exposure levels of 1.22 ^g/m3' (0.55 ppb) for suburban-weekend exposure,
1.47 ^g/m3 (0.66 ppb) for urban-week day exposure, and 2.88 ^g/m3 (1.3 ppb) for tollbooth worker 
exposure in the Baltimore, Maryland area.
6.4.4 Other Environmental Media
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Inhalation of 1,3-butadiene by the general population may also occur due to other sources. 1,3-Butadiene 
has been identified in cigarette smoke; therefore, smokers and those nearby are exposed to this compound 
(Adam et al. 2006; Bartle et al. 1969; Blomberg and Widmark 1975; Brunnemann et al. 1990; Carmella et 
al. 2009; Counts et al. 2006; Lofroth et al. 1989; Pankow et al. 2004, 2007; Penn and Snyder 2007; 
Thweatt et al. 2007; Vainiotalo et al. 2008). Reported delivery levels of 1,3-butadiene in the mainstream 
smoke of cigarettes range from 1.3 to 100 ^g/cigarette (Pankow et al. 2004; Thweatt et al. 2007).
Nazaroff and Singer (2004) calculated a 1,3-butadiene inhalation intake of 16-37 ^g/day for nonsmokers 
who live with a smoker. This value was based on an exposure relevant emission factor of 515 ^g
1.3-butadiene/cigarette and a 1,3-butadiene exposure concentration of 1.4-3.1 ^g/m3 (Nazaroff and Singer 
2004). Counts et al. (2006) measured 1,3-butadiene concentrations ranging from 11.2 to 59.3 ^g/cigarette 
in the mainstream smoke of 26 different commercial cigarettes sold in the United States.
1.3-Butadiene is present in the smoke from brush fires, wood fires, and municipal structural fires (Austin 
et al. 2001; Gustafson et al. 2007; Stephens and Burleson 1969), suggesting that inhalation of the smoke 
from wood fires will lead to low-level exposure to 1,3-butadiene. Gustafson et al. (2007) reported a mean
1.3-butadiene concentration of 0.33 ^g/m3 (0.15 ppb) in the personal air of individuals living in wood- 
burning homes and 0.14 ^g/m3 (0.063 ppb) in the personal air of a reference group. Its presence in waste 
incinerator emissions (Junk and Ford 1980) suggests that exposure to the general population may occur 
for those living nearby. Small amounts of 1,3-butadiene are produced by the thermal degradation of 
polyurethane-coated wire, an event that may occur during an electrical overload (Rigby 1981). The 
thermal degradation of other 1,3-butadiene-based plastics or rubbers may produce 1,3-butadiene (Miller 
1978), also leading to low-level exposure of the general population by inhalation.
If the mean daily urban air concentration of 1,3-butadiene is 0.29 ppb (0.64 ^g/m3), as determined in an 
analysis and compilation of experimental reports of ambient monitoring data obtained from 1970 to 1987 
(Shah and Heyerdahl 1988), a nonoccupational daily intake of 12.8 ^g per person can be obtained based 
on an average human intake of 20 m3 air/day. Marshall et al. (2006) calculated a 1,3-butadiene intake rate 
of 7.3 ^g/day based on an exposure concentration of 0.55 ^g/m3 and a mean breathing rate of 
13.1 m3/day. Kim et al. (2002) measured mean personal air exposure concentrations of 1.1 ^g/m3 
(0.50 ppb) during the night time and 0.8 ^g/m3 (0.36 ppb) during the day time for 12 residents of 
Birmingham, United Kingdom who were nonsmokers.
No data are available that quantify general population exposure to 1,3-butadiene by other routes of intake, 
such as ingestion of contaminated drinking water. Low-level exposure by ingestion of contaminated
1,3-BUTADIENE
6. POTENTIAL FOR HUMAN EXPOSURE
139
drinking water may occur as 1,3-butadiene has been qualitatively detected in U.S. drinking water supplies 
(EPA 1978; Kraybill 1980). Given that residues of 1,3-butadiene have been found in plastic and rubber 
food containers and in a few samples of the food contained in these containers (McNeal and Breder 
1987), very low-level exposure to the general population may occur by ingestion of contaminated foods 
packaged in these containers (Hughes et al. 2003; Leber 2001). Leber (2001) estimated an upper-bound
1.3-butadiene intake of 44 ng/day from food contact sources which include styrene butadiene rubber- 
containing chewing gum, polymeric coatings, closures with sealing gaskets, and other indirect additives.
According to the National Occupational Exposure Survey (NOES) conducted by NIOSH between 
1980 and 1983, 9,456 workers, of which 286 are women, were estimated to be exposed to 1,3-butadiene 
(NIOSH 1989). The NOES database does not contain information on the frequency, concentration, or 
duration of exposure of workers to any chemicals listed therein. These surveys provide only an estimate 
of the number of workers potentially exposed to chemicals in the workplace. During a study involving 
13,130 men who had been employed for at least 1 year at any of eight synthetic rubber plants in the 
United States or one in Canada between 1943 and 1992, it was estimated that 10,429 (79%) of these 
individuals had occupational exposure to 1,3-butadiene (Delzell et al. 2001; Macaluso et al. 2004). 
Occupational exposure to 1,3-butadiene is expected to be limited to inhalation of this compound, although 
dermal contact with liquified 1,3-butadiene may occur during a large spill, tank explosion, pipeline 
rupture, or similar catastrophic event. Specific industrial classifications or job descriptions involving 
exposure to 1,3-butadiene are provided below.
Levels of 1,3-butadiene measured in the air at styrene-butadiene rubber (SBR) plants have been reported 
(Anttinen-Klemetti et al. 2006; Jones and Harris 1983; Meinhardt et al. 1982; Sathiakumar et al. 2007; 
Ward et al. 2001). Table 6-5 lists 1,3-butadiene air concentrations associated with typical SBR 
operations. These concentrations were measured in air samples collected at different times between 1977 
and 1991 at a synthetic rubber plant in Canada (Sathiakumar et al. 2007). These data show that 
individuals directly involved in the production of styrene-butadiene rubber have the greatest exposure to
1.3-butadiene at these facilities, although high concentrations were also associated with some equipment 
maintenance and control technician operations as well. Air concentrations associated with tank farm and 
transfer pumphouse operations (mean, 103 mg/m3; 56.6 ppm) were at least an order of magnitude greater 
than those of any of the other operations. Maximum concentrations measured at this facility were as high 
as 1,490 mg/m3 (673 ppm).
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Table 6-5. Air Concentrations of 1,3-Butadiene Corresponding to Typical 
Operations Within a Styrene-Butadiene Rubber (SBR) Planta
O p era tio n n M e a n
C o n cen tra tio n  (m g /m 3)
M e d ia n  M in im u m  M a x im u m
SBR production
Polymerization
Tank farm, transfer pumphouse 231 103 33.1 0.13 1,490
Reactor, blowdown, panel board 261 9.9 2.2 0.04 146
Recovery, com pressor house, high 333 22.5 3.5 0.04 1,200
solids recovery 
Unspecified operative 35 2.4 0.91 0.00 34.3
Coagulation, blending, solutions prep 314 2.1 0.44 0.04 42.0
Finishing
Baler, packager, reclaim 111 0.64 0.33 0.07 4.2
Dryer, baler dryer 134 2.9 0.44 0.11 271
Unspecified operative 39 0.29 0.15 0.04 1.5
Maintenance, production, maintenance field 
Foreman, engineer 15 0.44 0.40 0.04 1.5
Instrument worker, m eter person, 56 4.9 0.42 0.04 108
electrician, maintenance inspector 
Pipefitter, oiler, mechanic, blacksmith, 250 9.7 1.8 0.04 234
boilermaker, outside machinist 
C leanup crew, laborer, w ork pool, utility 74 3.1 1.1 0.11 40.0
person
Technical/lab
Rubber control, technician 210 30.1 2.1 0.00 1,150
Butadiene control, hydrocarbon control, 41 4.9 0.15 0.00 67.4
technician
Shipping/distribution
Labor, utility person, service person 24 0.20 0.15 0.00 0.66
Utilities
Copolym er effluent operative 103 1.3 0.88 0.00 17.5
Unspecified/m iscellaneous operative 114 0.42 0.22 0.00 4.2
aAir samples were collected at different times at a Canadian synthetic rubber plant between 1977 and 1991 
Source: Sathiakumar et al. 2007
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1.3-Butadiene has been measured in the air of petrochemical facilities (Begemann et al. 2001a; Fustinoni 
et al. 2004; Lovreglio et al. 2006; Tsai et al. 2001, 2005). Mean time-weighted average concentrations of
1.3-butadiene were 10.23 mg/m3 (4.55 ppm) between 1979 and 1996 and 0.56 mg/m3 (0.25 ppm) between 
1997 and 2003 at the Deer Park and Norco Manufacturing complexes owned by Shell Oil Company (Tsai 
et al. 2005). Short-term exposures to this substance were as high as 987 mg/m3 (439 ppm) in 1979-1996 
and 337 mg/m3 (150 ppm) in 1997-2003. The decline in 1,3-butadiene levels in air at these facilities in 
recent years is attributed to the implementation of new health standards in 1996 (Tsai et al. 2001, 2005).
A walk-through survey of 11 monomers, 17 polymers, and 2 end-user plants found that personal 
exposures ranged from <0.006 ppm to 374 ppm ( 0.013-827 mg/m3) (Fasen et al. 1990).
Two studies have reported levels of 1,3-butadiene measured in human blood, breath, and urine. Perbellini 
et al. (2003) measured average 1,3-butadiene concentrations of 1.0, 1.9, and 1.0 ng/L in the alveolar air, 
blood, and urine, respectively, of 46 forestry workers who were nonsmokers and 3.6, 11.4, and 3.9 ng/L 
in the alveolar air, blood, and urine, respectively, of 15 forestry workers who were smokers. The 
individuals had not been involved in forestry work for 2 months; therefore, occupational exposure was not 
considered to be a contributing factor. Fustinoni et al. (2004) measured end-shift 1,3-butadiene levels of 
2.4, 3.8, and 4.3 ng/L in the exhaled air, urine, and blood, respectively, of 42 workers with a mean 
personal exposure of 11.5 ^g/m3 (5.20 ppb) and levels of 2.3, 3.1, and 5.9 ng/L in the exhaled air, urine, 
and blood, respectively, of 43 workers with a mean personal exposure of 0.9 ^g/m3 (0.4 ppb). Pre-shift 
levels in exhaled air and urine were 2.4 and 3.8 ng/L, respectively, for the higher exposed workers and 
below detection for the lower-exposed workers.
Other occupations where exposures to 1,3-butadiene may occur include petroleum refinery workers, 
professional bus, truck, and taxi drivers, parking garage attendants, tollbooth workers, and employees 
working in areas where smoking is permitted.
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
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The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Children are expected to be exposed to 1,3-butadiene primarily through inhalation of low levels in air. 
Children who live near areas of heavy vehicle traffic or near industrial facilities where 1,3-butadiene is 
produced or used may be exposed to higher levels of 1,3-butadiene. The available data indicate that 
exposure to 1,3-butadiene through ingestion of food and drinking water is expected to be low relative to 
inhalation exposure. Biomonitoring data for children, including levels of 1,3-butadiene and its 
metabolites measured in breast milk, neonatal blood, cord blood, and meconium fluid have not been 
located in the available literature.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
High levels of exposure to 1,3-butadiene are likely to be limited to those resulting from an occupationally 
related use of this compound. Inhalation is the most likely route of high exposure to 1,3-butadiene.
1.3-Butadiene is stored and transported in pressurized tanks, and it is possible that high levels of exposure 
by inhalation or dermal contact with the liquified gas may occur during the loading and unloading of 
these tanks, or by the accidental rupture of these tanks. Occupations where potentially high exposures to
1.3-butadiene may occur include those in styrene-butadiene rubber facilities, those in petroleum 
refineries, professional bus, truck, and taxi drivers, parking garage attendants, tollbooth workers, and 
employees working in areas where smoking is permitted. Individuals who live near facilities where
1.3-butadiene is produced or used have the potential for high exposure to this substance. Individuals who 
are frequently exposed to smoke from combustion sources, such as firefighters, may have high exposures 
to 1,3-butadiene (Austin et al. 2001). Individuals living very close to high traffic roads may be exposed 
to higher levels of butadiene.
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of 1,3-butadiene is available. Where adequate information is 
not available, ATSDR, in conjunction with NTP is required to assure the initiation of a program of
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research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of 1,3-butadiene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs
Physical and Chemical Properties. The physical and chemical properties of 1,3-butadiene are well 
documented (Amoore and Hautala 1983; Hansch et al. 1995; HSDB 2009; Lewis 2007; Lide 2008; 
McAuliffe 1966; O’Neil et al. 2006; NIOSH 2005), and its environmental fate can be estimated from 
these properties (Lyman et al. 1982). No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning 
and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit 
substance release and off-site transfer information to the EPA. The TRI, which contains this information 
for 2009, became available in February of 2011. This database is updated yearly and should provide a list 
of industrial production facilities and emissions.
The trends in the production and use of 1,3-butadiene are well documented (Chemical Market Reporter 
2006; Chemical Week 2008; Grub and Loser 2005; Kirshenbaum 1978; SRI 2008; Sun and Wristers
2002), and there do not appear to be any critical information gaps. 1,3-Butadiene monomer does not 
occur in most products used in the home, although residues of this compound in commercial packages, 
especially food containers (McNeal and Breder 1987), are not well described. It is clear that the majority 
of 1,3-butadiene is released to the atmosphere (TRI09 2011). The disposal of 1,3-butadiene appears to be 
a straightforward process (HSDB 2009). No data needs are identified.
Environmental Fate. The fate of 1,3-butadiene in the atmosphere is well understood (Atkinson 1985; 
Atkinson and Carter 1984; Atkinson et al. 1984; Kopczynski et al. 1972). The fate of 1,3-butadiene in 
soil and water is not well understood, and partitioning from these media has to be determined from the 
physical and chemical properties of this compound (Lyman et al. 1982). A reliable method capable of
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detecting 1,3-butadiene in soil and water was not located in the available literature, and it is not clear 
whether 1,3-butadiene is absent from these media or simply not yet detected. The persistence of 1,3-buta­
diene in soil and water is not known, and the degree of partitioning from one environmental compartment 
to another can only be estimated. Exposure via ingestion or dermal contact to populations surrounding 
hazardous waste sites cannot, therefore, be accurately determined. Experimental data that address the 
partitioning of 1,3-butadiene in the environment, its potential to enter drinking water supplies, and its 
lifetime in soil and water are necessary to completely characterize the environmental fate of this 
compound.
Bioavailability from Environmental Media. Numerous toxicokinetic and toxicity studies in 
humans and animals have demonstrated the bioavailability of 1,3-butadiene from air. No data on the 
bioavailability of 1,3-butadiene from other sources (water or soil, for example) were located in the 
available literature. In conjunction with the data needs for determining 1,3-butadiene in environmental 
media, bioavailability studies from environmental media would be useful.
Food Chain Bioaccumulation. In theory, 1,3-butadiene is not believed to bioconcentrate 
significantly in fish and aquatic organisms; thus, it is not expected to biomagnify in the food chain 
(Hansch and Leo 1995; Lyman et al. 1982). No data addressing this point, however, were located in the 
available literature. Validation of these theories by valid experimental studies will aid in establishing a 
quantitative determination of 1,3-butadiene exposure to the general public.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of 1,3-buta­
diene in contaminated media at hazardous waste sites are needed so that the information obtained on 
levels of 1,3-butadiene in the environment can be used in combination with the known body burden of
1.3-butadiene to assess the potential risk of adverse health effects in populations living in the vicinity of 
hazardous waste sites.
Data on the levels of 1,3-butadiene in environmental media are limited. Extensive data on the occurrence 
of 1,3-butadiene in ambient air samples are available (Curren et al. 2006; Grant et al. 2007; Oguz et al. 
2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004), but more data would be helpful. Data on the 
occurrence of 1,3-butadiene in water samples are very limited (Ewing et al. 1979). The presence of
1.3-butadiene in drinking water has been noted in the literature, but no concentrations or frequency of 
detection are available (EPA 1978; Kraybill 1980). The development of reliable analytical techniques for
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the analysis of 1,3-butadiene in soil and water will establish unambiguously the levels at which this 
compound is found in environmental media.
Exposure Levels in Humans. Limited data on levels of occupational exposure to 1,3-butadiene 
were available in the literature; however, occupational exposure to this compound appears to be limited to 
a readily definable group of industrial classifications (NIOSH 1989; Sathiakumar et al. 2007). Exposure 
levels for the general population are not well defined. Studies that correlate personal exposure with daily 
activities are necessary to adequately establish exposure levels for 1,3-butadiene. Biological monitoring 
studies cannot be performed until acceptable experimental techniques are developed. Exposure levels for 
those living near hazardous waste sites are not available and should be established.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. No information regarding exposures of children to 1,3-butadiene are 
currently available. Biomonitoring data for children, including levels of 1,3-butadiene and its metabolites 
measured in breast milk, neonatal blood, cord blood, and meconium fluid have not been located in the 
available literature. Studies are needed to help determine if there are differences between childhood and 
adult exposure to 1,3-butadiene.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries.
No exposure registries for 1,3-butadiene were located. This substance is not currently one of the 
compounds for which a sub-registry has been established in the National Exposure Registry. The 
substance will be considered in the future when chemical selection is made for sub-registries to be 
established. The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance.
6.8.2 Ongoing Studies
Ongoing studies related to the potential for human exposure to 1,3-butadiene were not located.
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring 1,3-butadiene, its metabolites, and other biomarkers of exposure and effect 
to 1,3-butadiene. The intent is not to provide an exhaustive list of analytical methods. Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis. Many 
of the analytical methods used for environmental samples are the methods approved by federal agencies 
and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). 
Other methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
No standardized method to test for the presence of 1,3-butadiene in biological materials presently exists. 
Only a limited number of techniques have been employed to measure this compound in biological 
materials.
Perbellini et al. (2003) have developed a method to measure unmetabolized 1,3-butadiene concentrations 
in human blood, urine, and exhaled air. Breath samples were collected by expiration into headspace vials. 
Venous blood samples with EDTA added as an anticoagulant or urine samples were injected into a glass 
tube. Samples were analyzed using gas chromatography-mass spectrometry (GC-MS). Reported 
detection limits for 1,3-butadiene were 0.5 ng/L in blood, 1 ng/L in urine, and 0.8 ng/L in alveolar air.
A technique for the determination of 1,3-butadiene in margarine samples was reported by Startin and 
Gilbert (1984). The margarine sample is placed in a vial, sealed, and heated to 70 °C where it is allowed 
to equilibrate for 1 hour. The amount of 1,3-butadiene in the sample is determined by withdrawing a 
headspace sample, and injecting it directly into a GC equipped with a MS detection system. Quantitation 
is obtained by comparison of the peak height to that of a standard of known concentration. The 
sensitivity of this method allows quantitation down to 0.001 mg/kg (1 ppb). A similar headspace 
technique was used to test for the presence of butadiene in olive oil, vegetable oil, and yogurt samples 
(McNeal and Breder 1987).
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7.2 ENVIRONMENTAL SAMPLES
Standardized methods for determining 1,3-butadiene in environmental samples are limited to air samples, 
as no methodology has been described for analyzing this compound in water or soil samples (EPA 1982, 
1986). A representative list of the methods available for the determination of 1,3-butadiene in air samples 
can be found in Table 7-1. The determination of 1,3-butadiene in personal air can be obtained using the 
procedures outlined in NIOSH Method 1024 (NIOSH 1994) and OSHA Method 56 (OSHA 2009a) or 
EPA Methods TO-14A and TO-15 (EPA 1999a, 1999b).
For NIOSH Method 1024, the air sample is obtained by passing a known volume of air (5-25 L) through 
a set of tandem coconut charcoal tubes, which adsorb 1,3-butadiene and remove it from the air stream 
(NIOSH 1994). The collected 1,3-butadiene is then removed from the adsorption tube by extraction with 
methylene chloride. Injection of the methylene chloride solution into a GC equipped with a flame 
ionization detector (FID) separates 1,3-butadiene from any interfering compounds that may be present. 
The choice of chromatography column for this determination is not crucial, as long as it cleanly separates
1,3-butadiene from other compounds.
The estimated quantitation limit (LOQ) of this method is 0.02 ppm, with an applicable range of 0.04­
220 ^g per sample (approximately 0.04-100 ppm) for a 25 L sample. The precision of this method 
appears to change as a function of the concentration being measured, due to desorption efficiencies 
changing as a function of sample concentration. With increasing concentration, the preparation of a 
standard becomes more difficult. A limitation of this study is the relatively high LOQ (20 ppb), since 
concentrations observed in environmental settings are often <1 ppb.
In NIOSH Method 1024, quantitation of 1,3-butadiene is accomplished by comparing the area under the 
sample's response signal to that of a known amount of 1,3-butadiene. The preparation and injection of a 
gaseous 1,3-butadiene standard is a difficult procedure; it must be performed carefully or erroneous 
results will occur. Sample storage appears to dramatically affect the results of the measurement. Samples 
stored at -4 °C displayed an average recovery of 93-98% over a 21-day period, while samples stored at 
room temperature ranged from 61 to 95%.
OSHA Method 56 for analyzing 1,3-butadiene in air samples is similar to the NIOSH method described 
above. Air is drawn through sampling tubes containing charcoal absorbent coated with 4-tert-butyl- 
catechol. The samples are then desorbed with carbon disulfide and analyzed using gas chromatograph-
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Table 7-1. Analytical Methods For Determining 1,3-Butadiene in Environmental
Samples
S a m p le  a ir P rep ara tio n  m ethod
A naly tica l
m ethod
S a m p le  
detec tion  limit
P e rc e n t
reco very R e fe re n c e
Personal air 
(Method 1024)
Pass air through 
charcoal tube followed 
by desorption with 
methylene chloride
GC/FID 0.04­
220 jg/sample 
(25L sample)
OO15 NIOSH 1994
Personal air 
(Method 56)
Pass air through 
charcoal tube coated 
with 4-tert-
butylcatechol followed 
by desorption with 
carbon disulfide
GC/FID 200 jg/m3 
(90 ppb)
77-94 OSHA 2009a
Air
(Method TO-14A)
Pressurized container 
sampling followed by 
cryogenic 
concentration
GC/MS/SIM or 
SCAN
No data No data EPA 1999a
Air
(Method TO-15)
Pressurized container 
sampling followed by 
multisorbent 
concentration and 
thermal desorption
GC/MS/SIM or 
SCAN
No data No data EPA 1999b
Air Collect air in Tedlar 
bag concentrate on 
Tenax cartridge, 
thermal desorption
GC/FID No data No data Stump and 
Dropkin 1985
Air Pass air through 
charcoal tube solvent 
desorption
GC/MS No data No data Texax Air 
Control 
Board 1990
Air
(real time)
Draw air into 12-foot 
sampling loop, direct 
injection
GS/MS No data No data Texax Air 
Control 
Board 1990
Air Pass air through 
sorbent tubes 
containing Carbopack 
B/Carbosieve SIII 
followed by thermal 
desorption
GC/MS 0.11-0.16 |jg/m3 >95% Kim et al. 
1999
FID = flame ionization detector; GC = gas chromatography; MS = mass spectrometry; SCAN = wide range of mass 
to charge ratio scanning; SIM = select ion monitoring
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flame ionization detector (GC-FID). The recommended air volume and sampling rate is 3 L at 
0.05 L/minute. The detection limit is 200 ^g/m3 and the quantitation limit is 343 ^g/m3. As with NIOSH 
Method 1024, the usefulness of OSHA Method 56 for analysis of 1,3-butadiene in environmental media is 
limited since the reported detection and quantitation limits are much higher than levels often observed in 
environmental settings.
1,3-Butadiene, along with other volatile hydrocarbons, has been found in ambient air samples by a 
technique that uses cryogenic concentration before GC analysis. This technique is performed by 
collecting a large volume of air in a specially designed bag or other sampling container and concentrating 
the volatile components by condensation at low temperatures. The sample is separated into its 
components by GC and quantified with an internal standard. Numerous variations of this method were 
found in the literature (Curren 2006; Graham et al. 2004; Lonneman et al. 1979; Neligan 1962; Stephens 
and Burleson 1967, 1969; Stump and Dropkin 1985).
EPA Methods TO-14A and TO-15 describe procedures for the analysis of volatile organic compounds 
(VOCs) in air (EPA 1999a, 1999b). Method TO-14A calls for cryogenic concentration of the air sample 
as described above. Method TO-15 calls for pressurized air sampling using a stainless steel canister. The 
sample is then passed through a solid multisorbent concentrator and the concentrator is finally dry-purged 
with helium. The sample is thermally desorbed prior to analysis. For both of these methods, analysis is 
performed using GC followed by either a specific or nonspecific detector. However, the use of a specific 
detector is recommended, such as linear quadrupole mass spectrometer operating in either select ion 
monitoring (SIM) mode or a mode that scans a wide range of mass to charge ratios (SCAN). Precision 
and recovery data for 1,3-butadiene are not specified in these methods. Kim et al. (1999) developed an 
improved method by using a combination Carbopack B/CarbosieveSIII sorbent as a collection material. 
Sample collection was followed by thermal desorption and GC/MS analysis. These authors reported a 
precision of 2.4-13%, recoveries of >95%, and a detection limit of 0.11-0.16 ^g/m3 for this method. 
Therefore, this method is useful for measuring 1,3-butadiene concentrations in the low ppb (^g/m3) range 
in environmental air samples.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of 1,3-butadiene is available. Where adequate information is
1,3-BUTADIENE
7. ANALYTICAL METHODS
151
not available, ATSDR, in conjunction with NTP is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of 1,3-butadiene.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect. No standardized method for 
the determination of biomarkers of exposure and effect for 1,3-butadiene was located.
Exposure. Biomarkers that have been proposed as indicators of exposure to 1,3-butadiene include the 
urinary metabolites 1,2-dihydroxybutyl mercapturic acid (DHBMA or M1) and 1- and 2-monohydroxy- 
3-butenyl mercapturic acid (MHBMA or M2) and the hemoglobin adducts 1- and 2-hydroxy-3-butenyl 
valine (MHB-Val) and N-(2,3,4-trihydroxy-butyl)valine (THB-Val) (Albertini et al. 2001; Boogaard et al. 
2001a; Carrieri et al. 2009; McDonald et al. 2004; Sapkota et al. 2006; Schettgen et al. 2009; Shen et al.
2009). Measurement of unmetabolized 1,3-butadiene in human blood and urine may be preferable for 
assessing very low levels of exposure to this substance (0.4 ^g/m3 median concentration in personal air) 
(Fustinoni et al. 2004; Perbellini et al. 2003; Schettgen et al. 2009).
Both the urinary metabolites and the hemoglobin adducts have been well correlated with exposure to
1,3-butadiene (Albertini et al. 2001; Preston 2007). Methods developed to measure these biomarkers 
have utilized either HPLC or GC followed by tandem MS (Boogaard et al. 2001a; Carrieri et al. 2009; 
Sapkota et al. 2006; Schettgen et al. 2009). Shen et al. (2009) has developed a method based on liquid 
chromatography/electrospray ionization-mass spectrometry to measure 3-butene-1,2-diol, a 1,3-butadiene 
urinary metabolite intermediate.
Effect. Biomarkers of effect resulting from 1,3-butadiene exposure, such as gene mutation and 
chromosomal changes, have been explored; however, no clear associations have been observed (Albertini 
et al. 2001; Preston 2007).
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Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Data on the determination of 1,3-butadiene in environmental media were limited. 1,3-Buta­
diene in air samples has been detected by techniques routinely used for detecting volatile hydrocarbons 
(Kim et al. 1999; Stump and Dropkin 1985; Texas Air Control Board 1990; EPA 1999a, 1999b). 
Improvements to these methods have made possible the detection of 1,3 butadiene concentrations in the 
low ppb (^g/m3) range in environmental air samples (Kim et al. 1999). Procedures accepted for the 
determination of volatile hydrocarbons in other environmental media (soil, water, sediment, plants, etc.) 
may also be suitable for 1,3-butadiene. This question can be answered only by the data obtained from 
properly designed experiments. The information will assist in determining the prevalence of this 
compound in the environment and aid in a quantitative determination of human exposure to 1,3-buta­
diene.
7.3.2 Ongoing Studies
Ongoing studies related to the development of analytical methods for 1,3-butadiene were not located.
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EPA (IRIS 2012) has established an inhalation reference concentration (RfC) for 1,3-butadiene of 0.9 ppb 
based on a BMCL10 of 0.88 ppm for ovarian atrophy in female B6C3F1 mice exposed to 1,3-butadiene by 
inhalation for 6 hours/day, 5 days/week for up to 103 weeks.
EPA has not established an oral reference dose (RfD) for 1,3-butadiene (IRIS 2012).
OSHA has required employers of workers who are occupationally exposed to 1,3-butadiene to institute 
engineering controls and work practices to reduce and maintain employee exposure at or below 
permissible exposure limits (PELs) (OSHA 2009b). The employer must use engineering and work 
practice controls to reduce exposures to not exceed 1 ppm for 1,3-butadiene at any time (OSHA 2009b).
EPA has designated 1,3-butadiene as a hazardous air pollutant (HAP) under the Clean Air Act (CAA) 
(EPA 2009b). 1,3-Butadiene is on the list of chemicals appearing in “Toxic Chemicals Subject to 
Section 313 of the Emergency Planning and Community Right-to-Know Act of 1986” and has been 
assigned a reportable quantity (RQ) limit of 100 pounds (EPA 2009d). The RQ represents the amount of 
a designated hazardous substance which, when released to the environment, must be reported to the 
appropriate authority.
The international and national regulations, advisories, and guidelines regarding 1,3-butadiene in air, 
water, and other media are summarized in Table 8-1.
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene
A g e n c y D escrip tion In form ation R e fe re n c e
INTERNATIONAL
Guidelines:
IARC 
W HO
NATIONAL
Regulations and 
Guidelines:
a. A ir
ACGIH
AIHA
EPA
EPA
Carcinogenicity classification 
A ir quality guidelines
Drinking w ater quality guidelines
Group 1
No guideline value is 
recommended at this 
time
No
IARC 2009 
W HO 2000
W HO 2006
TLV (8-hour TWA) 2 ppm ACGIH 2008
ERPG-1b 10 ppm AIHA 2008
ERPG-2b 200 ppm
ERPG-3b 5,000 ppm
RfC 0.9 ppb IRIS 2012
Inhalation unit risk 3 *1 0 '5 per ^g /m 3
AEG L-1c EPA 2009a
10 minutes 670 ppm
30 minutes 670 ppm
60 minutes 670 ppm
4 hours 670 ppm
8 hours 670 ppm
AEG L-2c
10 minutes 6,700 ppm
30 minutes 6,700 ppm
60 minutes 5,300 ppm
4 hours 3,400 ppm
8 hours 2,700 ppm
AEG L-3c
10 minutes 27,000 ppm
30 minutes 27,000 ppm
60 minutes 22,000 ppm
4 hours 14,000 ppm
8 hours 6,800 ppm
Level o f d istinct odor awareness 3.7 ppm
Hazardous air pollutant Yes EPA 2009b 
42 USC 7412
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene
A g e n c y D escrip tion In form ation R e fe re n c e
NATIONAL (cont.)
NIOSH
OSHA
b. Water 
EPA
c. Food 
FDA
d. Other 
ACGIH
Regulated flammable substances and 
threshold quantities for accidental 
release prevention01
REL (10-hour TWA)
IDLH (10% LEL)
Target organs
PEL (8-hour TWA) for general industry 
STEL (15-minutes)
Drinking water standards and health 
advisories
National primary drinking water 
standards
National recommended water quality 
criteria
EAFUSe
Carcinogenicity classification
10,000 pounds EPA 2009c 
40 CFR 68.130
Potential occupational NIOSH 2005 
carcinogens
2,000  ppm
Eyes, respiratory 
system, central 
nervous system, and 
reproductive system
1 ppm
5 ppm
OSHA 2009b 
29 CFR 1910.1051
No
No
No
No
A2f
EPA 2006a 
EPA 2003b 
EPA 2006b
FDA 2008 
ACGIH 2008
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene
A g e n c y D escrip tion In form ation R e fe re n c e
EPA Carcinogenicity classification 
RfD
Superfund, em ergency planning, and 
community right-to-know
Carcinogenic to 
humans by inhalation
No data
IR IS 2012
Designated C ER C LA  hazardous Yesg EPA 2009d
substance 40 C FR  302.4
Reportable quantity 100 pounds
Effective date of toxic chemical 01 /01 /1987 EPA 2009e
release reporting 40 C FR  372.65
N TP Carcinogenicity classification Known to be a human 
carcinogen
N TP 2005
aGroup 1: carcinogenic to humans
bERPG-1 is the maximum airborne concentration below which nearly all individuals could be exposed for up to 1 hour 
without experiencing other than mild, transient health effects; ERPG-2 is the maximum airborne concentration below 
which nearly all individuals could be exposed for up to 1 hour without experiencing irreversible or other serious 
adverse effects; and ERPG-3 is the maximum airborne concentration below which nearly all individuals could be 
exposed for up to 1 hour without life-threatening health effects (AIHA 2008).
cAEGL-1 is the airborne concentration of a substance above which it is predicted that the general population, 
including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory 
effects, however, the effects are not disabling and are transient and reversible upon cessation of exposure; AEGL-2 
is the airborne concentration of a substance above which it is predicted that the general population, including 
susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an 
impaired ability to escape; and AEGL-3 is the airborne concentration of a substance above which it is predicted that 
the general population, including susceptible individuals, could experience life-threatening health effects or death 
(EPA 2009a).
Basis for listing: flammable gas
eThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS. 
fA2: suspected human carcinogen
gDesignated CERCLA hazardous substance pursuant to Section 112 of the Clean Air Act
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, 
Compensation, and Liability Act; CFR = Code of Federal Regulations; EAFUS = Everything Added to Food in the 
United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines;
FDA = Food and Drug Administration; GRAS = Generally Recognized As Safe; iA r C = International Agency for 
Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System;
LEL = lower explosive limit; NIOSH = National Institute for Occupational Safety and Health; NTP = National 
Toxicology Program; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit;
REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose;
STEL = short-term exposure limit; TLV = threshold limit values; TWA = time-weighted average; USC = United States 
Code; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)— The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment.
Benchm ark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response. For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchm ark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration F actor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biom arkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
C ancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
D ata Needs— Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Em bryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environm ental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media.
Im m ediately Dangerous to Life or Health (IDLH)— The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
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Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.
In term ediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal C oncentration^ ) (LC lo )—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal C oncentration^ ) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)— The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)— The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lym phoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
M alform ations— Permanent structural changes that may adversely affect survival, development, or 
function.
M inim al Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying F actor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.
M orbidity— State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
M ortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
10. GLOSSARY
Immunological Effects—Functional changes in the immune response.
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M utagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
O ctanol-W ater Partition  Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
O rganophosphate or O rganophosphorus Com pound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests.
Pharm acokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharm acokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharm acodynam ic (PBPD) Model—A type of physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.
Physiologically Based Pharm acokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a
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variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)— An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
R eportable Q uantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio— The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term  Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized M ortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target O rgan Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Lim it Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-W eighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)— A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
U ncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND W ORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency- 
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the 
public. They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously 
published levels. For additional information regarding MRLs, please contact the Division of Toxicology 
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
Road NE, Mailstop F-62, Atlanta, Georgia 30333.
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APPENDIX B. USER'S GUIDE
C hapter 1 
Public Health Statem ent
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
C hapter 2 
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
In terp reta tion  of M inimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
C hapter 3 
H ealth Effects 
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure.
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See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose. A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond 
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the 
LSE table.
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(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (qi*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
SAMPLE
Table 3-1. Levels of Significant Exposure to [Chemical x] -  Inhalation
Exposure
Key to frequency/
figure3 Species duration
LOAEL (effect)
NOAEL Less serious Serious (ppm)
System (ppm) (ppm) Reference
7 8 9 10
i i i i
Resp 3b 10 (hyperplasia)
INTERMEDIATE EXPOSURE
5
Systemic I
18 Rat
CHRONIC EXPOSURE 
Cancer
13 wk
5 d/wk
6 hr/d
38
39
40
Rat
Rat
Mouse
11
18 mo 
5 d/wk 
7 hr/d
89-104 wk
5 d/wk
6 hr/d
79-103 wk
5 d/wk
6 hr/d
i
20
10
(CEL, multiple 
organs)
(CEL, lung tumors, 
nasal tumors)
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
10 (CEL, lung tumors, NTP 1982 
hemangiosarcomas)
12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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APPENDIX C. ACRONYM S, ABBREVIATIONS, AND SYM BOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLx 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
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DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram 
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F j first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Ko w  octanol-water partition coefficient
L liter
LC liquid chromatography
LC50  lethal concentration, 50% kill
LCL o lethal concentration, low
LD50 lethal dose, 50% kill
LDL o lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans--muconic acid
MAL maximum allowable level
mCi millicurie
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MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
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> greater than
> greater than or equal to
= equal to
< less than
< less than or equal to
% percent
a alpha
P beta
Y gamma
5 delta
micrometer
microgram
q i* cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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APPENDIX D. INDEX
absorbed dose.......................................................................................................................................................93
adenocarcinoma.................................................................................................................................................. 46
adsorbed............................................................................................................................................................. 130
adsorption.......................................................................................................................................... 121, 130, 148
aerobic.......................................................................................................................................................132, 133
ambient a ir ....................................................................................................................................... 108, 144, 150
anemia.........................................................................................................................................9, 10, 13, 37, 102
bioaccumulation.................................................................................................................................................121
bioavailability....................................................................................................................................................144
bioconcentration factor.....................................................................................................................................130
biodegradation..........................................................................................................................................132, 133
biomarker...........................................  7, 8, 11, 16, 17, 58, 61, 62, 87, 89, 93, 94, 95, 96, 106, 109, 147, 151
blood cell count........................................................................................................................................9, 10, 37
body weight effects............................................................................................................................................. 39
breast milk................................................................................................................................................ 142, 145
cancer............................................................4, 8, 9, 10, 13, 14, 20, 21, 43, 44, 45, 46, 92, 100, 102, 103, 109
carcinogen.......................................................................................................................................4, 46, 103, 156
carcinogenic.........................................................................  10, 19, 20, 46, 88, 95, 96, 99, 103, 104, 106, 156
carcinogenicity....................................................................................................8, 10, 61, 88, 95, 100, 103, 104
carcinoma.............................................................................................................................................................46
cardiovascular......................................................................................................................................................36
cardiovascular effects..........................................................................................................................................36
cholinesterase.......................................................................................................................................................40
chromosomal aberrations........................................................................................................52, 53, 54, 97, 104
clearance.............................................................................................................................. 61, 63, 69, 73, 74, 99
death..............................................................................................8, 9, 10, 13, 19, 21, 40, 41, 99, 100, 102, 156
deoxyribonucleic acid (see DNA)........................................................................................................................5
dermal effects.......................................................................................................................................................38
developmental effects..................................................................... 8, 9, 10, 12, 13, 42, 92, 100, 105, 106, 107
DNA (see deoxyribonucleic acid)............................................5, 49, 52, 54, 86, 87, 88, 93, 95, 106, 108, 109
elimination ra te .............................................................................................................................................63, 67
endocrine........................................................................................................................................................90, 91
fetus................................................................................................................................................................ 74, 91
fractional absorption...........................................................................................................................................98
gastrointestinal effects........................................................................................................................................36
general population...................................................................................................7, 8, 123, 137, 138, 145, 156
genotoxic...................................................................................................8, 19, 47, 54, 86, 87, 95, 97, 104, 110
genotoxicity................................................................................................ 47, 55, 86, 87, 88, 96, 100, 105, 109
groundwater..................................................................................................................................... 102, 129, 131
growth retardation............................................................................................................................................. 105
half-life........................................................................................................................... 7, 93, 121, 130, 131, 132
hematological effects..........................................................................................................................................36
hematopoietic.....................................................................................................................8, 39, 45, 49, 103, 104
hepatic effects......................................................................................................................................................38
hydrolysis.................................................................... 51, 57, 61, 62, 67, 68, 69, 74, 76, 77, 84, 85, 92, 98, 99
hydroxyl radical................................................................................................................................121, 131, 132
immune system..................................................................................................................................................105
immunological.......................................................................................................................................19, 39, 40
immunological effects.................................................................................................................................. 39, 40
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Kow......................................................................................................................................................................113
leukemia.......................................................................................................... 37, 39, 43, 44, 45, 46, 88, 92, 103
lymphatic......................................................................................................................................................... 4, 43
lymphopoietic..................................................................................................................................................8, 10
lymphoreticular................................................................................................................................................8, 10
micronuclei.............................................................................................................................. 49, 50, 52, 99, 104
musculoskeletal effects.......................................................................................................................................38
neonatal......................................................................................................................................................142, 145
neoplasm..............................................................................................................................................................46
neoplastic...........................................................................................................................................9, 10, 11, 38
neurobehavioral...........................................................................................................................................90, 105
neurological effects....................................................................................................................3, 12, 40, 99, 105
non-Hodgkin’s lymphoma................................................................................................................................. 44
ocular effects........................................................................................................................................................39
odds ratio..............................................................................................................................................................43
partition coefficients.......................................................................................  15, 55, 56, 67, 68, 69, 74, 79, 83
pharmacodynamic............................................................................................................................................... 64
pharmacokinetic................................................................................ 11, 63, 64, 65, 66, 91, 100, 102, 104, 105
rate constant..........................................................................................................................  17, 68, 74, 131, 132
renal effects..........................................................................................................................................................38
reproductive effects.............................................................................................................................. 10, 40, 104
respiratory effects........................................................................................................................................ 21, 103
sarcoma.......................................................................................................................................................... 44, 46
solubility............................................................................................................................................................ 113
spermatozoa......................................................................................................................................................... 12
systemic effects.....................................................................................................................................13, 21, 100
T 3..........................................................................................................................................................................22
thyroid......................................................................................................................................................10, 46, 57
toxicokinetic................................................................................ 11, 15, 16, 17, 19, 97, 98, 102, 103, 107, 144
tum ors...............................................................................................................................  10, 13, 40, 45, 96, 106
vapor pressure............................................................................................................................................ 113, 130
volatility............................................................................................................................................................. 130
volatilization.............................................................................................................................................. 121, 130

